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Abstract        1 
1 Abstract 
 
The chemotherapeutic cisplatin is widely used to treat various tumors. By inducing 
crosslinking of DNA, signaling and repair pathways are activated which are referred to as the 
DNA damage response (DDR). However, the cellular and molecular mechanisms of cisplatin 
treatment are incompletely understood. We set up a study to find new regulators in the DDR 
to cisplatin. Since ubiquitination plays a major role in the DDR, we applied a high-content 
siRNA screen targeting 327 human ubiquitin ligases and 92 deubiquitinating enzymes in 
U2OS cells. We detected phosphorylation of the histone variant H2AX (yielding γH2AX), a 
marker for DNA damage. Knockdown of one of the candidates, the ubiquitin ligase G2E3, led 
to decrease in γH2AX levels. G2E3 had previously been proposed to play a role in the DDR 
and in cell survival. However, little was known about the underlying mechanisms. In the work 
presented here, we show that G2E3 is a DNA damage-responsive, cell cycle-dependent 
survival factor. 
 
We found that G2E3 mRNA and protein levels are down-regulated upon DNA damage. 
Knockdown of G2E3 resulted in p53-independent apoptosis and decreased proliferation in 
colon carcinoma and osteosarcoma cell lines. Furthermore, we verified that G2E3 levels are 
maximal in G2-phase, suggesting a cell cycle-dependent regulation of G2E3. Hence, we 
propose that G2E3 acts as a pro-survival factor that protects normal cells against cell death. 
Upon DNA damage, G2E3 down-regulation contributes to apoptosis.  
 
So far, we did not identify a direct role of G2E3 in the DDR explaining changes in H2AX 
phosphorylation. However, we found that knockdown of G2E3 results in G1-arrest and 
decreased percentage of cells in S-phase in untreated and cisplatin treated U2OS cells. 
Correspondingly, we observed p53-dependent p21 induction in U2OS cells upon G2E3 
depletion. The tumor suppressor p53 becomes activated upon DNA damage and is an 
important transcription factor for genes involved in apoptosis and cell cycle arrest (e.g. p21). 
Based on our findings, we propose that after G2E3 knockdown arrested U2OS cells do not 
continue replicating their DNA and are therefore less prone to DNA damage by cisplatin 
treatment. This hypothesis is supported by the fact that knockdown of Mdm2, the main 
negative regulator of p53, also leads to induction of G1-arrest and exhibits decreased γH2AX 
levels upon cisplatin treatment. Interestingly, we found that depletion of the p53-pathway 
regulators RBBP6 and STUB1 results in decreased γH2AX levels similar to G2E3 
knockdown. This led us to further investigate the role of G2E3 in the p53-pathway. 
Overexpressed Mdm2 and G2E3 co-localized in subnuclear structures in untreated and 
cisplatin treated cells. Moreover, overexpressed G2E3 and Mdm2 were found in a complex 
as seen by co-immunoprecipitation. Mdm2 and p53 interacted independently of co-expressed 
HA-G2E3, and Mdm2 bound HA-G2E3 independently of co-expressed p53. Thus, G2E3, 
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Mdm2 and p53 might form a heterotrimeric complex. In search for the functional role of this 
interaction, we did not observe an impact of overexpressed G2E3 on p53 transcriptional 
activity or on Mdm2-dependent inhibition of p53 transactivation. Also, co-expression of Mdm2 
and HA-G2E3 did not affect their ubiquitination status or protein levels. However, siRNA-
mediated depletion of G2E3 resulted in decreased Mdm2 protein levels after cisplatin 
treatment independently of the p53-status. This result suggests that G2E3 regulates Mdm2 
levels independently of p53, the principal transcription factor for Mdm2 expression.  
 
In conclusion, our results suggest that G2E3 is required for cell proliferation and survival. 
DNA damage induces a strong down-regulation of G2E3 levels, possibly contributing to 
apoptosis. One of the mechanisms by that G2E3 ensures cell survival appears to consist in 






























2.1 DNA damage 
2.1.1 Genome integrity – at risk of DNA damage 
The integrity of the genome is a prerequisite for organism development and survival. 
Additionally, genetic information has to be accurately transmitted from one cell to the 
daughter cells. This requires correct DNA replication and distribution of chromosomes, but 
also the capability to cope with DNA damage and to minimize the number of mutations. The 
cell harbors an efficient genome maintenance machinery to identify and eliminate defects in 
the DNA. Thus, spontaneous mutations are very rare.  
Genome integrity is at risk due to endogenous and exogenous types of DNA damage. 
Endogenous damage originates from within the cell, e.g. from replication errors while 
unsuitable nucleotides are incorporated, or from exposure to reactive oxygen species (ROS) 
caused by metabolic side-products (reviewed in Marnett and Plastaras 2001; De Bont and 
van Larebeke 2004). On the other hand, exogenous damage is evoked externally by UV- and 
ionizing radiation (IR), or by cytotoxic agents like antimetabolites and replication inhibitors.  
 
The cellular response to damaged DNA is a very important issue in cancer biology for three 
reasons (Kastan and Bartek 2004). First of all, DNA damage can cause cancer. This has 
been shown in different studies of humans and animal models. Furthermore, susceptibility to 
cancer is often accompanied by mutations in genes involved in the response to DNA 
damage. Secondly and importantly, DNA-damaging agents are used to treat cancer. As 
detailed below, chemotherapeutics and radiotherapy are besides surgery the main 
approaches to medicate cancer. Thirdly and regrettably, side effects of cancer therapy are 
caused by damaged DNA, too. Examples include accumulation of mutations or cell death of 
noncancerous cells and induction of leukemia or new tumors years after chemotherapy 
treatment (Kastan and Bartek 2004).  
 
2.1.2 Chemotherapy  
2.1.2.1 DNA-damaging chemotherapeutics  
Cancer cells are more sensitive to genotoxic stress, leading to a higher rate of mutations. The 
reasons are defects in the genome maintenance system at various points, e.g. malfunctions 
in detecting or repairing DNA damage or in inactivating DNA-damaging molecules (reviewed 
in Jackson and Bartek 2009; Negrini, Gorgoulis et al. 2010). Proteins involved in DNA 
maintenance are called “caretakers” of the genome (Kinzler and Vogelstein 1997). During 
tumor progression, their function can get lost by inactivating mutations or gene repression, 
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leading to cells sensitive to DNA damage. This fact is used by chemotherapy and also 
radiotherapy with the aim to kill cancer cells. DNA-damaging chemotherapeutics cause cell 
cycle arrest and cell death. This occurs either directly or after replication during S-phase. If 
cells try to replicate damaged DNA, even more cells die: stalled replication forks finally result 
in highly toxic DNA double-strand breaks (DSBs). In this regard, DNA-damaging agents are 
more toxic to replicating cells which is advantageous since cancer cells are often 
characterized by an increased proliferation rate. 
 
Common DNA-damaging drugs include antimetabolites, alkylating agents, replication 
inhibitors and topoisomerase inhibitors (reviewed in Helleday, Petermann et al. 2008). 
Antimetabolites, e.g. nucleoside analogs like 5-fluorouracil, inhibit nucleotide metabolism and 
synthesis of DNA, hence interfere with replication and deplete cells of dNTPs. This leads to 
base damages and DNA single-strand breaks (SSB). Alkylating agents like mitomycin C and 
alkylating-like agents such as cisplatin induce different toxic lesions, i.e. DNA crosslinks, 
single-stranded DNA, DNA DSBs and bulky adducts. Inhibitors of replication, for example 
aphidicolin, inhibit DNA polymerases, impair replication fork progression and cause lesions in 
the DNA like DSBs (Saintigny, Delacote et al. 2001). Furthermore, inhibition of 
topoisomerases is a common strategy in cancer therapy. Inhibition of topoisomerase II (e.g. 
by etoposide) causes DNA DSBs. On the other hand, inhibition of topoisomerase I (e.g. by 
camptothecin) leads to supercoils upstream of replication forks and replication-associated 
DSBs (Helleday, Petermann et al. 2008). 
Remarkably, although most DNA-damaging drugs have been used for years, their detailed 
mechanisms of actions are mostly not well understood. 
 
Here, we introduce two DNA-damaging agents in more detail which are important for the 
results obtained. 
 
2.1.2.2 Selected chemotherapeutics: Cisplatin 
Platinating agents are used in the clinics since the 1970s to treat different types of cancer like 
testicular, ovarian, cervical, head and neck, lung and colorectal cancer. Cisplatin, together 
with oxaliplatin and carboplatin, is one of the most frequently prescribed chemotherapeutics 
for treating solid tumors. It was originally discovered in 1969 as a growth inhibitor of 
Escherichia coli (Rosenberg, VanCamp et al. 1969). The structure is depicted in Figure 2.1A. 
Cisplatin is given intravenously. After entering the cell, it becomes aquated by losing the 
chloride ions and exchanging them with two water molecules (Figure 2.1B). Now positively 
charged cisplatin can interact with nucleophilic molecules like DNA, RNA and proteins. It is 
believed that cisplatin preferentially binds DNA (favoring imidazole rings of guanosine and 
adenosine), leading to formation of mono-adducts and crosslinks (Yang and Wang 1999; 
Zorbas and Keppler 2005). More than 90 % of mono-adducts further react to become 
crosslinks (Rabik and Dolan 2007). As visualized in Figure 2.1C, crosslinks between two DNA 
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bases can be either within the same DNA strand (intra-strand crosslink) or between two DNA 
strands (inter-strand crosslink). The majority of crosslinks are intra-strand, mostly 1,2-d(GpG) 
crosslinks of adjacent guanine bases (Rabik and Dolan 2007). Crosslinking leads to torsion of 
the DNA by different angles and steric changes. It is still in debate whether inter- or intra-
strand crosslinks are more toxic to the cells. Anyhow, the conformational changes induced 
are the basis for recognition and processing of cisplatin-DNA-adducts. The pathways induced 













Figure 2.1: Cisplatin mechanism of action. 
(A) Chemical structure of cisplatin (taken from Rabik and Dolan 2007). (B) Cytotoxic pathway of 
cisplatin. Cisplatin is aquated in the cell, leading to binding to the DNA. Outcomes are either cell 
cycle arrest to repair DNA or apoptosis if damage is irreparable (taken from Alderden, Hall et al. 
2006). (C) Adducts formed by cisplatin and DNA can be either mono-adducts, intra-strand or inter-




2.1.2.3 Selected chemotherapeutics: Neocarzinostatin 
Neocarzinostatin (NCS) is a radiomimetic. Like radiotherapy, it causes DNA DSBs which are 
replication-independent and thus also kill non-replicating cells. NCS is a macromolecule 
composed of a 113 amino acid protein bound to an enediyne chromophore. Enediynes are 
cyclic, natural products from bacteria (Nicolaou, Smith et al. 1993). NCS is secreted by 
Streptomyces macromomyceticus and has anti-proliferative and anti-tumoral activity (Smith 
and Nicolaou 1996). Whereas the protein has stabilizing properties, the chromophore 
mediates DNA cleavage. Under reductive conditions in the cell, the NCS-epoxide forms a 
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highly reactive biradical intermediate which leads to DNA DSBs. NCS has been tested in 
clinical trials in Japan, for example for treatment of colorectal cancer and acute leukemia 
(Kimura 1978; Takahashi, Yamaguchi et al. 1993), but has only been used clinically in Japan 
against liver cancer. Still, it is a valuable agent in research as it can be used as a 
radiomimetic agent, thus rendering ionizing radiation unnecessary.  
 
2.2 The DNA damage response (DDR) 
Cells possess a highly developed system to recognize, signal and repair DNA when lesions 
occur. This is called the DNA damage response (DDR). Depending on the type of lesion, 
different mechanisms come into action, in a rapid and coordinated fashion. First, DNA 
damage is recognized by specific proteins, then mediators are recruited and signaling is 
amplified, so that transducer and effector proteins come into play (Jackson and Bartek 2009). 
During these processes, post-translational modifications play a major role, including 
phosphorylation and ubiquitination events. The cellular responses range amongst others from 
effects on the cell cycle and repair, on chromatin remodeling and transcription to effects on 
apoptosis and senescence (Jackson and Bartek 2009). The importance of these pathways 
becomes evident by the fact that defects have been related to higher risk of cancer and 
developmental and immunological diseases.  
Here, we want to focus on the response to DNA DSBs, DNA SSBs and crosslinking of DNA. 
The mechanisms of detecting and signaling these damages are described in the following 
passages.  
 
2.2.1 Phosphorylation events in the DDR 
Phosphorylation cascades play a major role in the DDR. Damaged DNA is recognized by 
kinases of the PIKK (phosphatidylinositol 3-kinase-related kinase) family. These are ATM 
(ataxia telangiectasia mutated), ATR (ATM and Rad3-related) and DNA-PK (DNA-dependent 
protein kinase). Interestingly, more than 900 phosphorylation sites of over 700 proteins were 
reported to be regulated by ATM and ATR in a large-scale proteomic analysis (Matsuoka, 
Ballif et al. 2007), indicating the importance of these kinases. Depending on the kind of DNA 
lesion, different response pathways are induced. Here, we want to introduce the two main 
responses, i.e. the response to DNA DSBs and to single-stranded DNA. 
 
2.2.1.1 ATM-Chk2 pathway as response to DNA double-strand breaks 
In recent years, extensive research has been conducted on the response to DNA DSBs. 
Double-stranded DNA activates ATM which phosphorylates the checkpoint kinase Chk2 
(Matsuoka, Huang et al. 1998; Matsuoka, Rotman et al. 2000). Both ATM and Chk2 lead to 
phosphorylation and thus activation of the transcription factor p53, an important target as 
detailed below. ATM has many more substrates in the DDR, for example Mdm2, BRCA1 and 
Nbs1 (Cortez, Wang et al. 1999; Khosravi, Maya et al. 1999; Gatei, Scott et al. 2000; Gatei, 
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Young et al. 2000). Mdm2 is the main negative regulator of p53 and BRCA1 plays an 
important role in the response and repair of DNA DSBs. Both proteins will be introduced in 
more detail below. Nbs1 is a component of the MRN (Mre11-Rad50-Nbs1) complex which 
plays a role in processing and repair of DSBs. The repair of DSBs is conducted by 
homologous recombination (HR) and non-homologous end joining (NHEJ) which are both 
controlled by ATM. Just as ATM, Chk2 has different substrates, which are involved in cell 
cycle and apoptosis. 
 
2.2.1.2 ATR-Chk1 pathway as response to single-stranded DNA 
Single-stranded DNA (ssDNA) leads to the activation of the ATR-Chk1 pathway. It has been 
reported that replicative stress in S-phase leads to stalled replication forks. As a result, the 
polymerase stalls, whereas the helicase continues to unwind the DNA. This results in ssDNA 
which is bound by RPA (replication protein A). ATR is found in a complex with ATRIP (ATR-
interacting protein) (Cortez, Guntuku et al. 2001). It is proposed that RPA binding to ssDNA 
facilitates the binding of ATRIP to this DNA region (Zou and Elledge 2003; Unsal-Kacmaz 
and Sancar 2004). ATR is then capable of phosphorylating substrates like the checkpoint 
kinase Chk1 (Liu, Guntuku et al. 2000; Zhao and Piwnica-Worms 2001), leading to activation 
of the cell cycle checkpoint. The ATR-Chk1 pathway also leads to phosphorylation and 
activation of p53. Many studies indicate that ATR plays a major role in the stress response to 
inhibited replication-fork progression. 
 
It has been shown that the ATM-Chk2 and ATR-Chk1 pathway can activate each other, 
leading to considerable cross-talk at several points, including downstream events. For 
instance, stalled replication forks can collapse into DNA DSBs which activate ATM. And 
DSBs are repaired by HR which involves DNA end resection, resulting in ssDNA, activating 
ATR (Shiotani and Zou 2009). A scheme of the pathways is depicted in Figure 2.2. 
 
It is of note that ATM and ATR can activate another stress response pathway via the mitogen 
activated protein kinase (MAPK) p38 and its substrate MK2 (MAPK activated protein kinase 
2) (Reinhardt, Aslanian et al. 2007; Reinhardt and Yaffe 2009).  
Naturally, also dephosphorylation events play a role in the DDR, but insights into the 
importance of phosphatases are not as extensive as of kinases. Phosphatases can control 
DDR events by dephosphorylating kinases or their substrates. A well-known example is WIP1 
(or PPM1D) which dephosphorylates important proteins like Chk1, Chk2, ATM, p38 and p53 
(Takekawa, Adachi et al. 2000; Lu, Nannenga et al. 2005; Fujimoto, Onishi et al. 2006; 








Figure 2.2: Kinase signaling in the DNA damage response.  
ATM and ATR are sensor kinases for DNA double-strand breaks (DSBs) and single-stranded DNA 
(ssDNA). Amongst others, they phosphorylate and thus activate the transducer kinases Chk1 and 
Chk2. Considerable cross-talk exists between the ATM-Chk2 and ATR-Chk1 pathway. DDR signaling 
can impair checkpoint activation, regulation of gene expression and DNA repair or can lead to 
apoptosis if damage is irreparable. 
 
 
2.2.1.3 Phosphorylation of the histone variant H2AX 
In mammals, 2-25 % of histones H2A are represented by the histone variant H2AX. Upon 
DNA damage, H2AX is specifically phosphorylated at Ser139 (Rogakou, Pilch et al. 1998; 
Fernandez-Capetillo, Lee et al. 2004). This is performed by kinases of the PIKK family, i.e. by 
ATM (Burma, Chen et al. 2001), by ATR (Ward and Chen 2001) and by DNA-PK (Stiff, 
O'Driscoll et al. 2004). The signal of phosho-H2AX (then called γH2AX) spreads on each side 
of the DNA lesion in a ca. 1-2 Mbp wide region (Rogakou, Boon et al. 1999; Bewersdorf, 
Bennett et al. 2006). It mostly occurs after formation of DNA DSBs (Rogakou, Pilch et al. 
1998), but is also induced during replication stress (Ward, Minn et al. 2004). Furthermore, it 
has been used as an indicator for genome instability and as marker in early stages of tumor 
progression (Gorgoulis, Vassiliou et al. 2005). γH2AX plays an important role in amplifying 
and maintaining DNA damage-induced checkpoints, but also in recruiting repair factors. The 
mechanisms of γH2AX function are not well understood. For instance, the response to DNA 
DSBs and involvement of γH2AX has been investigated in detail, but the consequences, e.g. 
how DSB repair is connected to cellular proliferation and survival are still not completely 
understood. Dephosphorylation of γH2AX has been reported to be mediated by different 
phosphatases, including PP2A (protein phosphatase 2A) (Chowdhury, Keogh et al. 2005), 
PP4 (Nakada, Chen et al. 2008) and WIP1 (Macurek, Lindqvist et al. 2010).  
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2.2.2 Ubiquitin ligases and deubiquitinating enzymes in the DDR 
2.2.2.1 Principles of ubiquitination 
Ubiquitin is a 76 amino acid long protein which covalently attached to other proteins has a 
multitude of functions. It targets proteins for proteasomal degradation, regulates protein 
localization, activity and protein interactions (reviewed in Bergink and Jentsch 2009; 
Komander and Rape 2012). Attachment of ubiquitin is mediated by ubiquitin-activating 
enzymes (E1), ubiquitin-conjugating enzymes (E2) and ubiquitin ligases (E3) as depicted in 
Figure 2.3 (reviewed in Deshaies and Joazeiro 2009; Schulman and Harper 2009; Ye and 
Rape 2009). In mammals, two E1s have been described as well as 35 E2s and more than 
600 E3s to date (Jackson and Durocher 2013). During ubiquitination, an isopeptide bond is 
formed between the C-terminus of ubiquitin and the lysine of a substrate (or another ubiquitin 
molecule) in an ATP-dependent manner.  
 
Two major E3 ubiquitin ligase families exist: the HECT (homologous to the E6AP carboxyl 
terminus) domain family (Rotin and Kumar 2009) and the group of RING (really interesting 
new gene) and RING-related E3s, including plant homeodomain (PHD) proteins and 
members of the U-box family (Deshaies and Joazeiro 2009). Since RING and PHD domains 
are so similar, it was in the past often difficult to assign proteins to one class or the other. 
PHD domains infrequently have E3 activity, but bind methylated histones and are involved in 
chromatin-mediated gene regulation (Musselman and Kutateladze 2011). HECT and RING 
ubiquitin ligases differ in their mechanism of action: HECT E3s contain a conserved catalytic 
cysteine which accepts ubiquitin from the E2 protein before it is transferred to a specific lysine 
of the substrate. In contrast, RING E3s work as scaffolds and facilitate the interaction 





Figure 2.3: Enzymatic cascade of ubiquitination.  
Ubiquitin attachment to a substrate is mediated by an ubiquitin-activating enzyme (E1), an ubiquitin-
conjugating enzyme (E2) and the ubiquitin ligase (E3). First, ubiquitin is transferred to E1, then 
activated to E2 and finally covalently attached to the substrate with the help of E3 (taken from Dikic, 
Wakatsuki et al. 2009). 
 
 
Ubiquitination is a reversible process like other post-translational modifications. Proteases 
that can cleave ubiquitin are called deubiquitinating enzymes (DUBs) of which ca. 100 are 
described to date. They are divided into five classes (four cysteine protease classes and one 
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metallo-protease class) (Vucic, Dixit et al. 2011). It is not known whether all ubiquitinated 
substrates have a corresponding DUB. 
 
The target protein can be linked to one ubiquitin molecule (mono-ubiquitination) or several 
lysines of the target are bound to ubiquitin (multi-ubiquitination). Mono-ubiquitination plays a 
role in processes like DNA repair, gene silencing and vesicle sorting. Beyond that, ubiquitin 
possesses seven lysine residues itself (Lys6, Lys11, Lys27, Lys29, Lys33, Lys48, Lys63) 
which can be used to link ubiquitin molecules to chains (Deshaies and Joazeiro 2009). 
Binding of ubiquitin chains to one or more lysine residues of a substrate is called poly-
ubiquitination. These structures have different functions, e.g. Lys63 ubiquitin chains mediate 
protein interactions and linkage via Lys48 is a signal for proteasomal degradation. Current 
research also investigates ubiquitin chains using other lysines of ubiquitin, with more and new 
functions becoming evident.  
 
2.2.2.2 Proteasomal degradation  
The connection between ubiquitination and proteasomal degradation is called the ubiquitin-
proteasome system (UPS), depicted in Figure 2.4. The 26S proteasome consists of a 20S 
core particle which is capped either at one end or both ends by a 19S regulatory particle. The 
regulatory particle contains ubiquitin receptors recognizing the ubiquitinated substrate and 
initiates degradation. The core particle comprises deubiquitinating enzymes and ATPases to 
cleave ubiquitin chains and to unfold the substrate, finally leading to proteolysis of the 
substrate. The "discovery of ubiquitin-mediated protein degradation" was rewarded with a 




Figure 2.4: The ubiquitin-proteasome pathway.  
Ubiquitin (Ub) is transferred to E1 in an ATP-dependent manner, from there to E2 and then by E3 to 
the substrate. A poly-ubiquitin chain marks substrates for ATP-dependent degradation in the  
26S proteasome (taken from Nakayama and Nakayama 2006). 
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For research purposes, the proteasome can be blocked by inhibitors like MG132 (Lee and 
Goldberg 1998). This is a potent, reversible and cell-permeable proteasome inhibitor which 
reduces the degradation of ubiquitin-conjugated proteins. Treatment with MG132 has been 
shown to result in accumulation of ubiquitin chains linked by Lys6, Lys11, Lys27, Lys33, 
Lys48 and Lys63 in HeLa cells (Meierhofer, Wang et al. 2008).  
 
2.2.2.3 Ubiquitin ligases in the DDR to DNA DSBs 
Ubiquitination plays an essential role in DNA damage signaling. A prominent example is the 
DDR to DNA DSBs. After phosphorylation of H2AX, MDC1 binds to γH2AX (Stucki, 
Clapperton et al. 2005) and becomes phosphorylated by ATM. This enables the RING 
ubiquitin ligase RNF8 to bind MDC1 and to ubiquitinate proteins at the site of damage (Huen, 
Grant et al. 2007; Kolas, Chapman et al. 2007; Mailand, Bekker-Jensen et al. 2007). The 
group of Mailand et al. has shown that RNF8 can ubiquitinate histones H2A and H2AX. 
Another RING ligase, RNF168, is recruited which interacts with ubiquitinated H2A and 
amplifies Lys63-linked ubiquitin chains (Doil, Mailand et al. 2009). Ubiquitination events by 
RNF8 and RNF168 are required so that further signaling proteins are recruited or retained at 
the DSB, like 53BP1, BRCA1 and RAD18 (Lukas, Lukas et al. 2011). BRCA1 (breast cancer 
type 1 susceptibility protein) is an ubiquitin ligase with important functions in the cell (Huen, 
Sy et al. 2010). It promotes the DSB repair pathway of homologous recombination (HR) and 
is necessary for resection of DSBs. Furthermore, it contributes to the G2/M-checkpoint and is 
recruited to sites of replication problems, e.g. in response to inter-strand crosslinks (ICLs) 
during S-phase.  
 
2.2.2.4 The ubiquitin-dependent Fanconi anemia pathway 
If the DNA is impaired by inter-strand crosslinks (ICLs), the Fanconi anemia (FA) pathway is 
induced. FA is a rare genetic disorder which is characterized by genomic instability, increased 
predisposition to cancer and a defect in repairing ICLs. Cells from FA patients are 
hypersensitive to crosslinking agents like cisplatin and mitomycin C. Till today, 15 genes have 
been shown to result in FA if mutated (FANCA to FANCP). The proteins encoded by these 
genes participate in four different complexes. The key event of the FA pathway is yet again 
an ubiquitination event. At first, the recognition complex consisting of the helicase FANCM 
detects ICLs (Meetei, Medhurst et al. 2005; Ciccia, Ling et al. 2007). The core complex, 
composed of several FANC proteins including the RING E3 ligase FANCL, is responsible for 
the mono-ubiquitination of the FANCD2-FANCI-complex (Meetei, de Winter et al. 2003; 
Smogorzewska, Matsuoka et al. 2007). This complex interacts with BRCA2 (FANCD1) and 
other repair enzymes. In this way, ICLs are first recognized and excised by NER, followed by 
translesion synthesis and HR-mediated repair (Bergink and Jentsch 2009).  
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2.2.2.5 Examples of deubiquitinating enzymes in the DDR  
Besides ubiquitin ligases, several deubiquitinating enzymes (DUBs) play an essential role in 
DDR pathways. An important example is the ubiquitin-specific protease USP1 which 
deubiquitinates FANCD2 (Nijman, Huang et al. 2005). USP1 is also involved in translesion 
synthesis (TLS) since it deubiquitinates PCNA (Huang, Nijman et al. 2006). Further 
representatives of DUBs in the DDR include USP3, USP16, BRCC36 and POH1/PSMD14 
that comprise negative regulators of the RNF8-dependent response to DNA DSBs described 
above (Dong, Hakimi et al. 2003; Doil, Mailand et al. 2009; Shao, Lilli et al. 2009; Shanbhag, 
Rafalska-Metcalf et al. 2010; Butler, Densham et al. 2012). 
 
2.2.3 The DDR after cisplatin treatment 
Cisplatin treatment leads to crosslinking of DNA. This prevents separation of DNA strands 
during transcription and replication and thus activates various signaling and repair pathways. 
The components and mechanisms involved are incompletely understood. It is known that 
DNA crosslinks activate the FA pathway as specified above. Furthermore, inter-strand 
crosslinks result in stalled replication forks, leading to DNA SSBs which activate the ATR-
Chk1 pathway. During repair of these lesions, DNA DSBs are induced which activate the 
ATM-Chk2 pathway. Upon cisplatin treatment, H2AX phosphorylation is induced and well 
detectable. The repair pathways are again complex. Crosslinks are primarily repaired by 
nucleotide excision repair (NER) (Huang, Zamble et al. 1994; Zamble, Mu et al. 1996). Also, 
mismatch repair pathways (MMR) are involved which contribute to cisplatin-induced 
apoptosis (Fink, Nebel et al. 1996). Intra-strand and inter-strand crosslinks have been shown 
to be bypassed by translesion synthesis (TLS) polymerases. Repair of inter-strand crosslinks 
is conducted by a complex interplay of NER, followed by translesion synthesis and HR-
mediated repair (Bergink and Jentsch 2009; Ho and Scharer 2010; Vasquez 2010). 
 
 
2.3 Regulation of p53 and Mdm2 
2.3.1 Regulation and post-translational modification of the tumor suppressor 
p53 
The tumor suppressor p53 is often dysregulated in cancer, either by genomic loss or point 
mutation or by changes in signaling pathways upstream of p53. Its function is abrogated in 
more than 50 % of human tumors (Hollstein, Sidransky et al. 1991). Importantly, p53 decides 
on the cell’s fate. Under unstressed conditions, the transcription factor is kept at low levels. 
Upon stress like damaged DNA, p53 becomes post-translationally modified which inhibits its 
degradation and promotes stabilization and thus transcriptional activity. This leads to 
induction of genes involved in processes like cell cycle arrest, DNA repair and apoptosis 
(reviewed in Vousden 2006; Menendez, Inga et al. 2009). Functions of p53 are highlighted in 
more detail below (see sections 2.4.2 and 2.4.4).  
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P53 consists of a transactivation, SH3, DNA binding, tetramerisation and regulatory domain. 
Extensive research has revealed how p53 levels and function are controlled. Different 
regulators affect the stability and activity of p53 by means of post-translational modifications, 
protein-protein interactions and subcellular localization (reviewed in Lavin and Gueven 2006; 
Horn and Vousden 2007; Meek and Anderson 2009). Post-translational modifications of p53 
include phosphorylation, acetylation, methylation, neddylation, sumoylation and 
ubiquitination. Here, we will focus on the ubiquitin-dependent regulation of p53, especially by 
the ubiquitin ligase Mdm2. 
 
More than ten ubiquitin ligases are involved in p53 regulation. Both mono- and poly-
ubiquitination of p53 occur. The main negative regulator of p53 function and stability is the 
RING E3 ligase Mdm2 (also called Hdm2). Mdm2 and p53 interact at the N-terminal domain 
of p53 which inhibits transactivation of genes by p53 (Momand, Zambetti et al. 1992; Kussie, 
Gorina et al. 1996). In addition, Mdm2 mediates the proteasomal degradation of p53 (Haupt, 
Maya et al. 1997; Kubbutat, Jones et al. 1997). Interestingly, low levels of Mdm2 lead to 
mono-ubiquitination of p53 which permits nuclear export of p53, whereas higher levels of 
Mdm2 result in poly-ubiquitination and hence degradation of p53 (Lohrum, Woods et al. 2001; 
Li, Brooks et al. 2003). Since Mdm2 is a direct target gene of p53 (Barak, Juven et al. 1993; 
Juven, Barak et al. 1993; Wu, Bayle et al. 1993), a negative feedback loop exists which leads 
to inhibition of p53 activity in later stages of the DDR. The importance of the relationship 
between p53 and Mdm2 was shown by mdm2 null mice which are characterized by 
embryonic lethality. Remarkably, this lethality can be rescued by double-knockout of mdm2 
and p53 (Jones, Roe et al. 1995; Montes de Oca Luna, Wagner et al. 1995).  
 
Upon cellular stress, the interaction between p53 and Mdm2 is disrupted, so that p53 
becomes stabilized. This is achieved by different mechanisms like phosphorylation of p53 at 
Ser15 and Ser20 by ATM, ATR, DNA-PK, Chk1 and Chk2 upon cellular stress and DNA 
damage (Chehab, Malikzay et al. 1999; Tibbetts, Brumbaugh et al. 1999; Chehab, Malikzay 
et al. 2000; Hirao, Kong et al. 2000; Saito, Goodarzi et al. 2002). Other ways are acetylation 
of p53 or indirect mechanisms like binding of p14-ARF to Mdm2 which frees p53 from Mdm2 
(Honda and Yasuda 1999; Weber, Taylor et al. 1999). A summary of the p53-Mdm2 pathway 
is depicted in Figure 2.5.  
 




Figure 2.5: The p53-Mdm2 pathway.  
Upon genotoxic stress, induction of the DDR activates kinase cascades of the ATR-Chk1 and ATM-
Chk2 pathway which lead to phosphorylation of p53. Post-translational modification of p53 leads to 
disruption of the p53-Mdm2 interaction and leads to transcription of p53 target genes involved in cell 
cycle arrest (e.g. p21) and apoptosis (e.g. Puma and Noxa). The ubiquitin ligase Mdm2 is negatively 
regulating p53 transcription and promotes its degradation. Being a target gene of p53, it is part of a 
negative feedback loop. Mdm2 can be inhibited by p14-ARF (abbreviated to ARF), leading to p53 
stabilization (modified from Sherr 2006). 
 
 
It is well established that further ubiquitin ligases regulate p53 in a Mdm2-independent 
manner. This became obvious when it was shown that p53 is still degraded in mdm2-deficient 
mice (Ringshausen, O'Shea et al. 2006). Examples include the ubiquitin ligases Pirh2 and 
COP1 that have been shown to ubiquitinate p53, leading to its proteasomal degradation 
(Leng, Lin et al. 2003; Dornan, Wertz et al. 2004). CHIP (or STUB1) is a chaperone-
associated ubiquitin ligase that leads to poly-ubiquitination and proteasomal degradation of 
p53 (Esser, Scheffner et al. 2005). Interestingly, regulation of p53 by ubiquitination does not 
only lead to its degradation. For example, Msl2 was reported to poly-ubiquitinate p53, 
resulting in nuclear export of p53 (Kruse and Gu 2009).  
 
Besides ubiquitin ligases, also DUBs are regulating p53. The first to be identified was HAUSP 
(Herpesvirus-associated ubiquitin-specific protease or USP7) which deubiquitinates p53 and 
also regulates Mdm2 stability (Li, Chen et al. 2002; Li, Brooks et al. 2004). Further examples 
of DUBs that deubiquitinate p53 are USP42 and USP10 (Yuan, Luo et al. 2010; Hock, 
Vigneron et al. 2011). 
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2.3.2 The ubiquitin ligase Mdm2 
2.3.2.1 Regulation and post-translational modification of Mdm2 
Mdm2 is the main negative regulator of p53, but also exhibits p53-independent functions. Its 
domain structure including the N-terminal p53-binding domain and the C-terminal RING 
domain is depicted in Figure 2.6. Mdm2 is found as a heterodimer with Mdmx (also called 
Mdm4) (Sharp, Kratowicz et al. 1999; Tanimura, Ohtsuka et al. 1999). Both proteins have 
sequence homology and a RING domain. Mdmx does not have ubiquitin ligase activity 
towards p53, but can repress p53 transactivation activity (Stad, Ramos et al. 2000). Further 
studies suggest that Mdm2 and Mdmx have different functions and thus different effects on 
p53 activity. Mdm2 has been shown to be regulated by diverse proteins. As mentioned 
above, the nucleolar protein p14-ARF can bind Mdm2 and thus prevent Mdm2 from 
degrading p53. Further nucleolar proteins including the ribosomal proteins RPL5, RPL11 and 
RPL23 interact with and hence inactivate Mdm2 in response to nucleolar stress, thus freeing 




Figure 2.6: Domain structure of Mdm2.  
Domains: p53 binding, acidic domain, zinc finger domain, RING finger domain, NLS = nuclear 
localization signal, NES = nuclear export signal (taken from Lee and Gu 2010). 
 
 
Mdm2 is post-translationally modified by proteins including ubiquitin ligases and DUBs. 
Examples include the ubiquitin ligase RBBP6 (Retinoblastoma binding protein 6) which 
interacts with Mdm2 and enhances Mdm2-mediated ubiquitination and degradation of p53 
due to increased p53-Mdm2-affinity (Li, Deng et al. 2007). Mdm2 was shown to be 
deubiquitinated by USP2a, which specifically binds and deubiquitinates Mdm2, but not p53 
(Stevenson, Sparks et al. 2007). The deubiquitinating enzyme HAUSP not only 
deubiquitinates and stabilizes p53, but also stabilizes Mdm2 in a p53-independent manner 
(Cummins, Rago et al. 2004; Li, Brooks et al. 2004).  
 
Like p53, Mdm2 is also regulated during the DDR. It was reported to be degraded upon DNA 
damage  which leads to accumulation and thus activation of p53 (Stommel and Wahl 2004). 
There is some debate about the degradation of Mdm2. It was shown that Mdm2 can be 
degraded due to auto-ubiquitination (Stommel and Wahl 2004; Stommel and Wahl 2005), but 
it was also reported that auto-degradation is not the only mechanism. Using a mouse model 
with inactivated Mdm2 RING domain, it became evident that Mdm2 E3 ligase activity is not 
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necessary for its destruction (Itahana, Mao et al. 2007). Furthermore, a recent study 
demonstrated that Mdm2 becomes phosphorylated at multiple sites by casein kinase 1 (CK1) 
in a cell-cycle and DNA damage-dependent manner which leads to ubiquitination and 
destruction of Mdm2 via SCFβ-TRCP (Inuzuka, Tseng et al. 2010). Additionally, it was reported 
that upon ionizing radiation or treatment with a radiomimetic, ATM is not only involved in 
phosphorylation of p53, but also phosphorylates Mdm2 (Khosravi, Maya et al. 1999).  
 
2.3.2.2 Regulation of Mdm2 expression and Mdm2 isoforms 
Expression of Mdm2 is regulated by two promoters, (P1) and (P2), both encoding full-length 
Mdm2 protein (Saucedo, Myers et al. 1999). Interestingly, p53 stimulates the internal mdm2 
promoter (P2) leading to synthesis of RNA lacking the non-coding exon 1 (Juven, Barak et al. 
1993; Barak, Gottlieb et al. 1994). This transcript is more efficiently translated than the one 
from the (P1) promoter (Landers, Cassel et al. 1997) which explains why activated p53 leads 
to strong increase in Mdm2 levels. The negative feedback loop model argues that this 
mechanism finally allows recovering of normal p53 levels (Wu, Bayle et al. 1993; Chen, 
Oliner et al. 1994).  
 
When investigating Mdm2 protein expression, different isoforms can be detected. More than 
40 Mdm2 splice variants and various isoforms were identified in both normal tissues and 
tumors (Bartel, Taubert et al. 2002). Full-length Mdm2 at 97 kDa is often seen as two bands 
in Western blot, arguing for the existence of two isoforms. Also, lower bands at 60 kDa are 
often observed. The mechanisms and biological roles of Mdm2 isoforms are largely unknown. 
Additional Mdm2 proteins seem to exist due to differences in mRNA splicing and post-
translational modifications (Olson, Marechal et al. 1993). Also, initiation of translation has 
been reported from two separate internal AUG codons (Cheng and Cohen 2007). The same 
group showed that Mdm2 transcripts initiated from the p53-activated (P2) promoter are 
preferentially the 97 kDa isoform. This isoform seems to be responsible for p53 degradation 
(Cheng and Cohen 2007).  
 
2.3.2.3 p53-independent functions of Mdm2 
The importance of Mdm2 is obvious since it is the main regulator of the p53 tumor suppressor 
pathway and important in tumor development. The mdm2 gene is amplified in ca. 10 % of all 
human cancers (Momand, Jung et al. 1998). It is of note that besides its role in regulating 
p53, Mdm2 fulfills p53-independent tasks in the cell. Mdm2 was reported to interact with 
chromatin and chromatin-associated proteins and to affect gene expression and DNA repair. 
For example, it can promote genetic instability and transformation by induction of 
chromosomal breaks and a delay in repair of DNA DSBs by interaction with Nbs1, a 
component of the MRN complex (Bouska, Lushnikova et al. 2008). The MRN complex is 
involved in detection and processing of DSBs. Furthermore, Mdm2 affects proliferation, 
apoptosis and epithelial-to-mesenchymal transition (EMT). For instance, Mdm2 has been 
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shown to target E-cadherin for proteasomal degradation (Yang, Zong et al. 2006). E-cadherin 
plays an important role in EMT, the process important in development of metastases when 
epithelial cells gain migratory and invasive properties and become mesenchymal cells.  
These examples show that Mdm2 has broader influence on the cell beyond regulating the 
tumor suppressor p53. 
 
2.4 Consequences of DNA damage 
Whereas the previous sections have described DNA damage signaling pathways and the 
proteins involved, we now want to focus on the consequences for the cell. As already seen in 
Figure 2.2, damaged DNA signaling results in checkpoint activation and cell cycle regulation, 
finally leading to repair of the damage or cell death. These processes are mostly 
accompanied by changes in gene expression. Here, we want to introduce the processes of 
cell cycle regulation, DNA repair and apoptosis in more detail, but also point out that these 
mechanisms cannot be regarded as operating fully independently from each other. 
 
2.4.1 Cell cycle regulation 
Damaged DNA results in activation of cell cycle checkpoints via pathways like the ATM-Chk2 
and ATR-Chk1 pathway described above. Signal transduction thereby aims at proteins 
involved in cell cycle progression. Cells progressing through the cell cycle are tightly 
regulated by complexes consisting of cyclins and cyclin-dependent kinases (CDKs) as 
depicted in Figure 2.7. In G1-phase where cells increase in size and prepare for DNA 
synthesis, cyclin D complexes with CDK4 and CDK6. Cyclin E and CDK2 are activated in late 
G1-phase and trigger progression into S-phase where DNA is replicated. During S-phase, the 
cyclin A-CDK2/CDK1 complex stimulates chromosome duplication and stays stable till entry 
into mitosis. The cyclin B-CDK1 complex is important at the G2/M-checkpoint for entry into 
mitosis. In this time period between DNA synthesis and mitosis (or M-phase), cells grow and 
ensure that they can progress to the final cell division phase which results in two daughter 
cells. Many genes show a cell-cycle specific expression, for example the transcription factor 
E2F1 which is expressed in G1/S-phase and induces transcription of genes like cyclin E, 
cyclin A and DNA-polymerase. Also, there are S-phase specific genes coding for histones 
and components required for DNA polymerase, for example the processivity factor PCNA 
(proliferating cell nuclear antigen) (Prelich, Tan et al. 1987). Genes specifically expressed in 
G2/M-phase include cyclin B1, Cdc25C and PLK1 (Polo-like kinase1) (Sadhu, Reed et al. 
1990; Hamanaka, Smith et al. 1995; Lee, Yuan et al. 1995).  
 




Figure 2.7: Scheme of the mammalian cell cycle.  
In G1-phase, cyclin D complexes with CDK4 and CDK6. Cyclin E and CDK2 are activated in late  
G1-phase and trigger progression into S-phase. During S-phase, the cyclin A-CDK2/CDK1 complex 
forms and stays stable till entry into mitosis. The cyclin B-CDK1 complex is important at the  
G2/M-checkpoint for entry into mitosis. The cyclin D-CDK4/CDK6 and cyclin E-CDK2 complex 
phosphorylate retinoblastoma protein (RB), leading to release of the transcription factor E2F (modified 
from Abrous, Koehl et al. 2005). 
 
 
If DNA damage occurs, cell cycle checkpoints are activated that delay progression through 
the cell cycle and give time to repair damaged DNA or to induce apoptosis if irreparable. 
Commonly, three cell cycle checkpoints can be distinguished: the G1/S-, the Intra-S- and the 
G2/M-checkpoint. These checkpoints are introduced in the next section.  
 
2.4.2 Cell cycle checkpoints 
2.4.2.1 The G1/S-checkpoint 
The G1/S-checkpoint leads to cell cycle arrest prior to DNA synthesis in S-phase. The main 
regulator of this checkpoint is p53. It becomes stabilized upon DNA damage via the  
ATM-Chk2 and ATR-Chk1 pathway as described above, promoting transcriptional activation 
of target genes like p21 (el-Deiry, Tokino et al. 1993; Waldman, Kinzler et al. 1995). The 
cyclin-dependent kinase inhibitor p21 hinders the complexes cyclin D-CDK4 and cyclin E-
CDK2 which are necessary for entry into S-phase (Harper, Adami et al. 1993; Brugarolas, 
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Chandrasekaran et al. 1995). Inhibition of CDKs influences the RB/E2F1-complex as 
depicted in Figure 2.8. The transcription factor E2F1 is inactive when bound to hypo-
phosphorylated RB (retinoblastoma protein). If RB is phosphorylated by CDKs, binding to 
E2F1 is reduced and gene expression activated. Thus, the CDK-inhibitor p21 represses E2F1 
activity which is important for maintenance of the checkpoint. Furthermore, p21 promotes  
G1-arrest by binding PCNA and thus inhibits its function during replication (Moldovan, 
Pfander et al. 2007). Progression to S-phase following G1-arrest is achieved by degradation 
of p21 (Gottifredi, McKinney et al. 2004).  
Apart from that, also p53-independent mechanisms have been described to play a role at the 





Figure 2.8: Mechanism of G1-arrest mediated by p53 and p21.  
Activation of p53 induces p21 expression. The cyclin-dependent kinase inhibitor p21 prevents 
phosphorylation of RB by inhibiting CDK4 and CDK2. This prevents RB from de-repressing E2F1, 
inhibiting E2F1 transcriptional activity, causing a G1-arrest.  
 
2.4.2.2 The Intra-S-checkpoint 
The intra-S-checkpoint plays an important role in regulation of DNA replication. Upon 
genotoxic stress, it inhibits firing from origins of replication which have not been initiated 
(Kastan and Bartek 2004). Regulation is accomplished by ATM and ATR signaling and leads 
to inhibition of CDK1 and CDK2 (Bartek and Lukas 2003; Hochegger, Dejsuphong et al. 
2007). One of the main mechanisms consists in the proteasomal degradation of the 
phosphatase Cdc25A which results in inhibition of the cyclin E/A-CDK2 complex since 
CDK2’s inhibitory phosphorylation is not removed (Mailand, Falck et al. 2000; Falck, Mailand 
et al. 2001).  
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2.4.2.3 The G2/M-checkpoint 
If damage occurs prior to mitosis, cells are arrested at the G2/M-checkpoint. Remarkably, p53 
and p21 are again required to maintain the G2-arrest (Bunz 1998; Taylor and Stark 2001). 
P53 is able to block CDK1 (also called Cdc2). The mechanism of CDK1 inhibition involves 
three transcriptional targets of p53, namely GADD45, p21 and 14-3-3-sigma (Chan, 
Hermeking et al. 1999; Wang, Zhan et al. 1999). Whereas p21 can inhibit CDK1 directly,  
14-3-3-sigma leads to localization of CDK1 in the cytoplasm which prevents its role during 
mitosis (Taylor and Stark 2001). In addition, GADD45 causes dissociation of CDK1 from 
cyclin B (Zhan, Antinore et al. 1999). Furthermore, p53 represses the cyclin B1 and cdc2 
gene. However, p53-independent mechanisms also exist. For example, activation of the 
ATM-Chk2 and ATR-Chk1 pathways results in inhibition of CDK1. This is conducted by Chk1 
and Chk2 through phosphorylation and hence inactivation of the phosphatase Cdc25 that 
usually activates CDK1 (Furnari, Rhind et al. 1997; Sanchez, Wong et al. 1997; Chaturvedi, 
Eng et al. 1999).  
It is generally accepted that multiple p53-dependent and p53-independent pathways regulate 
the G2/M-checkpoint in response to genotoxic stress. 
 
Some scientists define a forth checkpoint in the middle of mitosis, called metaphase 
checkpoint. This checkpoint is necessary to guarantee that the cell is ready to complete cell 
division. 
 
2.4.3 DNA repair 
If cells encounter DNA lesions, a complex system of repair mechanisms is applied. Since we 
did not investigate repair processes in more detail, we only briefly summarize them here 
(Bergink and Jentsch 2009; Jackson and Durocher 2013): DNA DSBs are repaired by 
homologous recombination (HR) or non-homologous end joining (NHEJ). Repair of simple 
base lesions is conducted by base-excision repair (BER). Bulky DNA adducts or UV-induced 
DNA lesions are repaired by nucleotide excision repair (NER). DNA crosslinks are repaired 
by proteins of the Fanconi anemia (FA) pathway, by NER and by HR, while mismatch repair 
(MMR) corrects for DNA base mismatches. If replication continues despite present lesions, 
the DNA-damage-tolerance pathway of postreplication repair (PRR) is employed. PRR can 
be carried out either as translesion synthesis (TLS) or as a mechanism involving a template-
switch combined with HR. 
 
2.4.4 Induction of Apoptosis 
If cells exhibit irreparably damaged DNA, a form of programmed cell death called apoptosis is 
initiated (reviewed in Taylor, Cullen et al. 2008). During apoptosis, cells decrease in size, 
their cytoskeleton is destructed and chromatin condenses and becomes fragmented. Often, 
these cells are disrupted into apoptotic bodies, i.e. membrane-enclosed fragments. Induction 
of apoptosis leads to activation of caspases (cysteine-dependent aspartate-directed 
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proteases). They exist as inactive precursor molecules (procaspases) and are activated by 
proteolytic cleavage of other (active) caspases. This proteolytic activation of caspases results 
in an irreversible cascade divided into initiator and executioner caspases. Initiator caspases 
start the proteolytic cascade and activate executioner caspases which cleave specific 
proteins in the cell like nuclear lamins, cell-cell adhesion molecules and proteins that lead to 
activation of endonucleases to break down DNA. Initiator caspases contain so-called caspase 
recruitment domains (CARD) which are needed to bind to adaptor proteins. Thus, 
procaspases are in close proximity and activate and cleave each other. The caspase cascade 
can be triggered in two ways as detailed below and depicted in Figure 2.9. 
  
2.4.4.1 Extrinsic pathway 
During the extrinsic apoptosis pathway, extracellular ligands bind death receptors, 
transmembrane proteins found on the cell surface (reviewed in Taylor, Cullen et al. 2008). 
Death receptors belong to the tumor necrosis factor (TNF) receptor family. Signal proteins 
that bind death receptors are for example TNF and Fas. Death receptors contain intracellular 
death domains which recruit further adaptor proteins to assemble initiator procaspases in a 
death-inducing signaling complex (DISC). In the case of the Fas ligand, procaspases 8, 10 or 
both are recruited. These initiator caspases then activate executioner procaspases, i.e. firstly 
caspase 3 which then cleaves and activates caspases 6 and 7. This caspase cascade finally 
results in cleavage of target proteins to promote the apoptotic process. 
 
2.4.4.2 Intrinsic pathway 
If cells encounter stress inside the cell, for instance DNA damage or lack of nutrients, they 
initiate the intrinsic apoptosis pathway (reviewed in Taylor, Cullen et al. 2008). This is 
characterized by release of mitochondrial proteins into the cytoplasm, some of which activate 
the caspase cascade. The intrinsic pathway is highly regulated by Bcl-2 family proteins. 
Whereas some are pro-apoptotic (like Bax, Bak), some are anti-apoptotic (like Bcl-2, Bcl-XL). 
These pro- and anti-apoptotic Bcl-2 proteins can form different combinations of heterodimers 
resulting in their mutual inhibition. Upon apoptotic stimulation, this inhibition is abrogated, 
leading to activation and oligomerization of the proapoptotic proteins Bax and Bak. This 
results in mitochondrial outer membrane permeabilization (MOMP) (Letai, Bassik et al. 2002; 
Kuwana, Bouchier-Hayes et al. 2005). The process of pore formation at the outer 
mitochondrial membrane enables release of cytochrome c into the cytoplasm. Cytochrome c 
binds the adaptor protein APAF1 (apoptotic protease activating factor 1) which oligomerizes 
into the heptameric apoptosome. As a consequence, initiator procaspases 9 are recruited 
and activated due to their proximity at the apoptosome, followed by activation of executioner 
procaspases. The resulting down-stream caspase cascade resembles the one induced by the 
extrinsic pathway, i.e. caspase 3 can be activated not only by caspase 8 and 10 (extrinsic 
pathway), but also by caspase 9 (intrinsic pathway), leading to activation of further caspases.  
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A characteristic of apoptosis lies in the cleavage of PARP-1 (poly(ADP-ribose) polymerase-1) 
by caspase 3 (Kaufmann, Desnoyers et al. 1993; Lazebnik, Kaufmann et al. 1994). PARP-1 
is a nuclear enzyme with an important role in DNA repair. Upon cleavage (by caspase 3, but 
also by caspase 7), its recruitment to sites of DNA damage is prevented. Cleaved caspase 3 
and cleaved PARP-1 are valuable markers of apoptosis which we used for immunoblotting.  
 
In order to amplify the caspase cascade, the extrinsic pathway sometimes leads to activation 
of the intrinsic pathway. This is mediated by activating a Bcl-2 family member called Bid. After 
the extrinsic pathway is activated via death receptors, caspase 8 cleaves Bid, resulting in a 
truncated molecule named tBid. tBid can inhibit anti-apoptotic Bcl-2 proteins at mitochondria 
and triggers assembly of pro-apoptotic proteins which results in cytochrome c release. In this 
way, the signal arising from the extrinsic pathway is amplified by combining it with the intrinsic 




Figure 2.9: Simplified scheme of apoptosis pathways in the cell.  
Depicted is the extrinsic and intrinsic apoptosis pathway. For details see text (taken from Ruwanpura, 
McLachlan et al. 2010). FADD = Fas-Associated protein with Death Domain. 
 
2.4.4.3 The role of p53 in apoptosis 
The tumor suppressor p53 performs important tasks during apoptosis, mainly via the 
mitochondrial pathway. After p53 stabilization and activation, it transactivates pro-apoptotic 
genes like Puma, Noxa and Bid, but can also repress anti-apoptotic genes like Bcl-2 and 
survivin (Moll, Marchenko et al. 2006). Puma (abbreviation for p53 upregulated modulator of 
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apoptosis) was shown to interact with anti-apoptotic Bcl-2 proteins, resulting in release of Bax 
and Bak to promote apoptosis (Nakano and Vousden 2001; Willis, Fletcher et al. 2007). 
Whether there is a direct interaction or an indirect mechanism between Puma and Bax and 
Bak is still in debate. Besides its role as a transcription factor, p53 interacts with Bcl family 
members like Bcl-XL and Bcl-2 and stimulates oligomerization of the proapoptotic proteins 
Bax and Bak (Mihara, Erster et al. 2003; Chipuk, Kuwana et al. 2004; Tomita, Marchenko et 
al. 2006).  
 
2.4.4.4 Ubiquitination in apoptotic pathways 
Several ubiquitin ligases and DUBs have been shown to play an important role in apoptosis. 
These include Mdm2 (by regulating p53) and inhibitor of apoptosis (IAP) proteins. 
Furthermore, ubiquitin ligase complexes have significant impact on regulation of apoptosis. 
For instance, the multi-subunit ubiquitin ligase SCFβ-TRCP is an important regulator of 
apoptosis with substrates like procaspase 3, p53 and the p53 family member p63 (Tan, 
Gallegos et al. 2006; Gallegos, Litersky et al. 2008; Xia, Padre et al. 2009). Besides ubiquitin 
ligases, DUBs are involved in apoptosis regulation, for example HAUSP (USP7), TNFAIP3 
and CYLD (Vucic, Dixit et al. 2011). 
 
2.4.5 Feedback mechanisms between DDR, cell cycle regulation and apoptosis 
pathways 
It is a well-known fact that pathways regulating DDR, cell cycle and apoptosis cannot be 
regarded as separated, but often as interdependent. An obvious example is that induction of 
the DDR can lead to apoptosis if damaged DNA is irreparable. On the other hand, induction 
of apoptosis via the extrinsic pathway, i.e. by binding of an extracellular ligand, finally results 
in activation of endonucleases that break down DNA and thus elicit a DDR to DNA breaks.  
In fact, proteins have been described to be involved in both DDR and apoptosis. The 
mechanisms which decide whether a cell conducts DNA repair or goes into apoptosis are not 
well understood. One crucial issue is the localization of proteins that influences their function. 
Another aspect, especially applying to ubiquitin ligases and DUBs, concerns the knowledge 
that enzymes can have different substrates, depending on the pathways involved. Still, open 
questions remain of how decisions are made in the cell.  
 
2.5 The ubiquitin ligase G2E3 
We performed a high-content siRNA screen to identify new regulators in the DNA damage 
response to cisplatin. As detailed in the results section, we studied the ubiquitin ligase G2E3 
in more detail.  
 
G2E3 was originally identified in a global gene expressing profiling with the GenBank 
reference KIAA1333 when Crawford et al. investigated transcriptional control of gene 
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expression in G2/M-phase (Crawford and Piwnica-Worms 2001). Additionally, they studied 
gene expression after DNA damage treatment using γ-irradiation. The authors conducted a 
microarray analysis of HeLa cells after double thymidine block and identified genes with 
maximal expression in G2- and M-phase. Interestingly, many of these genes were down-
regulated in response to γ-irradiation. One of the genes showing a maximal mRNA 
expression in G2/M-phase and decreased mRNA levels upon γ-irradiation was G2E3 (G2-
specific E3 ligase). 
 
2.5.1 Domains and ubiquitin ligase activity of G2E3  
G2E3 was proposed to have ubiquitin ligase activity since it consists of four domains that can 
act as E3 ligases. Three of these domains have similarity to both RING and PHD domains 
and the fourth C-terminal domain is a HECT domain (Figure 2.10). Domain structures were 
identified by Brooks et al. using SMART and PFAM (Brooks, Banerjee et al. 2007). It was 
shown that HECT is catalytically inactive, but controls subcellular localization of G2E3 
(Brooks, Helton et al. 2008). Reasons for lack of activity of the HECT domain are numerous: 
not matching amino acids in the E2 binding site and at the C-terminus of the HECT domain 
and poorly conserved residues surrounding the active site. Using an in vitro ubiquitination 
assay, PHD/RING2 and PHD/RING3 domain have been reported to possess ubiquitin ligase 
activity and to catalyze Lys48-linked poly-ubiquitination (Brooks, Helton et al. 2008). The 
authors tested seven out of 35 known E2 ubiquitin-conjugating enzymes and detected high 
reactivity with UbcH5a. Naturally, they cannot exclude that PHD/RING1 and HECT domain 
have in vivo ubiquitin ligase activity, perhaps with other E2 enzymes. Furthermore, they 
provide evidence that G2E3 is auto-ubiquitinated in an in vitro assay. Thus, G2E3 has 




Figure 2.10: Domain structure of G2E3.  
The scheme shows three domains with homology to both PHD and RING domain as well as a  
C-terminal HECT domain. The HECT domain is catalytically inactive, but controls subcellular 
localization of G2E3. PHD/RING2 and PHD/RING3 domain have been reported to possess ubiquitin 
ligase activity and to catalyze Lys48-linked poly-ubiquitination in an in vitro ubiquitination assay 
(taken from Brooks, Helton et al. 2008). 
 
2.5.2 Localization of G2E3  
It was reported by Brooks et al. that overexpressed GFP-G2E3 localizes to the nucleus of 
different cell types (including Cos-7, SiHa and BSC-40 cells). It was found in the nucleoli of 
HeLa cells and relocalizing to the nucleoplasm in response to DNA damage (γ-irradiation, 
doxorubicin and etoposide treatment) in this cell line (Brooks, Banerjee et al. 2007). The 
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authors state that GFP-G2E3 is not nuclear in primary WI-38 fibroblasts, the only non-
transformed cell line they examined. Transformed cells harbor differing characteristics which 
could account for the difference. Certainly, different localization can implicate different protein 
functions. Furthermore, the authors report that G2E3 is exported from the nucleus of Cos-7 
cells in a CRM1-independent manner (Brooks, Banerjee et al. 2007). CRM1 (exportin 1) is 
the major transport receptor for export of proteins out of the nucleus. 
 
2.5.3 G2E3 is repressed by p53 
The large intergenic noncoding RNA lincRNA-p21 was described to be a p53 target in 
response to DNA damage (Huarte, Guttman et al. 2010). Expression of lincRNA-p21 was 
shown to repress and activate different genes involved in apoptosis and cell cycle arrest. 
Besides many other genes, it was reported that p53 represses G2E3 expression via lincRNA-
p21. Gene repression via lincRNA-p21 is mediated by interaction with hnRNP-K 
(heterogeneous nuclear ribonucleoprotein K) which had been shown before to interact with 
repressive complexes. Huarte et al. show that hnRNP-K binds to the promoters of genes that 
are normally repressed in a p53- and lincRNA-p21-dependent fashion.  
 
2.5.4 Inactivation of G2E3 in mice and of its ortholog pie in Drosophila  
It was reported that G2E3 is essential for early embryonic development since G2E3 knock-
out mice display early embryonic lethality due to strong apoptosis of the blastocysts (Brooks, 
Helton et al. 2008). Heterozygous mice are phenotypically normal with no detectable changes 
in growth, viability, fertility or development. Using β-galactosidase as a marker under the 
control of the endogenous G2E3 promoter, the authors investigated protein expression in 
heterozygous mice. They show prevalent G2E3 expression within the central nervous system 
and during limb bud formation in the developing embryo (Brooks, Helton et al. 2008). In adult 
mice, β-galactosidase expression was enriched in brain (Purkinje cells of the cerebellum) and 
testis (interstitial cells and cells lining the ductus deferens). 
 
Remarkably, a G2E3 ortholog exists in Drosophila, called pineapple eye (pie) (Shi, Stampas 
et al. 2003; Brooks, Helton et al. 2008). The RING/PHD domain of both proteins is highly 
conserved. It was reported that like G2E3 pie is required for cell survival. Shi et al. 
investigated the adult eye phenotype and found that inactivation of pie leads to increased 
apoptosis (Shi, Stampas et al. 2003). However, the authors could not identify the molecular 
and biochemical function of pie. A recent publication reports that lack of pie does not result in 
apoptosis in germline stem cells (GSCs) of the Drosophila ovary (Xing, Kurtz et al. 2012). In 
this study, GSCs were used as a model to study adult stem cell renewal and pie was 
identified to be required for GSC self-renewing. As ubiquitin ligases often have different 
substrates and different functions, it is possible that pie exerts different functions depending 
on the cell type. More research is needed to elucidate the role of pie in Drosophila. 
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Taken together, these results suggest that the ubiquitin ligase G2E3 could play a role in cell 
cycle regulation and in the DDR. Furthermore, G2E3 is important for cell survival.  
 
2.6 Scope of the thesis 
Despite detailed insights into the cellular response to damaged DNA and the consequences, 
it is not surprising that open questions remain. For example, it has been shown how the 
chemotherapeutic cisplatin induces crosslinking of DNA. However, the cellular and molecular 
mechanisms of subsequently activated signaling and repair pathways are incompletely 
understood. Thus, identifying new proteins that regulate the DDR to cisplatin would help us to 
understand activated pathways in more detail. Since ubiquitination plays a major role in the 
DDR, we applied a high-content siRNA screen targeting human ubiquitin ligases and DUBs to 
find new regulators in the DDR to cisplatin. We thereby detected phosphorylation of the 
histone variant H2AX (yielding γH2AX), a marker for DNA damage. We identified a multitude 
of known and unknown regulators of the DDR to cisplatin. Knockdown of one of the 
candidates, the ubiquitin ligase G2E3, led to decrease in γH2AX levels upon cisplatin 
treatment. G2E3 had previously been proposed to play a role in the DDR and in cell survival. 
However, little was known about the underlying mechanisms. Therefore, the present work 
aimed at understanding how G2E3 is involved in the cellular response to DNA damage. The 
work presented here suggests that G2E3 is a DNA damage-responsive, cell cycle-dependent 
survival factor. We found that G2E3 mRNA and protein levels are down-regulated upon DNA 
damage. Knockdown of G2E3 resulted in p53-independent apoptosis and decreased 
proliferation in colon carcinoma and osteosarcoma cell lines. Furthermore, we verified that 
G2E3 levels are maximal in G2-phase, suggesting a cell cycle-dependent regulation of G2E3.  
In summary, our results suggest that G2E3 is a modulator of cell proliferation, survival and 
the DDR whose loss may contribute to apoptosis upon DNA damage.  
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3 Materials 
 
3.1 Technical devices 
 
Table 3.1: Technical devices  
 
Device Company 
Automated Cell Counter Countess® Invitrogen, Life Technologies 
Biomek 2000 Laboratory Automation 
Workstation 
Beckman Coulter 
Blotting chamber  Biozym 
Cell counting chamber Neubauer improved Brand 
Centrifuge 5415R Eppendorf 
Centrifuge 5810R Eppendorf 
Centrifuge Megafuge 1.0R Heraeus, Thermo Scientific 
Chemiluminescence imager Chemocam HR 
16 3200 
Intas Science Imaging Instruments 
Cytometer Celigo Cyntellect 
DNA gel chamber Biotech Service Blu 
Electrophoresis system for SDS-PAGE Amersham Biosciences, GE Healthcare 
Electroporator GenePulser II Bio-Rad Laboratories 
FACS machine EasyCyte plus Guava Technologies, Millipore 
Foil swelding machine Vacupack plus Krups 
Freezer -20 °C Liebherr 
Freezer -80 °C Heraeus, Thermo Scientific 
Heating Block Grant Instruments 
Heating Block HLC HLC Biotech 
Ice-machine B100 Ziegra 
Incubator for bacteria Memmert 
Incubator for bacteria Minitron Infors HT 
Incubator for cell culture Hera Cell 150 Heraeus, Thermo Scientific 
Laminar flow cabinet Hera Safe Heraeus, Thermo Scientific 
Liquid nitrogen tank LS 4800 Taylor-Wharton 
Luminometer DLReady™ Centro LB 960 Bertold Technologies 
Magnetic stirrer MR3001 Heidolph 
Microscope Axovert 40C Zeiss 
Microscope Axioscope 2 Plus  
Microscope, automated Pathway 855 Becton Dickinson 
Microwave  Cinex 
Mini Centrifuge MCF-2360 LMS 
PCR machine for qPCR CFX96, C1000 Bio-Rad Laboratories 
PCR machine Primus 25 advanced Peqlab 
pH-meter WTW-720 WTW 
Pipet Multipette Eppendorf 
Pipet, electric Portable-XP Drummond 
Pipets Eppendorf Research Series 2100 
(0.1-2.5μL; 0.5-10μL; 10-100μL; 100-
1000μL) 
Eppendorf 
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Pipette, multichannel Research Plus Eppendorf 
Power supply unit Powerpack P25T Biometra 
Refrigerator 4°C Liebherr 
Roller RM5 V-30 CAT 
Rotating wheel Test-tube rotator 34528 Snijders 
Rotator PTR 300 Grant Instruments 
Scales Acculab ALC-6100.1 Sartorius 
Scales LE623S Sartorius 
Scanner CanoScan 8600F Canon 
Sequencer, automated ABI 3100 Applied Biosystems, Life Technologies 
Shaker PROMAX 2020 Heidolph 
Sonication device Bioruptor Diagenode 
Spectrophotometer NanoDrop ND-1000 PeqLab 
Thermomixer comfort Eppendorf 
UV-transilluminator Intas UV system Gel 
Jet Imager 
Intas Science Imaging Instruments 
Vacuum pump IBS Integra Biosciences 
Vortex Genie 2 Scientific Industries 




Table 3.2: Consumables 
 
Product Company 
96-well plates for flow cytometry Becton Dickinson 
96-well plates for microscopy, clear bottom Becton Dickinson 
96-well plates for microscopy, clear bottom Corning 
96-well plates for qPCR 4titude 
96-well plates OptiplateTM 96 for luciferase assay Perkin Elmer 
Bacteria culture dishes Sarstedt 
Bacteria culture vials (14 cm) Becton Dickinson 
Cell culture dishes (10 cm, 15 cm) Greiner 
Cell culture plates (6-well, 12-well) Greiner 
Cell scraper (16 cm, 25 cm) Sarstedt 
Cryo tubes Cryoline Nunc, Thermo Scientific 
Electroporation cuvette Gene Pulser Bio-Rad Laboratories 
Filter tips (10 µl) Starlab 
Filter tips (20 µl, 200 µl, 1,000 µl) Sarstedt 
Parafilm Brand 
Pipet tips (10 µl, 20-200 µl, 1,000 µl) Greiner 
Pipet tips for screen (50 µl, 200 µl) Beckman Coulter 
Protran nitrocellulose transfer membrane Whatman 
Reaction tube (0.2 ml) Sarstedt 
Reaction tube (0.5 ml, 1.5 ml, 2.0 ml) Eppendorf 
Reaction tube (15 ml, 50 ml) Greiner 
Reservoir Beckman Coulter 
Reservoir (divided by length) Beckman Coulter 
Safe-lock reaction tube (1.5 ml) Eppendorf 
Sealing foil for 96-well plate Becton Dickinson 
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Sterile filter Millipore, Merck 
Syringe Henke-Sass 
Syringe cannula (different sizes) B.Braun 
Transparent sealing foil for 96-well plate 4titude 
Whatman paper Whatman 
 
3.3 Chemicals and reagents 
 
Table 3.3: Chemicals and reagents 
 
Substance Company 
Acetic acid Roth 
Acrylamide/bisacrylamide (A/BA) Roth 
Adenosin triphosphate (ATP) Fermentas, Thermo Scientific 
Agar Sigma-Aldrich 
Agarose Roth 
Albumin Fraction V (Bovine Serum Albumine, BSA) Roth 
Ammonium persulfate (APS) Roth 
Ammonium sulfate ((NH4)2SO4) Roth 
Ampicillin AppliChem 
Aprotinin AppliChem 
Bromophenol blue Sigma-Aldrich 
Calcium chloride dihydrate (CaCl2 x 2H2O) Roth 
Chloroform Roth 
Complete Mini, EDTA-free Protease Inhibitor Mix Roche 
Coelenterazine Promega 
Coenzyme A sodium salt hydrate Sigmal-Aldrich 
Dimethyl sulfoxide (DMSO) AppliChem 
Dithiotreitol (DTT) Sigma-Aldrich 
D-Luciferin ICN 
DNA ladder GeneRuler Fermentas, Thermo Scientific 
Deoxyribonucleotide triphosphates (dNTPs) Bio-Budget 
Deoxyribonucleotide triphosphates (dNTPs) in 
single tubes 
Primetech 
Dipotassium phosphate (K2HPO4) Roth 
Dithiothreitol (DTT) Roth 
DNA stain clear G (39804) Serva 
Ethanol 99.8% Roth 
Ethanol 99.9% p.a. (EtOH) Merck 
Ethylene diamine tetraacetatic acid (EDTA) Roth 
Ethylene glycol tetraacetic acid (EGTA) Roth 
Fetal calf serum HyClone Thermo Scientific 
Formaldehyde, 37% solution Roth 
Glycerol Roth 
Glycine Roth 
Glycogen blue Ambion, Life Technologies 
Glycylglycine AppliChem 
Guava ICF Cleaning Solution Millipore, Merck 
HEPES Roth 
Hi-Di Formamide Applied Biosystems, Life Technologies 
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Hoechst 33342 Invitrogen, Life Technologies 
Hydrogen chloride (HCl) Roth 
Isoamyl alcohol Roth 
Isopropanol Th. Geyer 
Kanamycin sulfate AppliChem 
Leupeptin Hemisulfat AppliChem 
Lipofectamine™ 2000 (LF2000) Invitrogen, Life Technologies 
Magnesium chloride (MgCl2) for PCR Fermentas, Thermo Scientific 
Magnesium chloride hexahydrate (MgCl2 x 6H2O) Roth 
Magnesium sulfate (MgSO4) AppliChem 
Methanol >99% (MetOH) Roth 
N-ethylmaleimide (04260) Fluka  
Nonidet P-40 substitute (NP-40) Sigma Aldrich 
Nuclease free water Ambion, Life Technologies 
Page Ruler™ Prestained Protein Ladder Fermentas, Thermo Scientific 
Passive Lysis Buffer (E1941) Promega 
Pefabloc SC protease inhibitor Roth 
Pepstatin A AppliChem 
Ponceau S Roth 
Potassium chloride (KCl) Roth 
Potassium hydrogenphosphate (KH2PO4) Roth 
Powdered milk Roth 
Propidium iodide (PI) Sigma-Aldrich 
Protein A Sepharose (PAS) Invitrogen, Life Technologies 
Protein G Sepharose (PGS) GE Healthcare 
RNase inhibitor Fermentas, Thermo Scientific 
Roti-Phenol Roth 
Rotiphorese Gel 30 Roth 
Sodium acetate (NaAc) Roth 
Sodium azide (NaN3) AppliChem 
Sodium bicarbonate (NaHCO3) Roth 
Sodium chloride (NaCl) Roth 
Sodium deoxycholate AppliChem 
Sodium dodecyl sulfate (SDS) Roth 
Sodium hydrogenphosphate heptahydrate 
(Na2HPO4 x 7H2O) 
Roth 
Sodium hydroxide (NaOH) Sigma-Aldrich 
Sucrose Sigma-Aldrich 
SYBR Green Invitrogen, Life Technologies 
Tetracycline Sigma-Aldrich 
Tetramethylethylenediamine (TEMED) Roth 
Thymidine Sigma-Aldrich 
Trasylol Bayer, Leverkusen 
Trehalose Sigma-Aldrich 
TRIS Tris(hydroxymethyl)aminomethane 
Trisamine (Tris) Roth 
Triton X-100 Applichem 
Trizol Invitrogen, Life Technologies 
Tween 20 Applichem 
Yeast extract Sigma-Aldrich 
β-Mercaptoethanol Roth 
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3.4 Buffers and Solutions 
 
 
RIPA lysis buffer, pH 7.5 
Triton X-100 1.0 % 
Sodium deoxycholate 1.0 % 
SDS 0.1 % 
NaCl 150 mM 
EDTA 10 mM 
Tris-HCl, pH 7.5 20 mM 
Trasylol 50,000 KIU 
dissolved in H2O 
 
Cell lysis buffer 
Urea 2 M 
RIPA lysis buffer 100% 
protease inhibitors:  
Pefabloc 10 µM 
Pepstatin A 1 µg/ml 
Leupeptin/Aprotinin 1 µg/ml 
 
Laemmli buffer, 6x 
Tris pH 6.8 0.35 M 
Glycerin 30.00 % 
SDS 10.00 % 
Dithiotreitol 9.30 % 
Bromophenol blue 0.02 % 
dissolved in H2O 
 
Ponceau S solution  
Ponceau S 0.5 % 
Acetic acid 1.0 % 
dissolved in H2O 
 
10x Phosphate buffered saline 
(PBS), pH 7.5 
NaCl 240.0 mM 
KCl 2.7 mM 
Na2HPO4 x 7H2O 8.1 mM 
KH2PO4 1.5 mM 
dissolved in H2O 
 
CoIP buffer 
Tris-HCl, pH 7.5 50 mM 
Sodium chloride 300 mM 
NP-40 1 % 
Sodium deoxycholate 0.1% 
Complete Mini, 
Protease Inhibitor Mix 
1 tablet 
dissolved in H2O 
 
SDS running buffer 
Tris 25.0 mM 
Glycin 86.1 mM 
SDS 3.5 mM 
dissolved in H2O 
 
Tris buffered saline + Tween 20 
(TBST), pH 7.6 
Tris 50 mM 
NaCl 150 mM 
Tween 20 0.1 % 
dissolved in H2O 
 
Western blot blocking solution 
Milk powder 5 % 
dissolved in TBST 
 
Western blot blocking solution for 
phospho-antibodies 
BSA 5 % 
dissolved in TBST 
 
10x Western Salt buffer, pH 8.3 
Tris 250 mM 
Glycin 1,92 M 
SDS 0.02 % 
dissolved in H2O 
 
Western blot transfer buffer, pH 8.3 
10x Western Salt buffer 10 % 
MetOH 20 % 
dissolved in H2O 
 
Firefly Buffer 
Glycylglycine 25 mM 
K2HPO4 15 mM 
EGTA pH 8.0 4 mM 
dissolved in H2O 
 
Renilla Buffer 
NaCl 1,1 M 
Na2EDTA 2.2 mM 
K2HPO4  pH 5.1 0.22 M 
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DNA gel loading buffer, 6x 
Sucrose 40 % 
Glycerin 10 % 
Bromophenol blue 0.25 % 
dissolved in H2O 
 
TAE buffer 
Tris  40 mM 
Acetic acid 20 mM 
EDTA 2 mM 
dissolved in H2O 
 
IF blocking solution 
FCS 5 % 
Triton X-100 0.1 % 
dissolved in PBS 
 
qPCR reaction mix 
10x qPCR reaction buffer 10 % 
SYBR Green 1:80,000 
MgCl2 3 mM 
Trehalose in 10 mM Tris, 
pH 8,5 
300 mM 
dNTPs 0.2 mM 
Triton X-100 0.25 % 
Taq polymerase 20 U/ml 
dissolved in H2O 
(shock-frozen in liquid nitrogen and  
kept at -20 °C) 
Luciferase Assay Reagent ‘Firefly’ 
MgSO4   15 mM 
ATP pH 7.0 4 mM 
Dithiothreitol 1.25 mM 
Coenzyme A 0.1 mM 
Luciferin 80 µM 
dissolved in Firefly buffer 
 
Luciferase Assay Reagent ‘Renilla’ 
BSA 0.5 mg/ml 
NaN3 1.5 mM 
Coelenterazine 1.5 µM 
dissolved in Renilla buffer 
 
qPCR reaction buffer, 10x 
Tris-HCl, pH 8,8 750 mM 
(NH4)2SO4 200 mM 
Tween 20 0.1% 




3.5 Chemotherapeutics and pharmacological inhibitors 
 
Table 3.4: Chemotherapeutics 
Name Systematic name Company 
Cisplatin cis-diammine-dichloroplatinum (II) Cis-Gry, Teva Deutschland 
Neocarzinostatin (NCS)  Sigma-Aldrich, #N9162 
 
 
Table 3.5: Inhibitors 
Name Target Company 
N-ethylmaleimide DUBs Fluka, #04260 
Nutlin-3 Mdm2 Sigma-Aldrich,#N6287 
MG132 Proteasome Calbiochem, #474791 
Z-VAD Caspases Sigma, #V116-2mg 
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3.6 Enzymes and buffers 
 
Table 3.6: Enzymes and buffers 
 
Reagent Company 
Buffer for KpnI Fermentas, Thermo Scientific 
Buffer for M-MuLV RT, 10x New England Biolabs (NEB) 
Buffer for Taq (KCl+, -MgCl2), 10x Fermentas, Thermo Scientific 
Calf Intestine Alkaline Phosphatase  Fermentas, Thermo Scientific 
Cloned Pfu reaction buffer, 10x Stratagene 
KpnI Fermentas, Thermo Scientific 
M-MuLV Reverse transcriptase (RT) New England Biolabs (NEB) 
Pfu Turbo DNA polymerase (2.5 U/µl) Stratagene 
RNase A (1 mg/ml) Qiagen, Venlo, Netherlands 
T4 ligase (200 U/µl) Fermentas, Thermo Scientific 
T4 ligase buffer Fermentas, Thermo Scientific 
Taq DNA polymerase (Taq) Fermentas, Thermo Scientific 
Taq DNA polymerase (Taq) for qPCR Primetech 






Table 3.7: Kits 
 
Name Company 
BigDye Terminator v3.1 Cycle Sequencing kit Invitrogen, Life Technologies 
Guava Check Kit Millipore, Merck 
Immobilon Western HRP Substrate Peroxide Solution  Millipore, Merck 
Invisorb Spin Plasmid Mini Kit Two Invitec, Stratec 
Pierce® BCA Protein Assay Kit Thermo Scientific 
PureYield™ Plasmid Midiprep System Promega 
QIAquick® PCR Purification Kit (250) Qiagen 
SuperSignal West Femto Maximum Sensitivity Substrate Thermo Scientific 
 
 
3.8 Oligonucleotides  
 
For the high-content siRNA screen on human ubiquitin ligases and deubiquitinating enzymes, 
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Table 3.8: Small interfering RNAs from Ambion/Life Technologies 
 
Target Sequence siRNA ID 













scrambled No. 2 
undisclosed 4390847 
(silencer select) 








G2E3-C sense: 5‘-GGAUGUCUCAGACUUAUAAtt-3’  
antisense: 5’- UUAUAAGUCUGAGACAUCCaa-3’ 
s31130 
(silencer select) 
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Table 3.9 Primers  
 
Name Sequence Application 
CMV promoter forward 5’-CGC AAA TGG GCG GTA GGC GTG-3’ sequencing 
of plasmids 
Seq22_KIAA1333* 5’-CAG AAA GAG ATG TTG AGA ATG-3‘ sequencing 
of G2E3 
Seq3_KIAA1333* 5’-GGA ATA GTG CCT TAG ATG C-3’ sequencing 
of G2E3 
Seq4_KIAA1333* 5’-GGA GAA AAT TCA GGC TTA TCC-3’ sequencing 
of G2E3 
HA-G2E3-XbaI-Fwd 5‘-GCC GCC TCT AGA AAT GAA AGT AAA CCT 
GGT GAC-3‘ 
cloning 
HA-G2E3-KpnI-Rev 5‘-CGG CGG GGT ACC TTA ATG TCC AAT GTA 
ATG AG-3‘ 
cloning 
anchored oligo-dT 5‘-dT23VN-3‘ RT-PCR 
random nonamer 5’-NNNNNNNNN-3’ RT-PCR 
GAPDH forward 5’-TGA AGG TCG GAG TCA ACG GAT TTG GT-3’ qPCR 
GAPDH reverse 5’-GCA GAG ATG ATG ACC CTT TTG GCT C-3’ 
p21 forward 5’-TAG GCG GTT GAA TGA GAG G-3’ qPCR 
p21 reverse 5’-AAG TGG GGA GGA GGA AGT AG-3’ 
Mdm2 forward 5’-TCA GGA TTC AGT TTC AGA TCA G-3’ qPCR 
Mdm2 reverse 5’-CTA TTG GAA ATG CAC TTC ATG C-3’ 
p53 forward 5’-ATG GAG GAG CCG CAG TCA GAT C-3’ qPCR 
p53 reverse 5’-GGG AGC AGC CTC TGG CAT TCT G-3’ 
G2E3-for2 5’-GGC GTG CCC CGA CGT ACA G-3’ qPCR 
G2E3-rev1 5’-AGC AAG GTT CTG TGA GTC ACC AGG-3’ 
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3.9 Plasmids 
 
Table 3.10: Plasmids 
 
Name Description 
pGL3-PG13-Luc pGL3 reporter plasmid containing 13 binding sites for p53 
upstream of Firefly luciferase gene (Kern, Pietenpol et al. 
1992) 
pRL-tk-RLuc pRL reporter plasmid (Promega) with thymidine kinase 
promoter upstream of Renilla luciferase gene 
pRc/CMV-p53 pRc/CMV vector (Invitrogen) with entire wild-type human p53 
cDNA. (Lin, Chen et al. 1994) 
pcDNA3-ΔNp63-alpha pcDNA3 expression vector (Invitrogen) with human ΔNp63-
alpha cDNA 
pcDNA3 expression vector (Invitrogen) for the exogenous expression of 
proteins under the control of a CMV promoter in eukaryotic 
cells 
pcDNA3-GFP expression vector for green fluorescent protein (GFP) 
pCMV-Mdm2 expression vector with entire human Mdm2 cDNA (kindly 
provided by Bert Vogelstein) 
pCMV-Mdm2-RING-mut expression vector with mutated RING domain of human Mdm2 
pCGN-HA expression vector for the exogenous expression of proteins 
with an N-terminal hemagglutinin (HA)-tag under the control of 
a CMV promoter in eukaryotic cells; includes ampicillin 
resistance gene 
pCGN-HA-G2E3 expression vector with entire human G2E3 cDNA (Franziska 
Schmidt) 
pEGFP-C3-G2E3 pEGFP-C3 (Clontech) is an expression vector for the 
exogenous expression of proteins with a N-terminal GFP-tag 
under the control of a CMV promoter. G2E3 was cloned into 
pEGFP-C3 using restriction sites for XhoI and KpnI (Brooks, 
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3.10  Antibodies  
 
Table 3.11: Primary antibodies for Western blot and co-immunoprecipitation (CoIP) 
 
Antibody Source  Company  Cat. No. Application Dilution 
β-Actin mouse Abcam ab6276-100 WB 50,000x 
β-Galactosidase mouse Promega Z378B CoIP n/a 
Caspase 3 rabbit  Cell Signaling 9662 WB 1000x  
Chk1 (2G1D5) mouse Cell Signaling 2360 WB 1000x  
Chk2 mouse Calbiochem CC44 WB 300x 
cleaved Caspase 3 rabbit  Cell Signaling 9664 WB 800x  
G2E3 goat Santa Cruz sc-160340 WB, CoIP 200x 
GFP mouse Clontech 632375 WB 2000x 
HA-HRP-coupled  mouse  Santa Cruz sc-7392 WB 2000x  
HA-tag (16B12) mouse  Covance  MMS-101P WB, CoIP 2000x  
IgG mouse Jackson 
ImmunoResearch 
115-007-003 CoIP n/a 
Mdm2 mouse Calbiochem  OP46 WB, CoIP 500x 
Mdm2 (2A9) mouse  Hybridoma supernatant WB 1.25x  
Myc-tag mouse Millipore  05-724 WB, CoIP 1000x 
p21  mouse  Calbiochem  OP64 WB 200x  
p53 (DO1) mouse Santa Cruz sc-126 WB, CoIP 1000x  
p53-HRP-Coupled  mouse  Santa Cruz sc-126HRP WB 750x  
PARP  mouse  Calbiochem  AM30 WB 1000x  
phospho-Chk1 (Ser317) rabbit Cell Signaling 2344 WB 1000x 
phospho-Chk2 (Thr68) rabbit Cell Signaling 2661 WB 1000x 
phospho-H2AX (Ser319) mouse  Millipore  05-636 WB 2000x  
 
 
All primary antibodies were diluted in Western blot blocking solution with 5 % milk powder. 
Antibodies against phospho-Chk1 and phospho-Chk2 were diluted in Western blot blocking 
solution with 5 % BSA. 
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Table 3.12: Primary antibodies for immunofluorescence 
 
Antibody Source  Company  Cat. No. Dilution  
53BP1 rabbit Santa Cruz sc-22760 300x 
H2AX pS319 mouse  Millipore  05-636  1500x 
HA-tag (16B12) mouse  Covance  MMS-101P  300x 
HA-tag rabbit Santa Cruz sc805 200x 
Mdm2 mouse Calbiochem  OP46  500x 
Myc-tag rabbit Abcam ab9106 300x 
p53 (FL393) rabbit  Santa Cruz  sc-6243 300x 
p53 (DO1) mouse Santa Cruz sc-126 500x 
 
All primary antibodies were diluted in IF blocking solution with 5 % FCS.  
 
 
Table 3.13: Secondary antibodies for Western blot 
 
Antibody Company Cat. No. Dilution 
HRP-coupled AffiniPure F(ab')2 
fragment, anti mouse IgG (H+L)  
Jackson Immunoresearch 711-036-152  10,000x 
HRP-coupled AffiniPure F(ab')2 
fragment, anti rabbit IgG (H+L)  
Jackson, Immunoresearch  715-036-150  10,000x 
HRP-coupled AffiniPure F(ab')2 
fragment, anti goat IgG (H+L)  
Jackson, Immunoresearch  705-036-147 10,000x 
 
 
All secondary antibodies were diluted in Western blot blocking solution with 5 % milk powder. 
 
 
Table 3.14: Secondary antibodies for immunofluorescence 
 
Antibody Company Cat. No. Dilution 
Alexa-Fluor-488 goat anti mouse Invitrogen, Life Technologies A-11017 500x 
Alexa-Fluor-488 goat anti rabbit Invitrogen, Life Technologies A-11034  500x 
Alexa-Fluor-546 goat anti mouse Invitrogen, Life Technologies A-11003  500x 
Alexa-Fluor-546 goat anti rabbit Invitrogen, Life Technologies A-10040 500x 
 
All secondary antibodies were diluted in IF blocking solution with 5 % FCS. 
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3.11  Human cell culture 
 
Table 3.15: Human cell lines 
 
Cell line Origin 
H1299 human non-small cell lung carcinoma cell line, homozygous partial 
deletion of TP53 gene 
HCT116 p53+/+ human colon carcinoma cell line 
HCT116 p53-/- p53-deficient human colon carcinoma cell line (Bunz 1998)  
SJSA human osteosarcoma cell line 
U2OS human osteosarcoma cell line 
 
 




Dulbecco’s Modified Eagle Medium (DMEM), powder Gibco, Life Technologies 
Fetal Calf Serum (FCS) Gibco, Life Technologies 
L-Glutamine Gibco, Life Technologies 
McCoy’s Medium  Gibco, Life Technologies 
PBS (tablets) Gibco, Life Technologies 
Penicillin/Streptomycin Gibco, Life Technologies 
Tetracyclin Gibco, Life Technologies 
Trypsin/EDTA Gibco, Life Technologies 
 
Dulbecco’s Modified Eagle’s Medium (DMEM) 
DMEM, powder 10.0 g/l 
NaHCO3 3.7 g/l 
HEPES 5.96 g/l 
dissolved in H2O 
 
Dulbecco’s Modified Eagle’s Medium (DMEM) with supplements 
DMEM  
FCS 10 % 
Penicillin/Streptomycin 50 U/ml 
L-Glutamine 200 µM 
Ciprofloxacin  10 µg/ml 
dissolved in H2O 
 
McCoy’s Medium with supplements 
McCoy’s medium  
FCS 10 % 
Penicillin/Streptomycin 50 U/ml 
L-Glutamine 200 µM 
dissolved in H2O 
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3.12  Bacteria 
 
Table 3.17: Bacteria strains 
 
Strain Description Company 
DH10B ElectroMAX electro-competent E.coli Invitrogen, Life Technologies 
DH10B  chemically competent E. coli self-made 
 
 








YT agar 15% 
2YT medium 100% 
 
3.13  Software and databases 
 
Table 3.19: Software 
 
Name Company 
Adobe Photoshop CS5 Adobe Systems, San Jose, CA, United States 
AttoVision (BD Pathway) Becton Dickinson 
BioEdit v7.0.5  
 
Tom Hall, Ibis Biosciences, Carlsbad, CA, United 
States 
Celigo Software Cyntellect 
CFX Manager Software (qPCR cycler) Bio-Rad 
Excel Microsoft 
Fiji (image processing) General Public License 
Guava Express Software  Millipore, Merck 
Intas ChemoStar Imager Intas Science Imaging Instruments 
ModFit LT Verity Software House, Topsham, ME, United States 
NanoDrop Software Peqlab 
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Table 3.20: Databases 
 
Name Source and details 
CASVM Server 1.0 www.casbase.org 
server for prediction of caspase substrates cleavage sites 
(Wee, Tan et al. 2007) 
(for G2E3, selected scanning window size was “all”) 
Ensembl Genome Browser www.ensembl.org 
genome database for vertebrates and other eukaryotic species 
GeneSapiens database www.genesapiens.org 
human gene expression data source  
(Kilpinen, Autio et al. 2008) 
PhosphoSitePlus® www.phosphosite.org 
online systems biology resource with information and tools to 
study protein post-translational modifications  
(Hornbeck, Kornhauser et al. 2012) 
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4 Methods 
 
4.1 Cell biology 
4.1.1 Culturing of human cells 
All work with cell cultures was conducted under sterile conditions. Human cell lines were 
cultured at 37 °C, 5 % CO2 and humidified atmosphere in cell culture dishes. Specific culture 
media were used for the different cell lines (Table 4.1). For sub-cultures, medium was 
removed and the cells were washed with PBS. Cells were incubated with 0.1 % trypsin/EDTA 
at 37 °C for 5 min in order to detach the cells from the bottom of the cell culture dish. Trypsin 
was inactivated by the addition of culture medium containing FCS. Cells were reseeded in a 
ratio of 1:2 to 1:15.  
 
Table 4.1: Culture media for human cell lines 
 
Cell line Culture medium 
H1299 DMEM with supplemtents 
HCT116 p53+/+ McCoy’s with supplemtents 
HCT116 p53-/- McCoy’s with supplemtents 
SJSA DMEM with supplemtents 
U2OS DMEM with supplemtents 
 
For experiments, cells were counted and seeded in desired amounts in 6-, 12- or 96-well cell 
culture plates. To determine the cell number, cells were centrifuged for 5 min at 209 g, 
medium was removed and fresh medium was added. Cells were counted using a Neubauer 
counting chamber (for HCT116 cell lines) or the Automated Cell Counter Countess® (for 
H1299, SJSA, U2OS cells).  
 
4.1.2 Freezing and thawing of cells 
For long-term storage, cells were stored in liquid nitrogen at -196 °C. Therefore, cells of low 
passage number in 15 cm cell culture dishes were washed with PBS and trypsinized with  
0.1 % trypsin/EDTA at 37 °C for 5 min. After inactivation of trypsin with culture medium, cells 
were centrifuged for 5 min at 209 g and resuspended in 5 ml pre-cooled FCS with  
10 % DMSO on ice. The suspension was aliquoted into five cryo vials and stored at -80 °C for 
24 h. Subsequently, aliquots were transferred into liquid nitrogen until further use.  
 
For thawing of cells stored at -196 °C, cryo vials were warmed up in a water bath of 37 °C. 
Cells were transferred into a 15 ml reaction tube filled with 3 ml pre-warmed culture medium. 
Methods        43 
Cells were centrifuged for 5 min at 209 g, the supernatant containing DMSO was removed 
and the cells carefully resuspended in 1 ml fresh culture medium. The cells were seeded in a 
cell culture dish. After 24 h, medium was exchanged to remove dead cells. Prior to 
experiments, cells were sub-cultured at least four times. 
 
4.1.3 Transfection of human cells 
For transient transfection of human cells with expression vectors, cells were seeded one day 
before transfection (forward transfection). For transient transfection of cells with siRNAs, cells 
were transfected and seeded at the same time (reverse transfection). 
 
4.1.3.1 Transient transfection with expression vectors 
For transient transfection with expression vectors in order to overexpress proteins, the 
desired number of cells was seeded the day before (Table 4.2). The cells were transfected at 
a confluence of about 80 % using the lipid-based transfection reagent Lipofectamine™ 2000. 
For this purpose, two different solutions were prepared in 1,5 ml reaction tubes. Solution A 
contained culture medium without supplements and plasmid DNA, solution B contained 
culture medium without supplements and LF2000: 
 
Table 4.2: Amounts of culture medium without supplements, plasmid DNA and LF2000 for 
different cell lines and cell numbers   
 
Cell line Cell number Wells per plate Solution A Solution B 
U2OS 11,500 96 25 µl DMEM(-)  
+ 200 ng DNA 
25 µl DMEM(-)  
+ 0.5 µl LF2000 
U2OS, H1299 150,000 12 100 µl DMEM(-)  
+ 1.2 µg DNA 
100 µl DMEM(-)  
+ 4 µl LF2000 
U2OS, H1299 300,000 6  200 µl DMEM(-)  
+ 2.4 µg DNA 
200 µl DMEM(-)  
+ 8 µl LF2000 
 
Both solutions were vortexed. Solution B was incubated for 5 min at room temperature. 
Thereafter, both solutions were mixed by carefully pipetting up and down and incubated for 
20 min at room temperature. The transfection mix was added dropwise to the cells seeded 
the day before. After 4 h of incubation at 37 °C, the medium was exchanged by fresh culture 
medium. Subsequently, cells were incubated for 24-48 h at 37 °C. 
 
Expression vectors which were used are listed in Table 3.10. 
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4.1.3.2 Transient transfection with siRNAs  
For the knockdown of proteins, cells were transiently reverse transfected with siRNAs. 
Transient transfection with siRNAs was performed using Lipofectamine™ 2000 with a final 
concentration of 10 nM per siRNA. For this purpose, two different solutions were prepared. 
Solution A contained siRNA in culture medium without supplements, whereas solution B 
contained LF2000 in culture medium without supplements. For required amounts, see  
Table 4.3: 
 
Table 4.3: Amounts of culture medium without supplements, siRNA and LF2000 for different 
cell lines and cell numbers   
 
Cell line Cell number Wells per plate Solution A Solution B 
U2OS 8,500 96 25 µl DMEM(-) +  
1.5 pmol siRNA 
14.75 µl DMEM(-)  
+ 0.25 µl LF2000 
U2OS 100,000 12 67.5 µl DMEM(-) +  
15 pmol siRNA 
28.65 µl DMEM(-)  
+ 1.35 µl LF2000 
HCT116 180,000  12 67.5 µl McCoy(-) +  
15 pmol siRNA 
28.65 µl McCoy(-)  
+ 1.35 µl LF2000 
U2OS 220,000 6  135 µl McCoy(-) +  
30 pmol siRNA 
57.3 µl McCoy(-)  
+ 2.7 µl LF2000 
HCT116 360,000 6 135 µl McCoy(-) +  
30 pmol siRNA 
57.3 µl McCoy(-)  
+ 2.7 µl LF2000 
 
Solution A and solution B were vortexed. Solution B was incubated for 5 min at room 
temperature. Thereafter, both solutions were mixed by carefully pipetting up and down and 
incubated for 20 min at room temperature. The transfection mix was added dropwise to 
empty wells of the cell culture plate. Afterwards, cells of desired number were added to the 
well. Medium was exchanged with fresh culture medium after 24 h of incubation at 37 °C. The 
total incubation time after transfection was 48-64 h at 37 °C, depending on the experimental 
setup. 
For double-transfection with two siRNAs, the total amount of siRNA was divided in halves and 
otherwise the protocol was used as described above. 
 
The used siRNAs are listed in Table 3.8. 
 
4.1.4 Chemical treatment 
For the treatment of cells, drugs were pre-dissolved in H2O or DMSO. In order to treat cells, 
drugs were added to pre-warmed culture medium at concentrations specified in Table 4.4. As 
control, cells were treated with an equal amount of the corresponding solvent (H2O or 
DMSO). 
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Table 4.4: Concentrations for chemical treatment 
 
Chemical Stock Final conc. Solvent Incubation time 
Cisplatin 3,33 mM 30 µM physiological salt 
solution 
8 h, 16 h 
MG132 10 mM 20 µM DMSO 4 h 
Neocarzinostatin 
(NCS) 
ca. 0,5 mg/ml 150 ng/ml 20 mM MES buffer, 
pH 5.5 
2 h 
Nutlin-3 20 mM 10 µM DMSO 16 h 
Thymidine 200 mM 2 mM H2O 16 h 
Z-VAD 20 mM 50 µM DMSO 16 h 
 
4.1.5 Generation of cell lysates for SDS-PAGE analysis 
For immunoblot analysis, cells were grown, transfected and treated in 12-well plates. All 
steps of cell harvest and lysis were performed on ice. Cells were harvested by scraping the 
cells in the culture medium of the well. The cell suspension was transferred to a  
1.5 ml reaction tube and centrifuged (5 min, 845 g). The cell pellet was washed with 1 ml PBS 
and centrifuged again (5 min, 845 g). The pellet was resuspended in cell lysis buffer 
containing RIPA, urea and protease inhibitors (see 3.4). For the cell lines U2OS, H1299 and 
SJSA cells, 60 µl cell lysis buffer was used per sample. For HCT116 cells, 160 µl cell lysis 
buffer was used per sample. After cell harvest, proteins were stored at -80 °C or used to 
determine the protein concentration. Protein concentration of each sample was determined 
using Pierce® BCA Protein Assay Kit (Thermo Scientific). After adjusting the protein 
concentrations with RIPA to equal amounts, 10 µl 6x Laemmli buffer was added to each 
sample. The samples were incubated for 5 min at 95 °C for protein denaturation. Afterwards, 
samples were shaken for 15 min at 1400 rpm and room temperature using the Thermomixer 
comfort to shear the DNA. Samples were stored at -20 °C or directly used for SDS-PAGE. 
 
4.1.6 Isolation of RNA 
For quantification of mRNA levels of genes of interest, RNA was isolated from human cell 
lines based on the guanidinium thiocyanate-phenol-chloroform extraction protocol 
(Chomczynski and Sacchi 1987). For this purpose, cells were grown in 6-well cell culture 
plates. Medium was removed and cells were washed once with PBS and incubated with  
1 ml Trizol for 5 min at room temperature. The solution was transferred to a 1.5 ml reaction 
tube. Samples were stored at -80 °C for later use or the procedure of RNA isolation was 
continued. Next, 200 µl Chloroform per 1 ml Trizol were added to the reaction tube. The tubes 
were shaken vigorously for 15 sec and incubated for 3 min at room temperature. The 
samples were centrifuged (12,000 g, 15 min, 4 °C). The colorless, upper phase (ca. 500 µl) 
containing RNA was transferred to another 1.5 ml reaction tube. After adding the same 
volume of isopropanol, the tubes were shaken vigorously for 15 sec and incubated at least  
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2 h at -20 °C. After centrifugation (12,000 g, 10 min, 4 °C), the supernatant was discarded 
and the pellet containing the precipitated RNA was washed with 1 ml 75 % Ethanol. The 
samples were centrifuged (7,500 g, 5 min, 4 °C) and the supernatant was discarded. The 
pellet was dried at 37 °C and then resuspended in 20 µl RNase-free water. The concentration 
and purity of RNA samples was determined using the spectrophotometer NanoDrop ND-1000 
(PeqLab). The absorbance at 230 nm, 260 nm and 280 nm was measured. Absorbance at 
260 nm was used to calculate the RNA concentration. Sufficient RNA purity was provided if 
the following ratios were measured: 
A260/A280 > 1.8 
A260/A230 > 2.0 
 
If RNA purity was not sufficient, a second purification step was performed. Therefore, the 
RNA was suspended in a total volume of 50 µl RNase-free water per sample. For better 
visualization, 1 µl Glycogen Blue was added to later stain the RNA pellet blue. For 
precipitation, 3 M sodium acetate was added at 1:10 dilution (5 µl) and 62.5 µl 100 % ethanol 
(1.25x). The tubes were incubated in liquid nitrogen for 5 min and then centrifuged (16,000 g, 
15 min, 4 °C). The supernatant was removed and 200 µl 70 % ethanol was added per 
sample. After centrifugation (16,000 g, 5 min, 4 °C), the supernatant was removed and the 
pellet was dried at 37 °C. The pellet was dissolved in 20 µl RNase-free water. RNA 
concentration and purity were measured using the spectrophotometer NanoDrop ND-1000. 
RNA samples were stored at -80 °C or used for cDNA synthesis and quantification of 
messenger RNA by qPCR (see 4.2.2). 
 
4.1.7 Flow cytometry 
Flow cytometry was used to investigate the cell cycle profile of human cells based on their 
DNA content (Van Dilla, Trujillo et al. 1969). For this purpose, DNA was stained with 
propidium iodide (PI) after permeabilization of the cell membrane and degradation of RNA 
using RNase (Krishan 1975). PI intercalates with the DNA. Cells in G2/M-phase contain the 
double amount of DNA than cells in G0- or G1-phase. The DNA content of cells in S-phase is 
between the content of cells in G0/G1- and G2/M-phase. The DNA content of each cell was 
determined by PI fluorescence intensity.  
Cells were harvested as described above (for details see 4.1.1) and all cells (also from 
growth medium) were collected. Cells were centrifuged (400 g, 7 min) and resuspended in 
500 µl PBS on ice. Cells were fixed with ice-cold 100 % EtOH by adding 1.5 ml 100 % EtOH 
dropwise to the cells while slowly vortexing them. Cells were incubated at -20 °C for one to 
four days, then centrifuged (400 g, 10 min) and rehydrated in PBS for 10 min. After 
centrifugation (400 g, 10 min), cells were resuspended in 100 µl RNase A (1 mg/ml) and 
incubated at 37 °C for 30 min in order to degrade RNA. Prior to analysis, samples were 
diluted by adding 200-400 µl PBS depending on the cell number per sample. 200 µl of this 
solution were pipetted into a 96-well plate for flow cytometry (Becton Dickinson). Propidium 
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iodide (Sigma-Aldrich) was added in a final concentration of 30 µg/ml. The cell cycle profile 
was obtained using the flow cytometer Guava EasyCyteplus by measuring 10,000 events per 
sample. The percentage of cells in each cell cycle phase was determined using the  
ModFit software.  
 
4.1.8 Cell synchronization by double thymidine block 
Cells can be synchronized in G1-phase by adding thymidine which inhibits DNA synthesis 
due to an imbalance in the cellular nucleotide pool (Xeros 1962). For synchronization of cell  
cultures, thymidine was added to the culture medium at a final concentration of 2 mM for  
16 h. Thymidine was washed away by adding pre-warmed culture medium to the cells for  
5 min for five times. Subsequently, cells were incubated for 9 h. Afterwards, a second 
treatment with 2 mM thymidine for 16 h was performed in order to arrest all cells at the  
G1/S-transition. After washing away thymidine by adding culture medium for five times  
(5 min each), cells were released in fresh culture medium. Cell cycle progression was 
monitored by taking a sample every 2 h and analyzing the DNA content of the samples by 
flow cytometry (see 4.1.7). 
 
4.1.9 Proliferation assay 
Proliferation of cells was investigated by measuring cell confluence over time using the Celigo 
cell cytometer (Cyntellect) which contained an embedded bright-field microscope. After rapid 
bright field imaging, images were segmented and analyzed for quantification of cell 
confluence. Cells were transfected and seeded in 12-well plates at low density (100,000 cells 
for HCT116 cells, 50,000 cells for U2OS). Cell confluence was measured daily for one week 
and every two days afterwards.  
 
 
4.2 Molecular Biology 
4.2.1 Polymerase chain reaction 
Polymerase chain reaction (PCR) is used to rapidly amplify a specific DNA template  
(Mullis and Faloona 1987). Two sequence-specific primers are necessary which are 
complementary to the 3' ends of the sense and anti-sense strand of the DNA template. A 
basic PCR comprises three steps: Firstly, the double-stranded DNA becomes single-stranded 
after denaturation at high temperature. Secondly, the primers anneal to the DNA template 
after the temperature is lowered. Thirdly, new DNA is synthesized starting at the primers 
using deoxyribonucleotide triphosphates (dNTPs) and a thermostable polymerase with an 
optimal temperature of around 70 °C. Up to 40 repetitions of these steps lead to amplification 
of the DNA template in a near-exponential manner. The amount of template was chosen 
depending on the source of DNA. PCR was performed using the PCR machine  
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Primus 25 advanced. Annealing temperatures lower than the melting temperatures of the 
primers were chosen. Elongation time was adjusted depending on the length of the product. 
 
4.2.2 Quantification of messenger RNA by PCR 
Quantification of messenger RNA (mRNA) is used to investigate gene expression on the 
basis of the amount of the transcribed gene in a sample. Since RNA cannot be amplified by 
PCR, it has to be converted into DNA first using the enzyme reverse transcriptase. 
Afterwards, mRNA is quantified by real-time PCR. These steps are explained below. 
 
4.2.2.1 Reverse transcription 
Reverse transcription of mRNA is done by a reverse transcriptase (RT) derived from moloney 
murine leukemia virus (M-MuLV). For synthesis of complementary DNA (cDNA), 1 µg total 
RNA was mixed with 2 µl primer which consisted of a combination of anchored oligo-dT 
primers (using 50 µM dT23VN) and random nonamer primers (using 15 µM nonamer primers). 
Furthermore, 4 µl dNTP mix (2.5 mM of each deoxyribonucleotide triphosphate, i.e. dCTP, 
dATP, dTTP, dGTP) and nuclease-free water to a total volume of 16 µl was added. The 
sample was heated to 70 °C for 5 min, centrifuged briefly and put on ice. The following 
components were added per sample (4 µl total volume, Table 4.5): 
 
Table 4.5: Reaction mix for RT 
 
Component Volume [µl] 
10x Reaction Buffer for M-MuLV Reverse Transcriptase (NEB) 2.0 
RNase Inhibitor (10 U, NEB) 0.25 
M-MuLV Reverse Transcriptase (25 U, NEB) 0.125 
H2O 1.625 
 
Samples were incubated at 42 °C for 1 h. Subsequently, the reverse transcriptase was 
inactivated at 95 °C for 5 min. Finally, the samples were diluted to a final volume of 50 µl by 
adding 30 µl nuclease-free water and stored at -20 °C or used for quantitative real-time PCR 
(qPCR). 
For each sample, a control was prepared without reverse transcriptase (instead, an equal 
volume of nuclease-free water was added) to check for contamination with genomic DNA: 
During qPCR, no product should be obtained if RT was not added. However, a contamination 
with genomic DNA could lead to a PCR product.  
 
4.2.2.2 Quantitative real-time PCR 
Quantitative real-time PCR is used to acquire semi-quantitative measurements of gene 
expression. A PCR reaction requires a DNA template to be amplified. In the case of qPCR, 
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the template is cDNA. Primer pairs were established for the detection of the specific genes of 
interest, amplifying cDNA fragments of these genes with a product size of 200-300 bp. If 
possible, a sequence for the primers was used that enabled intron-spanning qPCR in order to 
exclude the amplification of genomic DNA, potentially present due to contamination. Primer 
sequences used for qPCR are shown in Table 3.9. For the preparation of the qPCR reaction 
mix, a self-made 10x qPCR reaction buffer was prepared (for components see 3.4). The 
qPCR reaction mix contained amongst others dNTPs, the dye SYBR Green and  
Taq polymerase. SYBR Green is a dye which binds DNA and is used to detect and quantify 
PCR products.  
 
For qPCR, the following components with the exception of cDNA were mixed as a master mix 
in 1.5 ml reaction tubes on ice (Table 4.6): 
 
Table 4.6: Reaction mix for qPCR 
 
Component Stock conc. [µl] for 1 sample Final conc. 
qPCR reaction mix  14  
forward primer 10 pmol/µl 0.75 0.3 pmol/µl 
reverse primer 10 pmol/µl 0.75 0.3 pmol/µl 
H2O  8.5  
cDNA  1  
 
24 µl aliquots of the master mix were pipetted in the wells of a 96-well plate for qPCR on ice. 
1 µl of the respective cDNA was added. Samples without reverse transcriptase and samples 
with H2O instead of cDNA were used as negative controls for each primer pair. The plate was 
sealed, centrifuged briefly and placed into the PCR machine for qPCR CFX96, C1000  
(Bio-Rad). The following program was applied (Table 4.7): 
 
Table 4.7: Cycler program for qPCR 
 
Step Temperature Time  
DNA denaturation 95 °C 2 min  
DNA denaturation 95 °C 15 sec 
40x 
primer annealing and elongation 60 °C 1 min – plate read 
 79 °C 1 sec – plate read 
 84 °C 1 sec – plate read 
melting curve 55 °C - 95 °C (increment 0.5 °C) 
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Semi-quantitative analysis of mRNA expression was conducted by measuring the Ct-values 
of the reference gene GAPDH and the gene of interest. The ΔΔC t method was applied to 
calculate the relative expression of the investigated genes (Livak and Schmittgen 2001). The 
difference in expression is specified as n-fold expression. Therefore, the Ct-value of the 
genes of interest is subtracted from the Ct-value of the reference gene (ΔCt). Then, the  
ΔCt-values of the two groups (e.g. untreated/treated) are subtracted (ΔΔCt): 
∆∆Ct = (ΔCt(GAPDH, treated)-Ct(target gene, treated))-((Ct(GAPDH, untreated)-Ct(target gene, untreated)) 
 
Subsequently, ΔΔCt is inserted in the following equation:    n-fold expression = 2ΔΔCt 
 
 
4.2.3 Luciferase reporter assay  
4.2.3.1 Theoretical background 
Luciferase reporter assays are used to investigate the regulation of gene expression at the 
level of transcription. Here, the impact on the transcriptional activity of p53 was measured 
using the Dual Luciferase Assay as described by McNabb et al. (McNabb, Reed et al. 2005). 
Since two luciferase reporter genes are used, the assay is referred to as Dual Luciferase 
Assay. The expression of the first reporter (Firefly luciferase) changes depending on the 
transcriptional activity, whereas the second reporter (Renilla luciferase) serves as an internal 
control.  
Here, a p53-responsive promoter was coupled to the reporter gene Firefly luciferase. The 
reporter plasmid pGL3-PG13-Luc was used, containing 13 p53 binding sites upstream of the 
Firefly luciferase gene (according to human p53 consensus binding site  
5'-PPPC(A/T)(T/A)GYYY-3'). The Firefly luciferase enzyme catalyzes the oxidation of the 
substrate luciferin, leading to emission of chemiluminescence with an emission maximum at 
562 nm. Promoter activity is determined based on the assumption that the amount of emitted 
light is proportional to the amount of luciferase in the sample and hence proportional to the 
activity of the corresponding promoter. In order to correct for differences in transfection 
efficiency, cell lysis and pipetting, the Renilla luciferase gene under the control of a 
constitutively active promoter (thymidine kinase promoter) was used. For this purpose, the 
reporter plasmid pRL-tk-RLuc was cotransfected in cells of all samples. Renilla luciferase 
catalyzes the oxidation of the substrate coelenterazine which leads to emission of 
chemiluminescence with an emission maximum at 482 nm.  
Plasmids encoding reporter genes and the genes of interest were transfected in a suitable 
cell line. Here, p53-/- cells (H1299 lung carcinoma cells) were used to avoid endogenous p53 
background level. Also, this cell line is easily transfectable and sensitive to changes in 
promoter activity.  
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4.2.3.2 Transfection and luciferase reaction assay  
H1299 cells were transfected in 12 wells. For details of transfection, see 4.1.3.1. Cells were 
transfected with pGL3-PG13-Luc, pRL-tk-RLuc and pRc/CMV-p53. As positive controls, cells 
were additionally transfected with plasmids pCMV-Mdm2 and pcDNA3-ΔNp63-alpha. The 
proteins encoded by these plasmids, Mdm2 and ΔNp63-alpha, both repress p53 
transcriptional activity. The impact of HA-G2E3 on p53 transcriptional activity was 
investigated by transfection with different amounts of pCGN-HA-G2E3. 24 h after 
transfection, cells were lysed by scraping in the medium and transferred to a 1.5 ml reaction 
tube. After centrifugation (5 min, 845 g, 4 °C), the supernatant was discarded. The pellet was 
resuspended in 100 µl 1x Passive Lysis Buffer (Promega) and shaken for 15 min at room 
temperature and 1400 rpm. After centrifugation for 1 min at 18,407 g, 20 µl of the supernatant 
were pipetted into a 96-well plate for luciferase assay (OptiplateTM  96, Perkin Elmer). 20 µl of 
Passive Lysis Buffer were used as blank value. All samples were pipetted in triplicates. 
Luciferase Assay Reagent ‘Firefly’ (containing amongst others the substrate luciferin) and 
‘Renilla’ (containing the substrate coelenterazine) were prepared fresh each time and kept at 
room temperature (for components, see 3.4). Firefly and Renilla buffer stock solutions were 
kept at room temperature. Chemiluminescence emitted by Firefly and Renilla luciferase was 
quantified using the luminometer DLReady™ Centro LB 960 (Bertold Technologies). The 
plate-reading device had two injectors to dispense each assay reagent. The following 
program was used (Table 4.8): 
 
Table 4.8: Program for Dual Luciferase Assay 
 
Step Action Time Volume [µl]  
1 inject Luciferase Assay Reagent ‘Firefly’  100 
2 delay 2 sec  
3 quantitate Firefly luciferase activity 10 sec   
4 delay 2 sec  
5 inject Luciferase Assay Reagent ‘Renilla’  100 
6 delay 2 sec  
7 quantitate Renilla luciferase activity 10 sec  
 
 
When Luciferase Assay Reagent ‘Firefly’ was injected, the Firefly luciferase signal was 
generated and quantified. Addition of the Luciferase Assay Reagent ‘Renilla’ quenched the 
signal and simultaneously activated Renilla luciferase whose signal was also quantified. 
 
For analysis, the average per triplicate was calculated. After subtraction of blank value 
(Passive Lysis Buffer only) from Firefly and Renilla luciferase values, the ratio of the Firefly 
value to the Renilla value was calculated in order to normalize each sample.  
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4.2.4 Heat-shock transformation of chemically competent bacteria 
Amplification of plasmid DNA was performed using the chemically competent Escherichia coli 
strain DH10B. For transformation, 1 µl plasmid DNA was mixed gently with 50 µl of 
chemically competent bacteria in 1.5 reaction tubes. The samples were incubated on ice for 
30 min, followed by incubation for 10 min at 37 °C. Afterwards, samples were incubated for 
10 min on ice and 200 µl 2YT medium was added to the bacteria. The bacteria were 
incubated for 30 to 60 min at 37 °C and 220 rpm using a Thermomixer comfort. The bacteria 
were plated on agar plates with ampicillin (200 µg/ml) or kanamycin (25 µg/ml) and incubated 
at 37 °C overnight for selection of transformed cells. 
 
4.2.5 Transformation of electro-competent bacteria 
Transformation of bacteria with ligation reactions was performed using the electro-competent 
E.coli strain DH10B ElectroMAX (Invitrogen). For transformation, 7 µl bacteria culture were 
gently mixed with 0.3 µl ligation reaction in a 1.5 ml reaction tube. The mix was transferred 
between the metal plates of an electroporation cuvette (Bio-Rad). Electroporation was 
performed using a GenePulser II electroporator (Bio-Rad) with the parameters Ec1 – 1.8 kV 
(200 Ω, 25 µF). 150 µl 2YT medium were added to the bacteria. Bacteria were plated on agar 
plates with ampicillin (200 µg/ml) or kanamycin (25 µg/ml) for selection of transformed cells 
and incubated at 37 °C overnight.  
 
4.2.6 Isolation of plasmid DNA 
Plasmid DNA was isolated from bacteria that were grown overnight at 37 °C in 200 ml 2YT 
medium containing ampicillin (200 µg/ml) or kanamycin (25 µg/ml). For isolation and 
purification of plasmid DNA, the PureYield™ Plasmid Midiprep System (Promega) was used 
according to the manufacturer’s instructions. For isolation of plasmid DNA from smaller 
volumes, the Invisorb Spin Plasmid Mini Kit Two (Invitec) was used according to the manual. 
Therefore, bacteria were grown overnight at 37 °C in 5 ml of 2YT medium containing 
ampicillin or kanamycin.  
 
4.2.7 Determination of nucleic acid concentrations 
The concentration of DNA and RNA was determined using the spectrophotometer  
NanoDrop ND-1000 (PeqLab). The extinction at a wavelength of 260 nm was measured from 
a drop of 2 µl nucleic acid sample.  
 
4.2.8 DNA gel electrophoresis 
To separate DNA fragments by size, agarose gel electrophoresis was performed. Therefore, 
1 % agarose gels were prepared in TAE buffer. DNA was made visible by adding  
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DNA stain clear G (Serva) to the agarose gel before casting. 10 µl of samples were mixed 
with 1 µl 6x DNA gel loading buffer (see 3.4) before loading into gel pockets. A DNA ladder 
(Thermo Scientific) with bands of defined size was also loaded to determine the sizes of the 
DNA fragments. Agarose gel electrophoresis was performed for 30-60 min at 100-130 V. 
DNA fragments were visualized by UV light using a Gel Jet Imager (Intas Science Imaging 
Instruments). 
 
4.2.9 Cloning of HA-G2E3 into pCGN-HA 
The G2E3 gene was cloned into the vector pCGN-HA in order to overexpress a 
hemagglutinin (HA)-tagged G2E3 protein. The cloning strategy was to amplify the G2E3 gene 
using PCR and the pEGFP-C3-G2E3 vector of Brooks et al. (Brooks, Banerjee et al. 2007). 
Primers were designed to include XbaI and KpnI restriction sites. A restriction digest with 
XbaI and KpnI was performed for both insert (PCR product) and vector (pCGN-HA). After 
purification and ligation, bacteria were transformed with the newly generated plasmid  
pCGN-HA-G2E3 and colonies were picked for amplification and isolation (for details on 
transformation and isolation of plasmid DNA, see 4.2.5 and 4.2.6). Finally, the correct 
sequence of pCGN-HA-G2E3 was verified by sequencing (for details, see 4.2.10).  
 
The G2E3 gene was amplified by PCR using the PCR reaction mix and cycler program 
described in Table 4.9 and Table 4.10. Elongation time was calculated as 2 min for each kb 
of plasmid length plus 2 min. Since the G2E3 gene consists of 2240 bp, an elongation time of 
7 min was used. The reaction was done five times in parallel to gain a high amount of DNA. 
Amplification was checked by agarose gel electrophoresis. Primers used for cloning were  
HA-G2E3-XbaI-Fwd and HA-G2E3-KpnI-Rev, whose sequences are listed in Table 3.9. 
 
Table 4.9: PCR reaction mix 
 
Component Final conc. Per reaction [µl] 
10x cloned Pfu reaction buffer (Stratagene) 10 % 5.0 
dNTPs (20 mM) 200 µM 0.5 
Primer forward (5 µM) 250 nM 2.5 
Primer reverse (5 µM) 250 nM 2.5 
DNA template (plasmid, 100 ng/µl) 100 ng 1.0 
Pfu Turbo polymerase (Stratagene, 2.5 U/µl) 2.5 U 1.0 
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Table 4.10:  Cycler program for PCR 
 
Step Temperature Time  
DNA denaturation 95 °C 2 min  
DNA denaturation 95 °C 30 sec 
30x primer annealing 58 °C 1 min 
elongation 72 °C 7 min 
final elongation 72 °C 10 min  
 
The PCR product was purified using the QIAquick® PCR Purification Kit (Qiagen) according 
to the manufacturer’s instructions. The sample was eluted from the column using nuclease-
free water. The purified PCR product was used for restriction digest with XbaI and KpnI. The 
following restriction digest was performed with the insert (PCR product) and vector  
(pCGN-HA) (Table 4.11):  
 
Table 4.11: Reaction mix for restriction digest 
 
Component Insert Vector 
10x buffer for KpnI (Thermo Scientific) 10 µl PCR product 5 µg 
XbaI (10 U/µl) 4 µl 8 µl 
KpnI (10 U/µl) 1 µl 2 µl 
H2O ad 20 µl ad 50 µl 
 
To gain a higher amount of insert and vector, reactions were performed in parallel five times 
for the insert and three times for the vector. The samples were incubated at 37 °C for 4 h. 
Enzymes were inactivated by incubation at 80 °C for 30 min.  
The vector was dephosporylated by adding 1 µl of Calf Intestine Alkaline Phosphatase  
(CIAP, Fermentas, 1 U/µl) for 75 min at 37 °C to prevent self-ligation. Insert and vector were 
purified using the QIAquick® PCR Purification Kit (Qiagen) according to the manufacturer’s 
instructions. For ligation of insert and vector, different ratios of insert to vector were used  
(1:3, 1:5, 1:10 and controls without insert and without vector). 1 µl T4 ligase (Fermentas,  
200 U/µl) and 1 µl of 10x ligase buffer (Fermentas) were added to the reaction mix of vector 
and insert with addition of nuclease-free water to a final volume of 10 µl. Samples were 
incubated at 15 °C overnight. Electro-competent bacteria (Invitrogen) were transformed with 
ligation reactions as described in 4.2.5. Bacteria were plated on agar plates with ampicillin  
(200 µg/ml) and incubated at 37 °C overnight in order to select for cells transformed with 
pCGN-HA-G2E3. A Colony PCR was used to screen bacteria colonies for the presence of 
HA-G2E3. Single colonies were picked from agar plates. The pipet tip was smeared into a  
0.2 ml reaction tube and afterwards stored at 4 °C in a 2 ml reaction tube. PCR reaction mix 
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was added into the 0.2 ml reaction tubes containing bacteria. Primers used for Colony PCR 
were CMV promoter forward and G2E3-Rev1, whose sequences are listed in Table 3.9. 
The following PCR reaction mix was used (Table 4.12): 
 
Table 4.12: PCR reaction mix 
 
Component Final conc. Per reaction [µl] 
10x Taq buffer (KCl+, -MgCl2) 10 % 2.00 
dNTPs (20 mM) 200 µM 0.20 
Primer forward (10 µM) 200 nM 0.40 
Primer reverse (10 µM) 200 nM 0.40 
MgSO4 (25mM) 3 mM 2.40 
DNA template bacterial colonies  
Taq polymerase (5 U/µl) 1.25 U/reaction 0.25 
H2O  ad 20.00 
 
Colony PCR was performed using the PCR machine Primus 25 advanced. The following 
cycler program was used (Table 4.13): 
 
Table 4.13: Cycler program for Colony PCR 
 
Step Temperature Time  
lysis of bacteria, 
DNA denaturation 
95 °C 5 min  
DNA denaturation 95 °C 30 sec 
30x primer annealing 50 °C 30 sec 
elongation 72 °C 1 min 
 
Agarose gel electrophoresis was used to check for the amplification of the PCR product 
indicating a successful transformation of the bacterial colony. Pipet tips with positive bacterial 
colonies were transferred into 5 ml 2YT medium containing ampicillin to grow bacteria. 
Plasmids were isolated as described in 4.2.6. Plasmid sequence was determined as 
described in 4.2.10 with the primers listed in Table 3.9. 
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4.2.10 Sequencing of DNA 
Plasmid DNA was sequenced using the BigDye® Terminator v3.1 Cycle Sequencing Kit 
(Invitrogen). The method of sequencing used was originally developed by Sanger and 
colleagues (Sanger, Nicklen et al. 1977). It consists of a sequencing PCR in which 
fluorescently labeled dideoxynucleotide triphosphates (ddNTPs) are employed besides 
dNTPs. These ddNTPs lack the 3’-OH group which leads to termination of the elongation step 
if instead of dNTP such a ddNTP is incorporated. For this reason, the approach is also called 
chain-termination method. Chain-termination leads to PCR products of different sizes which 
are separated in a gel matrix. Since the termini are labeled by fluorescent ddNTPs, the 
sequence can be determined in automated sequencing machines.  
Here, the sequencing PCR was performed with 300 ng plasmid DNA which was mixed with 
the appropriate primer, sequencing mix (containing polymerase, dNTPs and ddNTPs) and 
sequencing buffer according to the manufacturer’s protocol. The following program was used 
for the sequencing PCR (Table 4.14): 
 
Table 4.14: Cycler program for sequencing PCR 
 
Step Temperature Time  
DNA denaturation 96 °C 2 min  
DNA denaturation 96 °C 10 sec 
26x primer annealing 55 °C 30 sec 
elongation 60 °C 4 min 
 
After the PCR reaction, an ethanol precipitation was performed. To this end, the PCR product 
was gently mixed with 1 µl 125 mM EDTA (pH 8), 1 µl 3 M sodium acetate and 50 µl  
100 % ethanol.  After incubation at room temperature for 5 min, samples were centrifuged at  
18,407 g for 15 min. The supernatant was discarded. After washing the pellet with 70 µl  
70 % ethanol, samples were centrifuged at 18,407 g for 5 min. The supernatant was removed 
and the pellet was dried at 37 °C. Afterwards, the pellet was resuspended in 15 µl  
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4.3 Biochemistry 
4.3.1 Separation of proteins by SDS-PAGE and Immunoblot analysis 
4.3.1.1 SDS-PAGE 
SDS-PAGE (Sodium dodecyl sulfate polyacrylamide gel electrophoresis) was developed by 
Shapiro et al. (Shapiro, Vinuela et al. 1967). It is a method whereby proteins are separated 
depending on their electrophoretic mobility and molecular weight. Using a sample buffer 
devised by Laemmli (Laemmli 1970), all proteins are bound by the anionic detergent sodium 
dodecyl sulfate (SDS) and are denatured by boiling in the presence of SDS. Thus, all proteins 
have a constant negative charge and move to the anode if an electric field is applied. The 
proteins migrate within a bipartite gel. Within the upper stacking gel with large pores, the 
denatured proteins are cumulated between the leading chloride ions and the trailing Glycine 
ions. For the stacking gel, an acrylamide/bisacrylamide (A/BA) concentration of 5 % and a  
pH of 6.8 were used. Subsequently, the proteins enter the resolving gel with an  
A/BA concentration of 12 % and therefore smaller pores and a pH of 8.8. Depending on the 
desired separation and the molecular weight of proteins, higher and lower percentages of 
A/BA might be used for the resolving gel. The proteins are separated depending on their 
molecular weight: Proteins with larger weight travel slower through the pores of the gel than 
those with lower weight. Details on the composition of the gels can be found in Table 4.15. 
First, the resolving gel was casted between two glass plates and covered by 2-propanol to 
obtain an even surface. After polymerization, 2-propanol was removed and the stacking gel 
was poured on top of the resolving gel. A comb with either 10 or 15 slots was inserted into the 
stacking gel to form slots for sample loading. Cell lysates were prepared as described in 
4.1.5. Before loading into the gel, samples were heated at 95 °C for 5 min and centrifuged  
(2 min, 9,391 g). 18 µl or 25 µl of cell lysates were loaded into the pockets of stacking gels 
with 15 or 10 slots, respectively. A prestained protein ladder was loaded into one pocket to 
estimate the size of the proteins investigated. The gels were run at 80 to 130 V for 2.5 to 3 h.  
 
Table 4.15: Composition of gels for SDS-PAGE  
 
Component for… …one stacking gel (5 %) …one resolving gel (12 %) 
Acrylamide/Bisacrylamide 500 µl 4.0 ml 
Tris-HCl, pH 6.8 (1 M) 380 µl - 
Tris-HCl, pH 8.8 (1.5 M) - 2.5 ml 
SDS (10%) 30 µl 100 µl 
H2O 2.1 ml 3.3 ml 
APS (10%) 30 µl 100 µl 
TEMED 3 µl 4 µl 
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4.3.1.2 Immunoblotting 
After separation of proteins by SDS-PAGE, they can be investigated by immunoblotting (also: 
Western blotting). This method was developed by Renart, Reiser et al. and further developed 
by Towbin, Staehelin et al. (Renart, Reiser et al. 1979; Towbin, Staehelin et al. 1979). 
Immunoblotting permits visualization of protein levels and post-translational modifications, but 
also investigation of protein interactions after co-immunoprecipitation (CoIP). For 
immunoblotting, proteins were transferred from the gel onto a nitrocellulose membrane with a 
pore size of 0.2 µm using the tank-blot technique (also: wet-blot, Bittner, Kupferer et al. 
1980). On the anode side, a stack consisting of one sponge, three Whatman papers and a 
nitrocellulose membrane was assembled. The gel was placed on top of this stack, followed by 
three Whatman papers and another sponge. All components were soaked in Western blot 
transfer buffer. The stack was embedded by two plastic holders and vertically inserted into a 
blotting chamber filled with Western blot transfer buffer. An electric field was applied for  
120 min at 100 V and 4 °C whereby proteins got bound to the membrane. Afterwards, the 
membrane was incubated in Ponceau S solution for 5 min in order to stain the proteins and 
thereby control the quality of the immunoblotting. 
 
4.3.1.3 Immunostaining 
To visualize specific proteins bound to the membrane, an immunostaining was conducted. 
Proteins were detected using a combination of two antibodies. While the primary antibody 
recognizes specifically an epitope of the protein of interest, the secondary antibody binds to 
the constant region of the primary antibody. Proteins bound by the primary antibody can be 
detected due to horseradish peroxidase (HRP)-conjugation of the secondary antibody and the 
usage of enhanced chemiluminescence (ECL) solutions. HRP catalyzes the oxidation of 
luminol by peroxide. The subsequent emission of visible light can be visualized by camera 
and indicates position and amount of the protein of interest on the membrane (Thorpe, Kricka 
et al. 1985). Besides whole proteins, also protein modifications can be investigated using 
antibodies directed against epitopes of post-translational modifications.  
For immunostaining, the membrane was incubated in blocking solution containing 5 % milk 
powder in TBST for 1 h. This was followed by incubation of the membrane with primary 
antibody diluted in blocking solution for 2 h at room temperature or overnight at 4 °C. Dilution 
ratios of applied primary antibodies are listed in Table 3.11. Thereafter, the membrane was 
rinsed three times in TBST and incubated in blocking solution for 30 min, followed by 
incubation with a HRP-conjugated secondary antibody at a dilution of 1:10,000 for 1 h at 
room temperature. Applied secondary antibodies are listed in Table 3.13. Afterwards, the 
membrane was rinsed three times in TBST, incubated in blocking solution for 30 min and 
again rinsed three times in TBST. The washing steps in blocking solution were performed 
under gentle shaking at room temperature. Substrate solution was added to the membrane to 
induce chemiluminescence: Immobilon Western HRP Substrate Peroxide Solution for strong 
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signals and SuperSignal West Femto Maximum Sensitivity Substrate for weak signals. The 
signal was detected using the Intas ChemoStar Imager Software. 
 
4.3.2 Co-immunoprecipitation 
Co-immunoprecipitation (CoIP) is the immunoprecipitation of protein complexes and used to 
investigate the physical interaction of proteins. For this purpose, cell lysates are incubated 
with an antibody which precipitates a known protein which is thought to have one or more 
interaction partners. Using this antibody, ideally entire protein complexes can be precipitated 
which makes it possible to identify known and unknown interaction partners of the protein of 
interest. After the antibody-antigen reaction, sepharose beads coupled to protein A or  
protein G are added. Protein A and protein G are bacterial proteins which bind to antibodies 
from many mammalian species. Thus, the protein of interest and its interaction partners get 
precipitated by protein A or protein G sepharose via the antibody bound to it. Centrifugation 
and several washing steps are applied to purify the protein complex. Immunoblotting is used 
to investigate the precipitated proteins and their putative interaction partners. Salt and 
detergent concentration of the buffers can be varied in order to detect weak or strong protein 
interactions. Here, a high salt CoIP buffer (see 3.4) was prepared and filtrated through a  
0.2 µm membrane filter. In some cases (then mentioned in the figure legend) the  
DUB inhibitor N-ethylmaleimide was added to the buffer in a concentration of 10 µM. 
 
Physical interactions of endogenous and exogenous G2E3, Mdm2 and p53 were assessed 
using CoIP. For CoIP of endogenous proteins, four to six 15 cm cell culture dishes with 
adherent cells of 90 % confluence were used per sample. Cells were washed once with PBS 
and harvested by scraping in 500 µl CoIP buffer per cell culture dish. For CoIP of exogenous 
proteins, U2OS cells in 6-well cell culture plates were transiently transfected with plasmids 
encoding HA-G2E3, p53 and Mdm2. Empty vector pcDNA3 was used as control. Cells were 
washed once with PBS and harvested by scraping in 400 µl CoIP buffer. Cells from two wells 
with the same transfection mix were combined to yield more lysate. All steps were performed 
at 4 °C or on ice if not stated otherwise. Cell lysates were transferred into 1.5 ml reaction 
tubes and pressed five times through a 26 G cannula attached to a 1 ml syringe, followed by 
sonication for 15 min at medium power with 15 sec on/off using the sonication device 
Bioruptor. Afterwards, cell debris was removed by centrifugation (15 min, 16,000 g). The 
supernatant was transferred to a new 1.5 ml reaction tube and incubated with 50 µl  
protein G sepharose (PGS) for 1 h on a rotating wheel for pre-clearing. PGS was washed 
three times in CoIP buffer before being added to the solution. Pre-clearing is necessary to 
remove all proteins that bind sepharose beads unspecifically. The pellet (resolved in CoIP 
buffer and 6x Laemmli buffer) and an aliquot of supernatant with 6x Laemmli buffer were 
stored for further analysis by SDS-PAGE and Western blot to investigate the quality of cell 
lysis. After pre-clearing, samples were centrifuged (4 min, 845 g). As input control, 60 µl 
supernatant were taken from each sample. 20 µl 6x Laemmli buffer were added to input 
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samples which were boiled at 95 °C for 5 min. The remaining supernatant was split in equal 
parts in several 1.5 ml reaction tubes for incubation with 2 µg of different antibodies:  
mouse-anti-p53 (Santa Cruz), mouse-anti-Mdm2 (Calbiochem) and control antibodies mouse-
anti-β-Galactosidase (Promega) and mouse-anti-IgG (Jackson ImmunoResearch), see also 
Table 3.11. For goat-anti-G2E3 antibody (Santa Cruz) 4 µg were used. 
As further controls for the specificity of the antibodies, they were added to 1.5 ml reaction 
tubes without cell lysates (filled with CoIP buffer only). All samples were incubated overnight 
on a rotating wheel. Then, 25 µl PGS beads were added per sample, followed by incubation 
on a rotating wheel for 1 to 2 h to allow coupling of antibodies to PGS. The beads were 
centrifuged (2 min, 845 g) and washed five times with 800 µl CoIP buffer with intermediate 
centrifugation steps (2 min, 845 g). After the last washing step, cells were centrifuged again 
(2 min, 4000 g). The supernatant was removed and the beads were resuspended in 25 µl  
3x Laemmli buffer, shortly vortexed and boiled at 95 °C for 5 min. Samples were stored at  
-20 °C or analysed by immunoblotting. 
 
4.3.3 Immunofluorescence staining and microscopy 
Immunofluorescence microscopy is applied to visualize proteins using a combination of a 
primary antibody against the protein of interest and a fluorophore-coupled secondary 
antibody. After excitation of the fluorophore, the emitted fluorescence is detected by a 
fluorescence microscope.  
 
Cells were transfected and seeded in triplicates in 96-well imaging plates (Becton Dickinson), 
for cell numbers see 4.1.3.1 and 4.1.3.2. All steps of immunofluorescence staining were 
performed at room temperature. After removing culture medium, cells were fixed by applying 
100 µl 3.7 % formaldehyde in PBS for 40 min. Then, cells were washed twice with PBS. For 
permeabilization, cells were incubated with 100 µl 0.5 % Triton X-100 in PBS for 15 min. All 
following steps were performed using blocking solution containing 0.1 %Triton X-100 and  
5 % FCS in PBS. Cells were incubated in 100 µl blocking solution for 15 min to block 
unspecific binding sites. Blocking solution contained Triton X-100 to keep the cells in a 
permeabilized state. 70 µl primary antibody diluted in blocking solution was added to the cells 
for 1 h (for dilutions of primary and secondary antibodies Table 3.12 and Table 3.14). Cells 
were washed three times with 100 µl blocking solution for 5 min each to remove unbound 
primary antibodies. Then, 70 µl secondary antibody in blocking solution was added to the 
cells and incubated for 45 min in the dark. Secondary antibodies were coupled to 
fluorophores; here Alexa488 and Alexa 546 were used. Furthermore, the nuclear stain 
Hoechst 33342 was added in a dilution of 1:2000 to the solution to stain nuclei. Cells were 
then washed for 5 min in blocking solution, followed by two times washing with PBS for 5 min 
each. Finally, cells were kept in 200 µl PBS and the plate was sealed with aluminium foil to 
prevent bleaching of fluorophores by ambient light. Immunofluorescence pictures were taken 
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using the high-content imaging platform BD Pathway 855 System (Becton Dickinson). For 
each well, nine single pictures were taken using a 10x magnification. For quantification of 
fluorescence intensity, the images were processed using the AttoVision software  
(Becton Dickinson): Cell nuclei were defined as regions of interest (ROI) on the basis of 
Hoechst staining. The average relative fluorescence intensity of the protein of interest within 
these ROIs was determined. Thereafter, the average fluorescence intensity per well was 
calculated. Background signals were subtracted, followed by a calculation of the average 
intensity of the well triplicates of each sample.  
If single pictures were taken, a magnification of 40x was used to take pictures of nuclei 
(Hoechst stain) and the immunostained protein(s) of interest. Background subtraction was 
performed using the image processing software Fiji with a rolling ball between 50 (for strong 
subtraction) and 1000 (for slight subtraction). Merged pictures were created using Fiji.  
 
4.3.4 Statistical analysis  
Calculations were performed with Microsoft Excel. To investigate statistical significance, an 
unpaired, two-tailed student’s t-test was conducted with an assumed significance for  
p-values < 0.05. Asterisks are used to visualize p-values in the following way:  
***  = p < 0.001 
**  = p < 0.01 
*  = p < 0.05 
n.s.  = not significant 
 
The number of independent experiments is stated with “n”. Error bars are depicted as 
standard deviation (SD) or standard error of the mean (SEM). 
 
4.3.5 High-content siRNA screen 
4.3.5.1 siRNA library 
For the high-content siRNA screen on ubiquitin ligases and deubiquitinating enzymes, the 
Silencer® Select Ubiquitin Library (Ambion) was used. The library was obtained as 
lyophilised siRNAs in 96-well plates and was dissolved in nuclease-free water to a final 
siRNA concentration of 5 µM. From this, dilution plates with a concentration of 167 nM were 
prepared. Transfection with siRNAs was performed with a final concentration of 10 nM per 
siRNA. Automated pipetting was performed by the Biomek 2000 Laboratory Automation 
Workstation (Beckman Coulter).  
The library consisted of siRNAs against 327 human ubiquitin ligases and 92 deubiquitinating 
enzymes (DUBs) with three different siRNAs per gene. The three different siRNAs targeting 
one gene were located on different 96-well plates in individual wells. The three 96-well plates 
with siRNAs against the same genes were treated side-by-side for transfection, 
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immunofluorescence staining and imaging. In total, fifteen 96-well plates were screened. Per 
plate, eight internal controls were loaded. 
 
4.3.5.2 High-content siRNA screen procedure 
U2OS cells were transfected with siRNAs in 96-well plates for microscopy (Becton Dickinson) 
using the Biomek 2000 Laboratory Automation Workstation (Beckman Coulter) and incubated 
for 48 h. The transfection procedure according to which the robot was programmed is 
described in 4.1.3.2. During the last 16 h of the incubation time, cells were treated with 30 µM 
cisplatin, followed by fixation and immunofluorescence staining of γH2AX. For 
immunostaining, γH2AX antibody (Millipore, 05-636) was used at a dilution of 1:1500 and 
detected by Alexa546-coupled secondary antibody. Hoechst 33342 was used to stain nuclei. 
For each well, nine images were taken with 10x magnification. Then, automated microscopy 
and image analysis were performed using the BD Pathway 855 System (Becton Dickinson). 
For details on immunofluorescence staining and microscopy, see 4.3.3.  
Eight internal controls were used per plate: two negative controls (control siRNA scrambled 
No. 1 and No. 2) and four positive controls. As positive controls, knockdowns of genes were 
performed for which a significant change in γH2AX fluorescence intensity was already 
established: Knockdown of Chk1 and p53 lead to increase in γH2AX levels, whereas 
knockdown of RNF8 and BRCA1 lead to decrease in γH2AX levels. Furthermore, cells in two 
wells were transfected with control siRNA scrambled No. 1 and No. 2 and left untreated to 
monitor successful cisplatin treatment.  
 
4.3.5.3 High-content siRNA screen data acquisition and analysis 
Image analysis was performed using the AttoVision Software (Becton Dickinson). First, nuclei 
were defined as regions of interest (ROIs) on the basis of Hoechst staining. For analysis,  
ca. 1000-3000 nuclei per well were utilized. The average γH2AX fluorescence intensity within 
these ROIs was determined and the average fluorescence intensity per well was calculated. 
Data were normalized to correct for differences between the plates due to variations during 
transfection and immunofluorescence staining.  
Normalization of screen data was performed using a robust z-score. The z-score is defined 
as the number of standard deviations from the mean. It gives information on the strength of 
an effect relative to the rest of the samples (Birmingham, Selfors et al. 2009). Since the  
z-score is sensitive to outliers, the robust z-score is generally used for siRNA screens. Here, 
the mean and standard deviation are substituted by median and median absolute deviation 
(MAD): 
z =
sample value− sample median
sample median absolute deviation
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Sample value refers to the average γH2AX fluorescence intensity per well. Sample median 
and sample median absolute deviation were calculated per plate. Using these values, the 
robust z-score was calculated for each well of the 96-well plate and thus for each siRNA.  
 
4.3.5.4 Hit Identification Strategy 
After normalization of data, a hit identification strategy was applied to take into account how 
many of the three different siRNAs per gene led to a significant decrease or increase of 
γH2AX fluorescence intensity. Hit identification was based on robust z-scores. Every siRNA 
with a robust z-score of ≥ 2 or ≤ -2 was considered as a hit. Also, the sum and the average of 
all three z-scores per gene were calculated to identify general trends. Candidates were 
identified if at least two siRNAs reached the threshold of ≥ 2 or ≤ -2. 
 
4.3.5.5 Validation of screen results and follow-up 
After identification of candidate genes that show a strong down- or up-regulation of γH2AX 
after knockdown, screen results were validated in a secondary screen. Therefore, knockdown 
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5 Results 
 
5.1 A high-content siRNA screen identifies new regulators in the 
DDR to cisplatin  
Cisplatin is a chemotherapeutic agent for the treatment of testicular, ovarian, lung, cervical, 
head and neck cancer. It induces intra- and inter-strand crosslinking of DNA and thus 
prevents separation of strands during transcription and replication. Cisplatin treatment is 
known to activate various signaling and repair pathways. However, the cellular and molecular 
mechanisms of cisplatin treatment are incompletely understood. Therefore, our aim was to 
find new regulators in the DNA damage response (DDR) to cisplatin which would help to 
understand these pathways in more detail. Secondly, we hoped to identify proteins whose 
inhibition or stabilization could sensitize cancer cells to chemotherapeutic treatment, which 
could be targets to improve therapy in the future.  
Ubiquitin ligases and deubiquitinating enzymes (DUBs) play a major role in the DDR. 
Examples are the ubiquitin ligases RNF8 and RNF168 that regulate the response to DNA 
double-strand breaks (DSBs) (Huen, Grant et al. 2007; Mailand, Bekker-Jensen et al. 2007; 
Doil, Mailand et al. 2009). Another important ubiquitin ligase is BRCA1 with different 
important roles in the DDR, in DNA repair and in cell cycle checkpoint control (reviewed in 
Huen, Sy et al. 2010). Additionally, Mdm2, the main negative regulator of the tumor 
suppressor p53, is an ubiquitin ligase which is posttranslationally modified after DNA damage 
(Khosravi, Maya et al. 1999).  
Considering the importance of the ubiquitin system in the DDR and open questions in the 
response to cisplatin treatment, we decided to perform a high-content siRNA screen and to 
deplete cells from human ubiquitin ligases and DUBs. 
 
5.1.1 High-content siRNA screen procedure 
For the high-content screen, U2OS cells were transfected with a siRNA library targeting  
327 human ubiquitin ligases and 92 DUBs. These were the genes known at the time of library 
preparation in 2008. Till now, more than 600 E3 ligases and ca. 100 DUBs have been 
identified (Jackson and Durocher 2013). During the screen, three different siRNAs per gene 
were used. The osteosarcoma cell line U2OS was chosen as it is widely used to study the 
DDR and is appropriate for siRNA screening due to its good transfection efficiency and 
suitable morphology for immunofluorescence microscopy (Doil, Mailand et al. 2009; Beck, 
Nahse et al. 2010; Cotta-Ramusino, McDonald et al. 2011). 
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The procedure of high-content siRNA screening is depicted in Figure 5.1. U2OS cells were 
transfected with siRNAs and treated with cisplatin. Cells were fixed and subsequently stained 
for phospho-H2AX. Phosphorylation of the histone variant H2AX at Ser139 (then named 
γH2AX) was used as mark of DNA damage induction and quantified by automated 
microscopy and image analysis as explained in section 4.3.5 and Figure 5.1. γH2AX was 
selected since it is a suitable read-out widely used in the field of DDR research (reviewed in 
Fernandez-Capetillo, Lee et al. 2004; Stucki and Jackson 2006). Moreover, other groups 
have used it already as marker in siRNA screening (e.g. Paulsen, Soni et al. 2009; Higgins, 
Prevo et al. 2010). Here, we chose γH2AX to gain insight into the different molecular 





Figure 5.1: High-content siRNA screen procedure to identify new regulators in the DNA 
damage response to cisplatin. 
(Pictures of microscope and numbered nuclei taken from BD Pathway User’s Manual – AttoVision 
1.5, 2006) 
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As statistical measure of H2AX phosphorylation, a robust z-score was assigned to each 
siRNA. For details on analysis and controls, refer to 4.3.5. Every siRNA with a robust z-score 
of ≥ 2 or ≤ -2 was considered as a hit. Candidates were identified if at least two siRNAs 
reached the threshold of ≥ 2 or ≤ -2. Figure 5.2 shows candidates with substantial increase 
(positive robust z-score) and decrease (negative robust z-score) in γH2AX fluorescence 
intensity. Increased H2AX phosphorylation after knockdown suggests that the encoded 
protein inhibits the DDR, whereas decreased γH2AX levels propose that the encoded protein 
supports the DDR upon cisplatin treatment. 
Upon identification of candidate genes that show a strong down- or up-regulation of γH2AX 
after knockdown, screen results were validated in a secondary screen. Therefore, knockdown 
of candidate genes was performed using the same procedure as for the high-content siRNA 
screen. This second screen was performed for 29 genes that were identified to show a down-
regulation of γH2AX fluorescence intensity after knockdown and for 13 genes with an up-
regulation of γH2AX. After validation, additional siRNAs were obtained for a total of  
10 candidates that showed the strongest changes in γH2AX levels. These top candidates 
were validated by investigating γH2AX levels through immunofluorescence staining and 




























Figure 5.2: High-content siRNA screen results: The influence of 327 human ubiquitin ligases 
and 92 DUBs on H2AX phosphorylation.  
U2OS cells were transfected with siRNAs targeting 327 human ubiquitin ligases and 92 DUBs using 
three different siRNAs per gene. Cells were treated with 30 µM cisplatin for 16 h (total incubation time 
48 h), fixed and stained for γH2AX. Automated microscopy and image analysis was performed using 
the BD Pathway System. A robust z-score was assigned to each siRNA as a measure of H2AX 
phosphorylation. Candidates with significant increase (positive robust z-score) and decrease (negative 
robust z-score) in γH2AX fluorescence intensity are depicted as average robust z-score of three 
siRNAs per gene. Marked in red is candidate G2E3 and marked in dark grey are candidates RBBP6 
and STUB1, used for further studies as detailed in the text. PC = positive control. 
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5.1.2 Candidates identified by high-content siRNA screening 
We identified various genes that showed a strong decrease in H2AX phosphorylation upon 
knockdown. Interestingly, plenty of them were described before to be involved in the DDR 
and DNA repair, but also in the p53-pathway. These will be discussed in more detail in 
section 6.4. Unexpectedly, we did not identify many genes with a strong increase in γH2AX 
fluorescence intensity upon knockdown. These could have been candidates whose inhibition 
would sensitize cells to cisplatin. Still, it would be interesting to explore these genes further. 
Together, these results of known regulators of the DDR and p53-pathway suggest that the 
developed screen procedure was suitable to identify new regulators in the DDR after cisplatin 
treatment. After further validation, we decided to study the ubiquitin ligase G2E3 whose 
knockdown led to decrease in γH2AX levels upon cisplatin treatment. We were interested in 
G2E3 since it had been proposed to play a role in the DDR and in cell survival, but only little 
was known about the underlying mechanisms. G2E3 was reported to show a maximal mRNA 
expression in  
G2/M-phase and decreased mRNA levels upon γ-irradiation (thus G2E3 is the abbreviation 
for G2-specific E3 ligase) (Crawford and Piwnica-Worms 2001). Localization of G2E3 was 
proposed to be regulated by DNA damage (Brooks, Banerjee et al. 2007). G2E3 consists of 
four domains that can act as E3 ligases (three domains with similarity to both RING and PHD 
domains and a fourth HECT domain), and in vitro ubiquitin ligase activity was shown for the 
PHD/RING2 and PHD/RING3 domain (Brooks, Helton et al. 2008). Furthermore, Brooks et al. 
established a G2E3 knock-out mouse which displays early embryonic lethality (Brooks, 
Helton et al. 2008). Together, these findings motivated us to study the role of G2E3 in the 
DDR, in cell survival and in cell cycle regulation. 
 
5.2 Investigation of the ubiquitin ligase G2E3 as a regulator of the 
DDR to cisplatin treatment 
5.2.1 Knockdown of G2E3 decreases phosphorylation of H2AX in U2OS cells 
Using the described high-content siRNA screen, we found that knockdown of G2E3 led to 
decreased H2AX phosphorylation in cisplatin treated U2OS cells. We used 
immunofluorescence staining and immunoblotting to validate this observation (Figure 5.3). 
Figure 5.3A shows that depletion of G2E3 by three different siRNAs resulted in decreased 
γH2AX levels as seen by immunofluorescence staining. Additionally, decreased 
phosphorylation of H2AX after knockdown of G2E3 by three different siRNAs was revealed 
using immunoblotting (Figure 5.3B). The three siRNAs efficiently depleted cells of G2E3 as 
seen by qPCR analysis (Figure 5.3C). Unfortunately, a high-quality antibody to stain 
endogenous G2E3 protein was not commercially available.  
 





Figure 5.3: Knockdown of G2E3 decreases 
phosphorylation of H2AX in U2OS cells after 
cisplatin treatment. 
(A) U2OS cells were transfected with three 
different siRNAs against G2E3. Cells were 
either left untreated or treated with 30 µM 
cisplatin for 16 h (total incubation time 64 h), 
fixed and stained for γH2AX. Automated 
microscopy and image analysis was performed 
using the BD Pathway System. Results were 
corrected for background fluorescence. Error 
bars are represented as SD (n = 3).  
* = p < 0.05, ** = p < 0.01 (student’s t-test).  
(B) U2OS cells were depleted of G2E3 by 
siRNA-mediated knockdown. Cells were either 
left untreated or treated with 30 µM cisplatin for 
16 h (total incubation time 64 h). Cell lysates 
were analyzed by immunoblotting for γH2AX 
levels. Actin staining served as loading control.  
(C) Knockdown efficiency of G2E3 siRNAs. 
U2OS cells were harvested 64 h after 
knockdown. G2E3 mRNA levels were analyzed 
by qPCR. Results were normalized to 
expression of the reference gene GAPDH. 
Error bars are represented as SD (n = 3). 
 
 
5.2.2 G2E3 does not influence pChk1 and pChk2 levels in the DDR to cisplatin 
Crosslinking of DNA induced by cisplatin treatment leads to stalled replication forks. This 
results in DNA single-strand breaks that activate the ATR-Chk1 pathway. During repair of 
these lesions, DNA double-strand breaks are induced which activate the ATM-Chk2 pathway. 
Both pathways lead to activation of the tumor suppressor p53. Since ATM (350 kDa) and 
ATR (300 kDa) are large-size proteins and their activation is difficult to detect in 
immunoblotting, we determined pChk1 and pChk2 levels. Chk1 and Chk2 are the second line 
activation regulators which also give insight into activation of these pathways. In order to 
study whether G2E3 plays a role in these pathways, we depleted p53-proficient and p53-
deficient cells of G2E3 and assessed pChk1 and pChk2 levels by immunoblotting. Both Chk1 
and Chk2 become phosphorylated upon cisplatin treatment. However, we could not observe 
strong changes in pChk1 and pChk2 levels upon G2E3 knockdown in p53-proficent and  
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p53-deficient cell lines when compared to control knockdown. Here we depict pChk2 levels in 
p53-proficient U2OS cells (Figure 5.4A) and pChk1 levels in p53-deficient  
HCT116 p53-/- cells (Figure 5.4B). Certainly, we cannot exclude that G2E3 plays a direct role 





Figure 5.4: G2E3 in the DNA damage response after cisplatin treatment: G2E3 knockdown does 
not influence pChk1 and pChk2 levels.  
(A) U2OS cells were depleted of G2E3 using three different siRNAs and either left untreated or treated 
with 30 µM cisplatin for 8 h (total incubation time 55 h). Cell lysates were analyzed by immunoblotting 
for pChk2 and total Chk2 levels. Actin staining served as loading control. (B) HCT116 p53-/- cells were 
transfected with two different siRNAs against G2E3 and either left untreated or treated with 30 µM 
cisplatin for 16 h (total incubation time 64 h). Cell lysates were analyzed by immunoblotting for pChk1 
and total Chk1 levels. Actin staining served as loading control. 
 
 
5.2.3 Subcellular localization of overexpressed G2E3 
Many proteins involved in the DDR and cell cycle regulation are characterized by changing 
their localization upon treatment with DNA-damaging reagents. Often, nucleo-cytoplasmic 
exchange is observed, e.g. for p53 (reviewed in O'Brate and Giannakakou 2003) and for the 
localization of cyclins and CDKs (reviewed in Yang and Kornbluth 1999). Therefore, we were 
interested in studying the localization of G2E3 within the cell. Since no antibody to detect 
endogenous G2E3 is commercially available, we cloned and overexpressed a HA-tagged 
version of G2E3 in U2OS cells, followed by immunofluorescence staining. As depicted in 
Figure 5.5 (upper panel), HA-G2E3 was localized to the nucleus and subnuclear structures of 
U2OS cells. We co-stained nucleoli using nucleophosmin and PML bodies, but could not 
observe a co-localization (data not shown). Upon cisplatin treatment, HA-G2E3 was still 
localized to nuclei of cells, but excluded from some areas of the nucleus (Figure 5.5, lower 
panel). Brooks et al. showed that in HeLa cells, GFP-G2E3 is primarily localized to the 
nucleolus, but localized to the nucleoplasm in a diffuse manner after DNA damage  
(γ-irradiation, doxorubicin and etoposide treatment) (Brooks, Banerjee et al. 2007). These 
results suggest that localization of G2E3 changes upon DNA damage. 
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Figure 5.5: Overexpressed HA-G2E3 localizes to nuclei and subnuclear structures in untreated 
cells and to nuclei with exclusion from some areas in cisplatin treated cells.  
U2OS cells were transiently transfected with a plasmid encoding HA-G2E3 for 24 h and either left 
untreated or treated with 30 µM cisplatin during the last 4 h. Cells were fixed and stained for HA-tag 
and Hoechst. Microscopy was performed using the BD Pathway System. 
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5.3 G2E3 as a regulator of apoptosis and cell cycle 
5.3.1 Knockdown of G2E3 results in p53-independent apoptosis in colon 
carcinoma and osteosarcoma cell lines 
Phosphorylation of H2AX is commonly used as marker of DNA damage, but was also found 
during apoptosis after induction of DNA fragmentation (Rogakou, Nieves-Neira et al. 2000). A 
link between apoptosis and DDR was also suggested by another group who showed that 
Chk2- and H2AX-associated signal transduction can be activated by death receptor signaling 
(Solier, Sordet et al. 2009). Therefore, we were interested to investigate the effect of G2E3 
depletion on apoptosis. We depleted colon carcinoma (HCT116) and osteosarcoma (U2OS, 
SJSA) cell lines of G2E3, followed by cisplatin treatment and immunoblotting (Figure 5.6A-D). 
Apoptosis was accelerated upon G2E3 knockdown in all cell lines, as detected by the 
apoptotic markers cleaved caspase 3 and cleaved PARP-1. Even in untreated cells, induction 
of apoptosis upon G2E3 knockdown was observed in some cases, giving a hint for its 
important role in cell survival (Figure 5.6A-C). Since p53 is an important regulator of 
apoptosis, we used HCT116 p53-/- cells to investigate whether p53 is required for apoptosis 
upon G2E3 knockdown. Strikingly, in p53-deficient cells, knockdown of G2E3 also leads to 
increased apoptosis (Figure 5.6B). This result suggests that G2E3 plays a p53-independent 
role in apoptosis and could function as an anti-apoptotic protein in the cell. These results are 
in line with Brooks, Helton et al. (2008) who established a G2E3 knock-out mouse which is 
characterized  by early embryonic lethality. The reasons are massive apoptosis and involution 
of the blastocyst. In order to investigate the p53-dependency of their observations, they 
established double heterozygous mice for G2E3 and p53 (i.e. G2E3-/+ and p53-/+). 
Remarkably, they did not obtain any G2E3-/-/p53-/- mice, meaning that loss of p53 could not 
rescue the lethal phenotype of G2E3 knock-out mice.  
In summary, G2E3 knockdown leads to increased apoptosis in various cell lines in a  
p53-independent manner. These results suggest that G2E3 plays an important role in cell 
survival. 
Interestingly, knockdown of G2E3 led to decreased H2AX phosphorylation only in U2OS cells 
as seen before in Figure 5.3, but not in HCT116 and SJSA cells, arguing for a cell type-









Results      73 
 





Figure 5.6: Knockdown of G2E3 results in apoptosis in colon carcinoma (HCT116) and 
osteosarcoma (U2OS, SJSA) cell lines.  
(A) HCT116 p53+/+, (B) HCT116 p53-/-, (C) U2OS and (D) SJSA cells were depleted of G2E3 by 
siRNA-mediated knockdown with two to three different siRNAs and either left untreated or treated with 
30 µM cisplatin for 16 h (total incubation time 64 h). Cell lysates were analyzed by immunoblotting. 
Markers for apoptosis are cleaved caspase 3 (Cleaved Casp. 3), total caspase 3 and cleaved PARP-1 
(total protein at 115 kDa and cleaved PARP-1 at 90 kDa). γH2AX staining was used as control for 
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5.3.2 Proliferation rate of cancer cells is decreased following depletion of 
G2E3  
To further evaluate the role of G2E3 in cell survival, we set out to study its impact on cell 
proliferation. We measured cell confluence over time after G2E3 knockdown in U2OS, 
HCT116 p53+/+ and HCT116 p53-/- cells. We found that cell proliferation was decreased after 
G2E3 knockdown with three different siRNAs in all cell lines (Figure 5.7A-C). The reason for 
reduced proliferation could be an increased susceptibility to apoptosis after G2E3 knockdown 
(as seen in Figure 5.6) or induction of cell cycle arrest. A main regulator of the cell cycle is 
p53, but also p53-independent cell cycle regulation exists. Interestingly, cell proliferation is 
also alleviated in p53-deficient HCT116 cells (Figure 5.7B). To clarify if G2E3 also plays a 
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Figure 5.7: Proliferation rate of cells is decreased following depletion of G2E3.  
(A, B) Conducted with Ann-Christine Loock. HCT116 p53+/+ and HCT116 p53-/- cells were depleted of 
G2E3 by siRNA-mediated knockdown with three different siRNAs. Error bars are represented as 
SEM (n = 4). (C) U2OS cells were depleted of G2E3 by siRNA-mediated knockdown with three 
different siRNAs. Error bars are represented as SEM (n = 3). Cell proliferation was investigated by 
measuring cell confluence over five days with the Celigo cell cytometer (Cyntellect).  
 
 
5.3.3 Knockdown of G2E3 results in G1-arrest and decreased percentage of 
cells in S-phase in untreated as well as cisplatin treated U2OS cells 
To further explore whether the decrease in cell proliferation is due to increased apoptosis 
and/or cell cycle arrest, we performed cell cycle analysis using flow cytometry of propidium 
iodide stained U2OS cells after G2E3 knockdown (Figure 5.8). Thereby, knockdown of 
Mdm2, which results in a G1-arrest, served as positive control for induction of cell cycle 
arrest. This was previously shown in untreated and UV-irradiated U2OS cells (Kranz, 
Dohmesen et al. 2008). It is generally accepted that Mdm2 inhibits p53 functions like 
induction of G1-arrest and apoptosis. In this way, Mdm2 knockdown leads to increased p53 
activity as seen by G1-arrest in Figure 5.8A. Mdm2 was also shown to positively regulate 
transition from G1- to S-phase by stimulating the S-phase inducing transcription factor E2F1 
(Martin, Trouche et al. 1995) and by inhibiting retinoblastoma protein (RB) (Xiao, Chen et al. 
1995). This is a second explanation why Mdm2 knockdown results in G1-arrest. G1-arrest 
leads to a decreased percentage of cells in S-phase. We found that depletion of G2E3 
resulted in G1-arrest and reduced number of cells in S-phase. This was true not only for 
untreated (Figure 5.8), but also for cisplatin treated U2OS cells (Figure 5.9). These 
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Figure 5.8: Knockdown of G2E3 results in G1-arrest and decreased percentage of cells in S-
phase in untreated cells.  
(A, B) U2OS cells were depleted of G2E3 and Mdm2 by siRNA-mediated knockdown. Cell cycle 
analysis was performed by flow cytometry of propidium iodide stained cells. Percentage of cells in  
S-phase is depicted separately for improved visualization (B). Error bars are represented as  







Figure 5.9: Knockdown of G2E3 results in G1-arrest and decreased percentage of cells in S-
phase after cisplatin treatment.  
(A, B) U2OS cells were depleted of G2E3 and Mdm2 by siRNA-mediated knockdown and treated with 
30 µM cisplatin for 16 h (total incubation time 64 h). Cell cycle analysis was performed by flow 
cytometry of propidium iodide stained cells. Percentage of cells in S-phase is depicted separately for 
improved visualization (B). Error bars are represented as SD (n = 3). * = p < 0.05, ** = p < 0.01 
(student’s t-test). 
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5.4 G2E3 in the p53-pathway  
5.4.1 Knockdown of G2E3 results in p53-dependent p21 induction in U2OS 
cells 
As described above, G2E3 knockdown led to G1-arrest and lower percentage of cells in  
S-phase in untreated as well as cisplatin treated cells. Cell cycle arrest is mainly regulated by 
p53 and its target gene p21, a cyclin-dependent kinase inhibitor. Our purpose was to analyze 
whether knockdown of G2E3 would result in induction of these known cell cycle regulators. 
Indeed, analysis by immunoblotting revealed that p53 and p21 were induced upon G2E3 
knockdown in U2OS cells (Figure 5.10A, columns 1, 2 and 3). Knockdown of Mdm2 served 
as positive control since it causes p53 induction and p21 expression. We also performed a 
double-knockdown of Mdm2 and G2E3 to investigate whether induction of p21 after G2E3 
knockdown depends on Mdm2 (Figure 5.10A, columns 4, 5 and 6). No additive effect after 
double-knockdown of G2E3 and Mdm2 was observed regarding p21 levels, which could 
mean that induction of p21 after G2E3 depletion is dependent on Mdm2. Furthermore, we 
demonstrated with three different siRNAs targeting G2E3 that transcription of p21 was slightly 
induced upon G2E3 knockdown (Figure 5.10B). This was dependent on p53 since a double-
knockdown of G2E3 and p53 abolished p21 induction, as depicted in Figure 5.10C (columns 
4, 5 and 6).  
Knockdown of G2E3 in U2OS cells led to induction of G1-arrest as seen by flow cytometry 
(Figure 5.8 and Figure 5.9) and induction of p53 and p21 (Figure 5.10). These results suggest 
that reduction in H2AX phosphorylation upon G2E3 knockdown in cisplatin treated U2OS 
cells (Figure 5.3) could be explained by induction of cell cycle arrest: Arrested cells do not 
continue replicating their DNA and are therefore less prone to be harmed by cisplatin 
treatment. This hypothesis is supported by the fact that also Mdm2 knockdown led to 
induction of G1-arrest and exhibited decreased γH2AX levels upon cisplatin treatment as 
seen in the screen (Figure 5.2). Reduced phosphorylation of H2AX upon Mdm2 knockdown 
was also detected in UV-irradiated U2OS cells (Kranz, Dohmesen et al. 2008).  
These results point towards a connection between G2E3 and the p53-pathway and motivated 
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Figure 5.10: Knockdown of G2E3 results in 
p53-dependent p21 induction in U2OS cells. 
(A) U2OS cells were transfected with 
combinations of siRNAs targeting G2E3 and 
Mdm2 as indicated. Knockdown of p53 served 
as control. After 48 h, cells were harvested and 
cell lysates were analyzed by immunoblotting 
using the indicated antibodies. Actin staining 
served as loading control. (B) U2OS cells were 
depleted of G2E3, p21 and p53 by siRNA-
mediated knockdown. After 64 h, cells were 
harvested and p21 mRNA levels were analyzed 
by qPCR. Results were normalized to 
expression of the reference gene GAPDH. 
Error bars are represented as SD (n = 3).  
* = p < 0.05, ** = p < 0.01, n.s. = not significant 
(student’s t-test). (C) U2OS cells were 
transfected with combinations of siRNAs 
targeting G2E3 and p53 as indicated. 
Knockdown of Mdm2 served as control. After 
64 h, cells were harvested and cell lysates 
were analyzed by immunoblotting using the 
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5.4.2 Depletion of the p53-pathway regulators RBBP6 and STUB1 results in 
decreased γH2AX levels similar to G2E3 knockdown 
Considering the obtained results, we started to investigate the role of G2E3 in the  
p53-pathway. Interestingly, knockdown of two more screen candidates led to a decrease in 
γH2AX levels comparable to G2E3 depletion (Figure 5.2) which are known as regulators of 
the p53-pathway: RBBP6 (or PACT) and STUB1 (or CHIP). The Retinoblastoma binding 
protein 6 (RBBP6) interacts with Mdm2 and enhances Mdm2-mediated ubiquitination and 
degradation of p53 due to increased p53-Mdm2-affinity (Li, Deng et al. 2007). Furthermore, 
RBBP6 knockdown attenuates the interaction of p53 and Mdm2 and reduces 
polyubiquitination of p53 and thus enhances p53 accumulation which leads to apoptosis and 
cell growth retardation. The ubiquitin ligase STUB1 (or CHIP) was identified to target p53 for 
proteasomal degradation (Esser, Scheffner et al. 2005).  
Decrease in H2AX phosphorylation after knockdown of RBBP6 and STUB1 and cisplatin 
treatment could be validated by immunoblotting with three different siRNAs targeting each 
gene (Figure 5.11A,B). Knockdown of RBBP6 and STUB1 also led to induction of p21 in 





Figure 5.11: Knockdown of RBBP6 or STUB1/CHIP decreases phosphorylation of H2AX in 
U2OS cells.  
U2OS cells were transfected with three different siRNAs targeting (A) RBBP6 or (B) STUB1/CHIP and 
either left untreated or treated with 30 µM cisplatin for 16 h (total incubation time 64 h). Cell lysates 
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Since RBBP6, STUB1 and Mdm2 are involved in the p53-pathway and led to decreased 
H2AX phosphorylation and p21 induction upon knockdown similar to G2E3 depletion, we 
assumed that G2E3 might play a role in the p53-pathway and continued our studies in this 
direction. 
 
5.4.3 Overexpressed Mdm2 and G2E3 co-localize and relocalize to subnuclear 
structures in untreated and cisplatin treated cells 
With the aim to study the role of G2E3 in the p53-pathway, we next asked whether G2E3 
might co-localize with p53 and Mdm2. To this end, we co-expressed Mdm2 and a HA-tagged 
version of G2E3 in U2OS cells. Since both proteins are ubiquitin ligases and could potentially 
ubiquitinate or even degrade each other, we additionally applied the proteasome inhibitor 
MG132. Remarkably, we observed a co-localization of co-expressed HA-G2E3 and Mdm2, 
both relocalizing to subnuclear structures in untreated U2OS cells (Figure 5.12). Co-
localization could be detected in approx. 50 % of cells expressing both HA-G2E3 and Mdm2. 
We wondered whether co-localization would be dependent on the ubiquitin ligase activity of 
Mdm2. Therefore, we co-expressed HA-G2E3 and a version of Mdm2 harboring a mutated 
RING domain (Mdm2 RING mutant). Interestingly, HA-G2E3 and Mdm2 RING mutant could 
still co-localize and relocalize to subnuclear structures. Hence, colocalization of these 
proteins was independent of Mdm2 ubiquitin ligase activity. Furthermore, HA-G2E3 and 
Mdm2 still co-localized upon cisplatin treatment (Figure 5.13) as well as upon NCS treatment, 
showing that damaged DNA did not affect or abolish co-localization of both proteins. 
However, when co-expressing HA-G2E3 and p53, we could not observe a co-localization of 
both proteins (data not shown). We also investigated co-localization of HA-G2E3 with  
p14-ARF, a regulator of Mdm2, but did not detect any.  
The co-localization of HA-G2E3 and Mdm2 was a first hint that these proteins could be found 
in a complex. To validate the interaction between HA-G2E3 and Mdm2, we performed  
co-immunoprecipitation experiments.  
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Figure 5.12: Overexpressed Mdm2 and G2E3 co-localize and relocalize to subnuclear 
structures in untreated cells. Co-localization is independent of Mdm2 ubiquitin ligase activity 
since Mdm2 RING mutant and G2E3 also co-localize.  
U2OS cells were transiently transfected with plasmids encoding (A) HA-G2E3, (B) Mdm2,  
(C,D) HA-G2E3 and Mdm2, (E) Mdm2 RING mutant and (F) HA-G2E3 and Mdm2 RING mutant for 24 
h and treated with 20 µM of the proteasome inhibitor MG132 during the last 4 h. Cells were fixed and 
stained for HA-tag, Mdm2 and Hoechst. Microscopy was performed using the BD Pathway System. 
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Figure 5.13: Overexpressed Mdm2 and G2E3 co-localize and relocalize to subnuclear 
structures in cisplatin treated cells.  
U2OS cells were transiently transfected with plasmids encoding (A) Mdm2, (B) HA-G2E3,  
(C,D) HA-G2E3 and Mdm2 for 24 h and treated with 30 µM cisplatin and 20 µM of the proteasome 
inhibitor MG132 during the last 4 h. Cells were fixed and stained for HA-tag, Mdm2 and Hoechst. 
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5.4.4 Overexpressed G2E3 and Mdm2 are found in a complex 
Since co-expressed Mdm2 and HA-G2E3 were found to co-localize, we wanted to test 
whether both proteins can be found in a complex. Therefore, we performed co-
immunoprecipitation (CoIP) experiments. We co-expressed Mdm2 and HA-G2E3 in U2OS 
cells. Since both proteins are ubiquitin ligases and could potentially ubiquitinate or degrade 
each other, we applied the proteasome inhibitor MG132, as was done for immuno-
fluorescence experiments in Figure 5.12 and Figure 5.13. We were able to precipitate 
overexpressed Mdm2 using a Mdm2 antibody and overexpressed HA-G2E3 using a HA-tag 
antibody. We found HA-G2E3 bound to precipitated Mdm2. Vice versa, Mdm2 was bound by 
precipitated HA-G2E3 (Figure 5.14). These results argue in favor of an interaction of G2E3 
and Mdm2 when co-expressed.  
 
 
Figure 5.14: Overexpressed G2E3 and Mdm2 are found in a complex.  
Conducted by Ann-Christine Loock. U2OS cells were transiently transfected with plasmids encoding 
Mdm2 and HA-G2E3 for 24 h. An empty plasmid (pcDNA3) was transfected as control. During the 
last 4 h, cells were treated with 20 µM of the proteasome inhibitor MG132. Immunoprecipitation using 
a Mdm2 and a HA-tag-specific antibody was performed and precipitated proteins were analyzed by 
immunoblotting. To control for unspecific binding, β-Galactosidase (β-Gal) was used as control 
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Here, two bands for Mdm2 were detected at around 100 kDa. For Mdm2, different splice 
variants, post-translational modifications and various isoforms are known (for details see 
section 2.3.2.2). Full-length Mdm2 at 97 kDa is often seen as two bands in Western blot 
which are supposed to be isoforms. Mdm2 transcripts initiated from the p53-activated (P2) 
promoter are preferentially the 97 kDa isoform. This isoform was shown to be responsible for 
p53 degradation (Cheng and Cohen 2007). Also, lower bands at 60 kDa are often observed. 
Additional Mdm2 proteins seem to exist due to differences in mRNA splicing and post-
translational modifications (Olson, Marechal et al. 1993). The mechanisms and biological 
roles of Mdm2 isoforms are largely unknown.  
 
5.4.5 Mdm2 and p53 interact independently of co-expressed HA-G2E3 
Since Mdm2 binds and inhibits p53, we addressed the question whether interaction with p53 
would be disturbed by Mdm2-G2E3-interaction. We conducted CoIP of combinations of co-
expressed HA-G2E3, Mdm2 and p53 alone, in pairs and of all three proteins together in 
U2OS cells (Figure 5.15). Input samples of all combinations are depicted in Figure 5.15A. We 
found that Mdm2 and p53 could interact independently of co-expressed HA-G2E3 (Figure 
5.15B, columns M and N, and Figure 5.15C, columns F and G). We further investigated 
whether the interaction of Mdm2 and G2E3 would be disrupted by co-expressing p53. 
Interestingly, we observed that HA-G2E3 and Mdm2 interacted independently of co-
expressed p53 (Figure 5.15B, columns D, G, K and N). We also studied whether G2E3 could 
bind p53. This was the case though the interaction was only weakly detectable and 
independent of co-expressed Mdm2 (Figure 5.15B and Figure 5.15C, columns E and G in 
each sub-figure).  
These results suggest that the three proteins form a complex when overexpressed, but that 
binding between two interaction partners is independent of the third one. Whether all three 
proteins are bound to each other or whether G2E3 is bound to Mdm2 and p53 to Mdm2 
without interacting with G2E3 is not known. Further studies are necessary to answer these 
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Figure 5.15: Mdm2 and p53 interact independently of co-expressed HA-G2E3. HA-G2E3-
Mdm2-interaction is independent of co-expressed p53. Overexpressed G2E3 and p53 are 
found in a complex.  
U2OS cells were transiently transfected with plasmids encoding Mdm2, p53 and HA-G2E3 for 24 h. 
The ratio was 40 % HA-G2E3, 35 % Mdm2, 25 % p53, filled with empty plasmid (pcDNA3) up to  
100 %. During the last 4 h, cells were treated with 20 µM of the proteasome inhibitor MG132. Cells 
were harvested for co-immunoprecipitation (CoIP). The DUB inhibitor N-ethylmaleimide was added to 
the CoIP buffer. (A) Immunoblotting of input samples before immunoprecipitation is depicted.  
(B) Immunoprecipitation using a Mdm2 and a HA-tag-specific antibody was performed and 
precipitated proteins were analyzed for Mdm2, p53 and HA-G2E3 by immunoblotting.  
(C) Immunoprecipitation using a p53 and β-Galactosidase (β-Gal) antibody was performed and 
precipitated proteins were analyzed by immunoblotting using the indicated antibodies.  
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5.4.6 An endogenous interaction of G2E3 and Mdm2 is not detectable 
independent of p53-status 
When we observed an interaction of co-expressed Mdm2, G2E3 and p53, we next wanted to 
check for an endogenous interaction. Mdm2 and p53 are low-abundant proteins, mainly 
because p53 is kept at low levels by ubiquitin-mediated degradation through Mdm2. Given 
the fact that we wanted to precipitate endogenous proteins of low concentration and were not 
provided with a high-quality G2E3-antibody, we used four to six 15 cm cell culture dishes to 
precipitate endogenous p53, Mdm2 and G2E3. We used SJSA cells with a comparatively 
high Mdm2 expression since the mdm2 gene is ca. 25-fold amplified in this cell line (Chen, Lu 
et al. 1999; Tovar, Rosinski et al. 2006). We performed CoIPs in p53-proficient cell lines 
(U2OS, SJSA, Figure 5.16B,C) and p53-deficient cell lines (H1299 and HCT116 p53-/-, Figure 
5.16A). As was done for immunofluorescence and exogenous CoIP experiments, we inhibited 
the proteasome by MG132 treatment since Mdm2 and G2E3 could potentially ubiquitinate or 
degrade each other. MG132 treatment was only used for p53-deficient cell lines, since it 
would lead to accumulation and thus activation of p53 in p53-proficient cells. It was reported 
that p53 can repress and activate gene expression via the large intergenic noncoding RNA 
lincRNA-p21 which is a p53-target in response to DNA damage (Huarte, Guttman et al. 
2010). One of the genes repressed via p53 and lincRNA-p21 was G2E3. Activated p53 could 
thus repress G2E3 mRNA expression which would have resulted in even lower endogenous 
G2E3 levels.  
We were able to precipitate endogenous Mdm2, p53 and G2E3 with the respective 
antibodies. However, we could not detect any interaction between the proteins under the 
conditions applied. Even the interaction of Mdm2 and p53 was not detectable in p53-
proficient U2OS and SJSA cells. This could be due to the fact that we did not inhibit the 
proteasome by MG132 treatment which supports detection of the Mdm2-p53-interaction as 
seen in overexpression experiments (Figure 5.15). One reason for not detecting an 
endogenous interaction of G2E3 with Mdm2 or p53 could be extremely low levels of 
detectable endogenous G2E3. G2E3 was also not measurable in input samples (Figure 
5.16A-C). Interestingly, the molecule size of G2E3 was smaller in SJSA cells (ca. 65 kDa) 
than the reported size of 80 kDa which was detected in all other cell lines. SJSA cells could 
harbor a G2E3 isoform. This is possible considering that 15 G2E3 transcripts including eight 













Figure 5.16: An endogenous interaction of G2E3 and Mdm2 is not detectable in p53-proficient 
(U2OS, SJSA) and p53-deficient (H1299 and HCT116 p53-/-) cell lines.  
(A) H1299 and HCT116 p53-/- cells were treated with 20 µM of the proteasome inhibitor MG132 for 4 
h and harvested for co-immunoprecipitation (CoIP). The DUB inhibitor N-ethylmaleimide was added 
to the CoIP buffer. Immunoprecipitation using a Mdm2- and a G2E3-specific antibody was performed 
and precipitated proteins were analyzed by immunoblotting. A β-Galactosidase (β-Gal) antibody was 
used to control for unspecific binding. (B) SJSA and (C) U2OS cells without MG132 treatment were 
harvested for CoIP. The DUB inhibitor N-ethylmaleimide was added to the CoIP buffer. 
Immunoprecipitation using a Mdm2, a p53 and a G2E3-specific antibody was performed and 
precipitated proteins were analyzed by immunoblotting using the indicated antibodies. 
Immunoprecipitation using a β-Galactosidase (β-Gal) and Immunoglobulin G (IgG) antibody was 
performed as control to detect unspecific binding.  
Results      89 
5.4.7 Overexpressed G2E3 has no impact on p53 transcriptional activity and 
on Mdm2-dependent inhibition of p53 transactivation 
Activation and stabilization of the tumor suppressor p53 turns on expression of genes that are 
involved in cell cycle arrest and apoptosis. Many positive and negative regulators of p53 
activity are known. To shed more light on the functional relevance of the interaction between 
HA-G2E3, Mdm2 and p53, we investigated the impact of G2E3 on p53 transcriptional activity. 
To this end, we performed a luciferase reporter assay in p53-deficient H1299 cells by co-
expressing different combinations of p53, Mdm2 and HA-G2E3 (Figure 5.17). We made use 
of a reporter construct harboring a p53-responsive promoter containing 13 p53 binding sites 
upstream of the Firefly luciferase gene.  
As expected, co-expression of Mdm2, the ubiquitin ligase negatively regulating p53, led to 
concentration-dependent decrease in p53 transcriptional activity. We overexpressed the p53 
family member ΔNp63 as an additional positive control. P63 was shown to activate and 
repress transcription of a β-galactosidase reporter gene downstream of p53 DNA-binding 
sites (Yang, Kaghad et al. 1998): Thereby, the so-called TAp63 isoform can transactivate p53 
target genes and thus mimic p53 function, whereas the ΔNp63 isoform lacks the N-terminal 
transactivation domain and has a dominant negative effect on p53. As expected, 
overexpression of ΔNp63 suppressed p53 transcriptional activity (Figure 5.17). On the 
contrary, we did not observe an impact of overexpressed HA-G2E3 on p53 activity under the 
conditions applied and using different plasmid amounts. Furthermore, overexpressed  
HA-G2E3 did not influence the negative regulation of Mdm2 on p53. Mdm2 repressed p53 
activity in a concentration-dependent manner which was not affected by co-expression of HA-
G2E3. We conclude that G2E3 does not impair p53 transcriptional activity and Mdm2-
dependent inhibition of p53 transactivation. It should be further tested if G2E3 affects p53 
transcriptional activity upon cisplatin treatment. 
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Figure 5.17: Overexpressed G2E3 has no impact on p53 transcriptional activity and on Mdm2-
dependent inhibition of p53 transactivation.  
Luciferase assay: p53-deficient H1299 cells were transfected with the reporter plasmid  
pGL3-PG13-Luc to detect p53 transcriptional activity and with different combinations of plasmids 
encoding the proteins p53, ΔNp63, Mdm2 and HA-G2E3. After 24 h of transfection, cells were lysed 
and luciferase activity was determined and normalized to co-transfected Renilla. Error bars are 




5.4.8 Co-expression of Mdm2 and HA-G2E3 does not affect their protein levels 
To elucidate the function of G2E3, we wanted to clarify whether the ubiquitin ligases G2E3 
and Mdm2 regulate each other by ubiquitination and degradation. Furthermore, we 
investigated whether G2E3 could ubiquitinate p53. 
Whereas substrates for G2E3 are not established, it is known that Mdm2 ubiquitinates not 
only itself and p53 (Fang, Jensen et al. 2000), but also proteins like IGF-1R (insulin-like 
growth factor 1 receptor) (Girnita, Girnita et al. 2003), PCAF (p300/CREB-binding protein-
associated factor) (Jin, Zeng et al. 2004) and E-cadherin (Yang, Zong et al. 2006). We co-
expressed HA-G2E3 and Mdm2 and investigated their protein levels and ubiquitination status 
after treatment with the proteasome inhibitor MG132 by immunoblotting. We did not detect 
mono- or poly-ubiquitination of HA-G2E3, Mdm2 and p53. Also, no increased degradation of 
one of the proteins was observed and protein levels did not change under the conditions 
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applied (Figure 5.18). Mdm2 and p53 are high-turnover proteins: p53 has a half-life of about 
30 min (Maltzman and Czyzyk 1984) and Mdm2 of about 20 min (Olson, Marechal et al. 
1993) in untreated cells. Due to this fact, treating the cells with MG132 for 4 h led to 
accumulation of p53 and Mdm2 (Figure 5.18). Interestingly, treatment with MG132 also 
caused accumulation of HA-G2E3 which appears to be a high-turnover protein, too. 
As seen in Figure 5.18 and also in Figure 5.15A, co-expression of HA-G2E3, Mdm2 and p53 
did not lead to ubiquitination or degradation of HA-G2E3 and Mdm2. Furthermore, HA-G2E3 
did not affect regulation of p53 levels by Mdm2. We therefore concluded that G2E3 did not 
ubiquitinate and/or degrade Mdm2 and vice versa. Moreover, G2E3 did not ubiquitinate 




Figure 5.18: Co-expression of Mdm2 and HA-G2E3 does not affect their protein levels.  
U2OS cells were transiently transfected with plasmids encoding Mdm2 (50 %) and HA-G2E3 (50 %) 
for 24 h. During the last 4 h, cells were treated with 20 µM of the proteasome inhibitor MG132 (or 
DMSO as control). Cell lysates were analyzed by immunoblotting using the indicated antibodies. 
Coexpression of 5 % GFP plasmid served as control for transfection efficiency. Actin staining served 
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5.4.9 Overexpressed HA-G2E3 does not affect Mdm2 and p53 levels in 
cisplatin treated cells, but HA-G2E3 levels are down-regulated by 
cisplatin treatment 
Overexpressed HA-G2E3 does not affect Mdm2 and p53 levels as stated previously (Figure 
5.18). We next asked whether G2E3 would have an influence on Mdm2 or p53 levels 
following cisplatin treatment. Therefore, we overexpressed HA-G2E3 in the presence of 
cisplatin and explored Mdm2 and p53 levels by immunblotting (Figure 5.19). Just as in 
untreated cells, HA-G2E3 did not influence Mdm2 and p53 levels upon cisplatin treatment. 
Surprisingly, cisplatin treatment led to strong decrease in HA-G2E3 levels. Phosphorylated 
Chk1 was used as a control for cisplatin treatment which activates the ATR-Chk1 pathway. 
Phospho-Chk1 levels did not change upon HA-G2E3 overexpression which means that HA-




Figure 5.19: Overexpressed HA-G2E3 does not affect Mdm2 and p53 levels in cisplatin treated 
U2OS cells. HA-G2E3 protein levels are down-regulated by cisplatin treatment.  
U2OS cells were transiently transfected with a plasmid encoding HA-G2E3 or with an empty plasmid 
(pcDNA3) as control. Cells were either left untreated or treated with 30 µM cisplatin for 16 h (total 
incubation time ca. 48 h). Cell lysates were analyzed by immunoblotting using the indicated 
antibodies. Staining of pChk1 was used as control for cisplatin treatment. Coexpression of 5 % GFP 
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In order to investigate whether HA-G2E3 levels are decreased due to reduced G2E3 protein 
stability, we overexpressed HA-G2E3 in the presence of cisplatin and the proteasome 
inhibitor MG132. Extenuated HA-G2E3 levels were not rescued by MG132 treatment, which 
means that G2E3 protein stability was not affected (Figure 5.20A). Decreased HA-G2E3 
levels could also be the result of increased apoptosis and thus proteolytic cleavage following 
cisplatin treatment. To test this possibility, we analyzed if caspase inhibition by Z-VAD 
treatment would abrogate decreased HA-G2E3 levels upon cisplatin treatment. Z-VAD is an 
irreversible, cell permeable caspase inhibitor that was shown to inhibit apoptosis induced by 
Fas (Chow, Weis et al. 1995), cycloheximide, etoposide and staurosporine (Zhu, Fearnhead 
et al. 1995). Interestingly, Z-VAD treatment indeed rescued the decrease in HA-G2E3 levels, 
arguing for an apoptosis-dependent cleavage of HA-G2E3 (Figure 5.20B). To explore this 
further, we used the CASVM software (Wee, Tan et al. 2007) to predict caspase cleavage 
sites based on algorithms developed by Wee et al. (Wee, Tan et al. 2006). We found  
27 potential caspase cleavage sites for G2E3. To assess if HA-G2E3 was cleaved upon 
cisplatin treatment, we looked for fragments of HA-G2E3 by immunoblotting, but unfortunately 
could not detect any using the HA-tag antibody (data not shown). This was probably because 
the antibody only detects the HA-tag, which allows detection only of tagged fragments. Since 
three potential cleavage sites are at amino acid 8, 21 and 22, fragments could be very small 
and difficult to observe whereas the bigger fragment(s) would not contain the HA-tag 
anymore. We suggest investigating GFP-tagged G2E3 since GFP-tag is larger compared to 
HA-tag and is not cleaved by caspases. Thus, overexpressing GFP-G2E3 would enable us to 
detect potential G2E3 cleavage fragments. To determine G2E3 caspase cleavage sites in 
more detail, a systematic approach with mutated G2E3 protein forms should be conducted. 
Furthermore, we were interested if phosphorylation of H2AX is only caused by activation of 
the ATR-Chk1 and ATM-Chk2 pathway or if induction of apoptosis contributed to it. We found 
that under the conditions applied (30 µM cisplatin treatment for 16 h), γH2AX levels are 
decreased upon cisplatin treatment and caspase inhibition by Z-VAD compared to cisplatin 
treatment alone (Figure 5.20B). Thus, phosphorylation of H2AX upon cisplatin treatment is to 
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Figure 5.20: Decrease in HA-G2E3 
protein levels upon cisplatin 
treatment is not due to proteasome 
activity, but dependent on 
apoptosis. 
U2OS cells were transiently 
transfected with a plasmid encoding 
HA-G2E3 or with an empty plasmid 
(pcDNA3) as control. Coexpression of 
5 % GFP plasmid served as control for 
transfection efficiency (* = unspecific 
band). (A) Cells were either left 
untreated or treated with 30 µM 
cisplatin for 16 h. During the last 4 h, 
cells were treated with 20 µM of the 
proteasome inhibitor MG132 (or DMSO 
as control). Total incubation time was 
ca. 48 h. Cell lysates were analyzed by 
immunoblotting using the indicated 
antibodies. γH2AX staining was used 
as control for cisplatin treatment. Actin 
staining served as loading control.  
(B) Cells were either left untreated or 
treated with 30 µM cisplatin and/or  
50 µM caspase inhibitor Z-VAD for  
16 h (DMSO as control). Total 
incubation time was ca. 48 h. Cell 
lysates were analyzed by immuno-
blotting using the indicated antibodies. 
Markers for apoptosis are cleaved 
caspase 3 (Cleaved Casp. 3), total 
caspase 3 and cleaved PARP-1  
(total protein at 115 kDa and cleaved 
PARP-1 at 90 kDa). γH2AX staining 
was used as control for cisplatin 
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5.4.10  Loss of G2E3 results in decreased Mdm2 protein levels after cisplatin 
and neocarzinostatin treatment independent of p53-status 
So far, overexpression and co-expression of HA-G2E3 and Mdm2 did not reveal the 
relevance of their interaction. Thus, we conducted G2E3 knockdown experiments and 
investigated its impact on Mdm2. We already could show that knockdown of G2E3 induces 
p53 and p21 in U2OS cells, but had no impact on Mdm2 levels in this cell line (Figure 5.10). 
Interestingly, we noticed that G2E3 knockdown led to a strong decrease in Mdm2 levels after 
cisplatin treatment in both HCT116 p53+/+ and HCT116 p53-/- cells, hence in a  
p53-independent manner (Figure 5.21A,B). Furthermore, we detected decreased Mdm2 
levels upon G2E3 knockdown also in neocarzinostatin treated HCT116 p53-/- cells (Figure 
5.21C). Interestingly, decrease in Mdm2 protein levels was also seen in untreated cells after 







Figure 5.21: Knockdown of G2E3 results in 
decreased Mdm2 protein levels after 
cisplatin and neocarzinostatin treatment 
independent of p53-status.  
(A) HCT116 p53+/+ and (B) HCT116 p53-/- cells 
were depleted of G2E3, Mdm2 and p53 by 
siRNA-mediated knockdown and either left 
untreated (untr.) or treated with 30 µM 
cisplatin for 16 h (total incubation time 64 h). 
Cell lysates were analyzed by immunoblotting 
using the indicated antibodies. γH2AX staining 
was used as control for cisplatin treatment. 
Actin staining served as loading control.  
(C) Conducted by Ann-Christine Loock. 
HCT116 p53-/- cells were depleted of G2E3 
and Mdm2 by siRNA-mediated knockdown 
and either left untreated or treated with  
150 ng/ml neocarzinostatin (NCS) for 2 h (total 
incubation time 48 h). Cell lysates were 
analyzed by immunoblotting using the 
indicated antibodies. γH2AX staining was used 
as control for NCS treatment. Actin staining 
served as loading control. 
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In the hope to identify the relationship between G2E3 and Mdm2, we explored the reasons for 
this observation. We tested whether decreased Mdm2 level upon G2E3 knockdown in 
cisplatin or neocarzinostatin treated cells were due to an impact of G2E3 knockdown on 
Mdm2 mRNA levels, Mdm2 protein stability or due to an indirect effect.   
 
 
5.4.10.1 G2E3 knockdown does neither affect Mdm2 mRNA levels nor 
Mdm2 protein stability 
We first investigated how G2E3 knockdown affects Mdm2 mRNA levels. Mdm2 is 
transcriptionally regulated by a p53-independent (P1) and a p53-responsive (P2) promoter 
that both encode full-length Mdm2 (see section 2.3.2.2). We determined Mdm2 mRNA level 
by qPCR in both HCT116 p53+/+ and HCT116 p53-/- cells, which we did not find to be changed 
upon G2E3 knockdown in untreated and cisplatin treated cells (Figure 5.22A,B). We 
concluded that the decrease in Mdm2 levels after depletion of G2E3 was not regulated on the 
transcriptional level. 
To analyze whether Mdm2 protein stability was changed, we treated cells with the 
proteasome inhibitor MG132 after G2E3 knockdown and cisplatin treatment. We used 
HCT116 p53-/- cells to prevent accumulation and activation of p53 upon MG132 treatment. 
This would induce Mdm2 on the transcriptional level and by this would complicate the 
experimental setting due to additionally affecting Mdm2 expression. Interestingly, G2E3 
knockdown did not impair Mdm2 protein stability since Mdm2 levels remained unchanged 












Figure 5.22: G2E3 knockdown does neither affect Mdm2 mRNA levels nor Mdm2 protein 
stability.  
(A) HCT116 p53+/+ and (B) HCT116 p53-/- cells were depleted of G2E3, Mdm2 and p53 by siRNA-
mediated knockdown and either left untreated or treated with 30 µM cisplatin for 16 h (total incubation 
time 64 h). Cells were harvested and Mdm2 mRNA levels were analyzed by qPCR. Results were 
normalized to expression of the reference gene GAPDH. Error bars are represented as SEM (n = 3). 
(C) Conducted by Ann-Christine Loock. HCT116 p53-/- cells were transfected with two different siRNAs 
targeting G2E3 and either left untreated or treated with 30 µM cisplatin for 16 h. During the last 4 h, 
cells were treated with 20 µM of the proteasome inhibitor MG132 (or DMSO as control). Cell lysates 
were analyzed by immunoblotting using the indicated antibodies. γH2AX staining was used as control 
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5.4.10.2 Apoptosis induced by G2E3 knockdown results in decrease of 
Mdm2 protein levels in p53-proficient, but not in p53-deficient cells 
As shown in Figure 5.22, G2E3 knockdown did not affect Mdm2 mRNA levels and Mdm2 
protein stability. We therefore reasoned that an indirect effect could be the explanation for the 
decrease in Mdm2 levels upon G2E3 knockdown. Depletion of G2E3 causes increased 
apoptosis in cisplatin treated cells (Figure 5.6). It had previously been reported that Mdm2 
can be cleaved during apoptosis by a caspase 3-like activity (Chen, Marechal et al. 1997; 
Erhardt, Tomaselli et al. 1997). However, the identity of the responsible caspase remained 
unknown. Only recently, it has been revealed that Mdm2 is a direct target of caspase 2 
cleavage in response to DNA damage (Oliver, Meylan et al. 2011).  
Hence, we asked whether induction of apoptosis after G2E3 knockdown could be the cause 
for decreased Mdm2 levels. Therefore, HCT116 p53+/+ cells were depleted of G2E3 by siRNA 
and either left untreated or treated with cisplatin and/or the caspase inhibitor Z-VAD. 
Interestingly, upon cisplatin treatment and caspase inhibition, Mdm2 protein levels after G2E3 
knockdown were comparable to Mdm2 protein levels after control knockdown (Figure 5.23A). 
The reduction in Mdm2 protein levels in this cell line seemed to depend on apoptosis induced 
by G2E3 knockdown. Surprisingly, caspase inhibition did not rescue the decrease in Mdm2 
levels in G2E3 depleted HCT116 p53-/- cells (Figure 5.23B). Here, the mechanism seemed to 
be different from HCT116 p53+/+ cells though HCT116 p53-/- cells also show increased 
apoptosis upon G2E3 knockdown and cisplatin treatment, as seen in Figure 5.6B.  
In summary, decrease in Mdm2 levels can be rescued by caspase inhibition using Z-VAD in 
p53-proficient, but not in p53-deficient HCT116 cells.  
As was shown in Figure 5.20B, phosphorylation of H2AX upon cisplatin treatment in U2OS 
cells was due to activation of the ATR-Chk1 and the ATM-Chk2 pathway, but also to some 
extent due to apoptosis. Also in HCT116 p53+/+ and HCT116 p53-/- cells, γH2AX levels in 
control transfected cells were lower after cisplatin and Z-VAD treatment compared to cisplatin 
alone (Figure 5.23A,B). This means that phosphorylation of H2AX after cisplatin treatment 
was in part apoptosis-dependent under the conditions applied. Unexpectedly, knockdown 
with si-G2E3-A led to increased γH2AX levels in HCT116 p53+/+ and HCT116 p53-/- cells 
independent of Z-VAD treatment (Figure 5.23A,B) which is difficult to explain. For this siRNA, 
the impact on phosphorylation of H2AX seemed to be apoptosis-independent.  




Figure 5.23: Apoptosis induced by G2E3 knockdown results in decrease of Mdm2 protein 
levels in p53-proficient, but not in p53-deficient cells.  
(A) HCT116 p53+/+ and (B) HCT116 p53-/- cells were transfected with two different siRNAs targeting 
G2E3 and either left untreated or treated with 30 µM cisplatin and/or 50 µM caspase inhibitor Z-VAD 
for 16 h (DMSO as control). Cell lysates were analyzed by immunoblotting using the indicated 
antibodies. Markers for apoptosis are cleaved caspase 3 (Cleaved Casp. 3), total caspase 3 and 
cleaved PARP-1 (total protein at 115 kDa and cleaved PARP-1 at 90 kDa). γH2AX staining was used 
as control for cisplatin treatment. Actin staining served as loading control. 
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5.5 Regulation of G2E3 expression – G2E3 levels and cell cycle 
dependency 
5.5.1 G2E3 levels are maximal in G2-phase 
The group of Crawford et al. performed a global gene expression profiling in HeLa cells after 
double thymidine block and identified genes with maximal expression in G2- and M-phase 
that were down-regulated in response to γ-irradiation (Crawford and Piwnica-Worms 2001). In 
their publication, G2E3 was one of the candidates with mRNA expression maximal in  
G2-phase and decreased mRNA levels upon γ-irradiation. HeLa cells, used in the microarray 
study, do not have functional p53 due to infection with human papillomavirus (HPV). The viral 
protein E6 binds p53 (Werness, Levine et al. 1990) and together with the cellular protein  
E6-AP leads to its ubiquitin-dependent degradation (Scheffner, Werness et al. 1990; 
Huibregtse, Scheffner et al. 1991; Scheffner, Huibregtse et al. 1993). In contrast, U2OS cells 
contain wild-type, functional p53 and we set out to test whether G2E3 expression is also 
maximal in G2-phase of U2OS cells. To this end, we synchronized U2OS cells by double 
thymidine block in G1-phase. After release from the block, we harvested cells at different 
timepoints to analyze G2E3 mRNA levels during the cell cycle. Cell cycle phases were 
monitored by flow cytometry of propidium iodide stained cells (Figure 5.24A). We found that 
G2E3 expression was indeed maximal in G2-phase in U2OS cells (Figure 5.24B). In contrast 
to HeLa cells with a four times higher G2E3 expression in G2-phase compared to S-phase, 







Figure 5.24: G2E3 levels are maximal in G2-phase. Legend on next page. 
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Figure 5.24: G2E3 levels are maximal in G2-phase.  
(A) U2OS cells were arrested in G1-phase using a double thymidine block and cell cycle phases 
were monitored by flow cytometry of propidium iodide stained cells. For each of the three 
independent experiments, flow cytometry data was acquired. Here, data are only shown for the first 
experiment, but equivalent synchronization was achieved each time. After release from the double 
thymidine block, cells proceeded into S-phase (0-4 h), then entered G2-phase (6-10 h) and 
underwent mitosis, whereupon they reentered G1-phase. (B) U2OS cells were harvested at each 
timepoint. G2E3 mRNA levels were analyzed by qPCR. Results were normalized to expression of the 




5.5.2 Endogenous G2E3 mRNA and protein levels are decreased after DNA 
damage independent of p53-activation or -status 
As mentioned earlier, G2E3 mRNA expression was reported to be decreased upon  
γ-irradiation (Crawford and Piwnica-Worms 2001). It was of interest to us whether G2E3 
mRNA expression is also decreased upon treatment with other DNA-damaging reagents like 
cisplatin and NCS. To this end, we treated U2OS cells with cisplatin and NCS and 
determined G2E3 mRNA level by qPCR. Indeed, we observed a down-regulation of G2E3 
expression after DNA damage (Figure 5.25A). As mentioned above, it was reported that p53 
can repress G2E3 transcription via the large intergenic noncoding RNA lincRNA-p21 which is 
a p53-target in response to DNA damage (Huarte, Guttman et al. 2010). In order to identify 
the mechanism of G2E3 down-regulation, we tested whether decrease in G2E3 mRNA levels 
upon cisplatin and NCS treatment is due to induction of p53. We depleted cells of p53 by 
siRNA and determined G2E3 mRNA level. Interestingly, reduction in G2E3 expression did not 
depend on p53 since decrease in G2E3 levels could not be rescued by p53 depletion (Figure 
5.25A). This result was further confirmed by treatment of HCT116 p53+/+ and HCT116 p53-/- 
cells with cisplatin (Figure 5.25B). Again, G2E3 mRNA levels were decreased upon cisplatin 
treatment. This was the case for both p53-proficient and p53-deficient cells, arguing for a 
p53-independent mechanism.  
Furthermore, we explored whether we can detect G2E3 down-regulation upon DNA damage 
also on the protein level. Due to the antibody of bad quality, we precipitated G2E3 out of four 
15 cm cell culture dishes that were treated with cisplatin and the proteasome inhibitor 
MG132. We found that also G2E3 protein levels are decreased after cisplatin treatment 
(Figure 5.25C). These results suggest that G2E3 does not only regulate parameters within 













Figure 5.25: Endogenous G2E3 mRNA and protein levels are decreased after DNA damage 
independent of p53-activation or -status.  
(A) U2OS cells were transfected with control- and p53-siRNA and either left untreated or treated with 
30 µM cisplatin for 16 h or 150 ng/ml neocarzinostatin (NCS) for 2 h (total incubation time 64 h). Cells 
were harvested and G2E3 and p53 mRNA levels were analyzed by qPCR. Results were normalized to 
expression of the reference gene GAPDH. Error bars are represented as SD (n = 3). * = p < 0.05,  
** = p < 0.01 (student’s t-test). (B) HCT116 p53+/+ and HCT116 p53-/- cells were transfected with  
si-control and either left untreated or treated with 30 µM cisplatin for 16 h (total incubation time 64 h). 
Cells were harvested and G2E3 mRNA levels were analyzed by qPCR. Results were normalized to 
expression of the reference gene GAPDH. Error bars are represented as SD (n = 3). * = p < 0.05,  
** = p < 0.01 (student’s t-test) (C) U2OS cells were either left untreated or treated with 30 µM cisplatin 
for 16 h and during the last 4 h with 20 µM of the proteasome inhibitor MG132. Cells were harvested 
and immunoprecipitation using a G2E3-specific antibody was performed. Precipitated G2E3 was 
analyzed by immunoblotting using the indicated antibodies. To control for unspecific binding, β-
Galactosidase (β-Gal) was used as control antibody. As further control, lysis buffer without cell lysate 
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6 Discussion 
 
The chemotherapeutic cisplatin is widely used to treat various solid tumors, including 
testicular, lung and head and neck cancer. By inducing crosslinking of DNA, it prevents 
separation of strands during transcription and replication. As a result, complex signaling and 
repair pathways are induced. However, the cellular and molecular mechanisms upon cisplatin 
treatment are incompletely understood. The discovery of new regulators in the DNA damage 
response (DDR) to cisplatin would help us to extend our knowledge of the pathways 
activated. Since ubiquitination plays a major role in the DDR, we applied a high-content 
siRNA screen targeting human ubiquitin ligases and deubiquitinating enzymes to identify new 
regulators in the DDR to cisplatin.  
 
One of these candidates was the ubiquitin ligase G2E3 whose knockdown led to decreased 
γH2AX levels after cisplatin treatment. We got interested in G2E3 since it had been proposed 
to play a role in the DDR and in cell survival, but only little was known about underlying 
mechanisms.  
G2E3 had previously been defined as G2-specific E3 ligase since it showed maximal mRNA 
expression in G2/M-phase (Crawford and Piwnica-Worms 2001) and contains two  
E3 ligase domains with in vitro ubiquitin ligase activity (Brooks, Helton et al. 2008). Further 
studies proposed a change in G2E3 localization upon DNA damage (Brooks, Banerjee et al. 
2007). Moreover, a G2E3 knock-out mouse was reported to display embryonic lethality 
(Brooks, Helton et al. 2008), pointing towards an important role of G2E3 in cell survival. 
Together, these data motivated us to study the role of G2E3 in the DDR, in cell survival and 
in cell cycle regulation. 
 
6.1 G2E3 – a DNA damage-responsive, cell cycle-dependent 
survival factor  
6.1.1 Summary and implications of our findings  
In the work presented here, we found G2E3 to modulate cellular proliferation, survival and the 
DDR. We show that G2E3 is regulated in a DNA damage-responsive manner since G2E3 
mRNA as well as protein levels are decreased upon DNA damage treatment (Figure 5.19 and 
Figure 5.25). Knockdown of G2E3 resulted in p53-independent apoptosis and decreased 
proliferation (Figure 5.6 and Figure 5.7). Furthermore, we verified previous findings that G2E3 
levels are maximal in G2-phase, arguing for a cell cycle-dependent regulation of G2E3 
(Figure 5.24 and Crawford and Piwnica-Worms, 2001). 
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Thus, we propose a model in which G2E3 acts as a pro-survival factor that protects normal 
cells against cell death. Upon DNA damage, G2E3 supports cells to go into apoptosis by its 





Figure 6.1: Model of G2E3 affecting cellular survival.  
G2E3 is down-regulated in a DNA damage-responsive manner. G2E3 knockdown induces  
p53-independent apoptosis and decreased proliferation. G2E3 expression is cell cycle-dependent, with 
maximal levels in G2-phase. We propose an anti-apoptotic role of G2E3 in healthy cells. Upon DNA 
damage, down-regulation of G2E3 might support cells to go into apoptosis.  
 
 
6.1.2 Interdependence of apoptosis and the DNA damage response 
There is increasing evidence that pathways regulating DDR, cell cycle and apoptosis cannot 
be regarded as separated, but often as interdependent. Examples include induction of 
apoptosis if DNA damage is irreparable, or activation of the DDR when endonucleases break 
down DNA during the apoptotic process. However, open questions remain as to how 
decisions are made in the cell and which parameters decide on cell survival versus apoptosis. 
Our findings suggest a role of G2E3 in regulation of cellular proliferation, survival and the 
DDR. Examples for proteins that have been described to be involved in both DDR and 
apoptosis include γH2AX and p53. Phosphorylation of H2AX at Ser139 does not only 
represent a marker of damaged DNA, as it can be also detected after initiation of DNA 
fragmentation during apoptosis (Rogakou, Nieves-Neira et al. 2000). Moreover, a recent 
paper showed that H2AX is involved in mechanisms which decide whether a cell conducts 
DNA repair or induces apoptosis. Cook et al. reported that upon DNA damage, the protein 
tyrosine phosphatase EYA can dephosphorylate H2AX at Tyr142 promoting DNA repair. The 
authors show that this phosphorylation of H2AX affects the decision of repair/survival versus 
apoptosis (Cook, Ju et al. 2009). The tumor suppressor p53 is another example for a protein 
that interconnects DDR, apoptosis and cell cycle regulation. It has cytoplasmic functions in 
mitochondrial apoptosis, but also acts as a transcription factor not only for apoptosis genes, 
but also genes inducing cell cycle arrest like p21. Naturally, localization of a protein in the cell 
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determines its functions. Protein export, as seen for p53, can balance cellular responses like 
cell cycle arrest with apoptosis (Vousden 2006). Nevertheless, p53 is often lost or 
dysregulated during tumorigenesis and it is not well understood which proteins decide on cell 
survival or cell death in this situation. Since G2E3 is a DNA damage-responsive, cell cycle-
dependent protein, it could play an essential role in the decision process of survival versus 
apoptosis independently of p53.  
Here, we want to discuss our findings pointing to an important role of G2E3 in cell 
proliferation, survival and the DDR.  
 
 
6.1.3 Regulation of G2E3 
6.1.3.1 DNA damage-responsive regulation of G2E3 mRNA levels 
We found that endogenous G2E3 mRNA levels were decreased upon cisplatin and NCS 
treatment (Figure 5.25A). This is in line with a microarray analysis performed in HeLa cells 
where G2E3 mRNA levels were down-regulated upon γ-irradiation (Crawford and Piwnica-
Worms 2001). We had reasoned that G2E3 might be transcriptionally repressed by p53 via 
the large intergenic noncoding RNA lincRNA-p21 which is a p53-target in response to DNA 
damage (Huarte, Guttman et al. 2010). However, we found that down-regulation of G2E3 
upon DNA damage was independent of p53-activation or -status (Figure 5.25A,B). Since 
regulation of G2E3 on the transcriptional level was independent of p53, further possibilities 
have to be considered. Much is known about transcriptional activation, but much less about 
transcriptional repression, especially in response to DNA damage. Further transcription 
factors that could be involved in regulation of G2E3 expression include those of the E2F 
family. In mammals, eight E2F family members are known. E2F1, E2F2 and E2F3A can 
interact with RB and are believed to function mainly in transcriptional activation (Polager and 
Ginsberg 2009). On the other hand, E2F4, E2F5, E2F6, E2F7 and E2F8 have been shown to 
play a role in gene repression, which suggests a possible involvement of these family 
members in repression of G2E3 levels upon DNA damage. A hint towards a potential 
regulation of G2E3 by E2F comes from a recent paper. Varanasi et al. have performed a 
microarray analysis in untreated Saos2 cells transfected with control or E2F3 siRNA to 
identify transcriptional targets of E2F3 (Varanasi, Do et al. 2012). They identified Rad18, a 
protein involved in DNA repair, and characterized the relationship of E2F3 and Rad18 further. 
Interestingly, their microarray revealed G2E3 to be repressed upon E2F3 knockdown. Hence, 
it is possible that E2F3 leads to transcriptional activation of G2E3. However, the fact that 
E2F3 is induced upon DNA damage by transcriptional and posttranslational mechanisms and 
required for DNA damage-induced apoptosis, argues against this idea (Martinez, Goluszko et 
al. 2010). In this way, active E2F3 would lead to G2E3 expression upon DNA damage which 
is not the case since G2E3 levels are down-regulated upon DNA damage. 
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Which makes the picture even more complicated is the existence of extensive crosstalk 
between the RB-E2F and Mdm2-p53 pathway. For instance, E2F7 is up-regulated by p53 
upon DNA damage, leading to E2F7-mediated transcriptional repression (Carvajal, Hamard 
et al. 2012). In order to test whether transcription factors of the E2F family are involved in 
repression of G2E3 expression upon DNA damage, we suggest performing knockdown of 
each of these transcription factors, followed by treatment with a DNA-damaging agent and 
detection of G2E3 mRNA levels thereafter (similar to our experiment in Figure 5.25A). 
Although there are also p53-independent functions of E2Fs, we suggest performing the 
experiments exploring if E2Fs are involved in G2E3 transcription in a p53-/- background.  
 
Another possibility to find out how G2E3 expression is regulated would be to identify the 
transcription factor that activates G2E3 expression and which might be repressed upon DNA 
damage. This could be investigated by analyzing the G2E3 promoter region for conserved 
binding sites of known transcription factors. Additionally, p63 and p73 should be investigated 
as potential transcription factors regulating G2E3 expression. Due to high sequence 
homology with p53, p63 and p73 can activate some target genes of p53. Here, we want to 
focus on p73. Like p53, p73 has been shown to be activated upon treatment with cytotoxic 
agents like cisplatin and doxorubicin (Gong, Costanzo et al. 1999; Irwin, Kondo et al. 2003). 
P73 can mediate p53-independent transcription and has been shown to repress gene 
expression, for example of the human telomerase reverse transcriptase (hTERT) (Racek, 
Mise et al. 2005). Thus, p73 activation after cisplatin treatment could lead to G2E3 
repression. These are examples of transcription factors that could regulate G2E3 expression, 
further possibilities exist. For future investigations, it is of importance to understand how 
G2E3 expression is regulated since transcriptional control contributes to the decision in which 
process a protein is involved.  
 
6.1.3.2 DNA damage-responsive regulation of G2E3 protein levels 
Besides DNA damage-dependent down-regulation of G2E3 mRNA levels, we found 
overexpressed HA-G2E3 protein levels to be down-regulated by cisplatin treatment (Figure 
5.19). This effect could be rescued by caspase inhibition using Z-VAD (Figure 5.20B), 
suggesting a caspase-dependent cleavage of G2E3. Therefore, we propose that G2E3 is not 
only regulated on the level of gene expression, but also on the protein level. We found G2E3 
to have 27 potential caspase cleavage sites (see section 5.4.9) using the CASVM prediction 
software (Wee, Tan et al. 2007). A systematic approach with G2E3 plasmids containing 
mutated caspase cleavage sites should be performed to determine if G2E3 can be 
proteolytically cleaved by caspases. Furthermore, overexpression of GFP-tagged G2E3 
followed by cisplatin treatment would potentially enable us to detect a G2E3 cleavage 
fragment since a GFP-tag is larger compared to HA-tag and is not cleaved by caspases.  
Up to now, we could not elucidate whether decreased levels of overexpressed HA-G2E3 
upon cisplatin treatment are dependent on the DDR or apoptosis. In order to test this, we 
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suggest inducing DNA damage-independent apoptosis, e.g. by activating the extrinsic 
pathway with TRAIL or FAS ligand. Furthermore, we found also endogenous G2E3 protein 
levels to be decreased upon cisplatin treatment (Figure 5.25C). It should be investigated 
whether this decrease can be rescued by caspase inhibition using Z-VAD or whether it is 
dependent on regulation on the transcriptional level as seen in Figure 5.25A,B. 
 
6.1.3.3 Cell cycle-dependent regulation of G2E3 levels 
Besides its DNA damage-responsive regulation, G2E3 expression is cell cycle-dependent. 
We found G2E3 levels to be maximal in G2-phase of U2OS cells (Figure 5.24B). This is 
consistent with the microarray analysis of HeLa cells showing up-regulation of G2E3 mRNA 
levels in G2-phase (Crawford and Piwnica-Worms 2001). In contrast to HeLa cells with a four 
times higher G2E3 expression in G2-phase compared to S-phase, we found a twofold higher 
G2E3 expression in U2OS cells. This difference could be due to cell type-specific effects. For 
instance, the protein regulating G2E3 expression could be differently expressed in HeLa cells 
compared to U2OS cells. Furthermore, both cell lines vary in their p53 activity. Unlike HeLa 
cells with compromised p53 function, U2OS cells feature functional p53 which potentially 
could repress G2E3 expression via lincRNA-p21 as described above (Huarte, Guttman et al. 
2010). However, induction of lincRNA-p21 had only been reported in response to DNA 
damage, whereas here untreated cells were investigated. Hence, further mechanisms could 
apply.  
 
Up-regulation of G2E3 expression in G2-phase could possibly be associated with a function 
of G2E3 during the cell cycle. Many more proteins with cell cycle specific expression have 
been described. Genes specifically expressed in G2/M-phase include cyclin B1, Cdc25C and 
PLK1 (Polo-like kinase1) (Sadhu, Reed et al. 1990; Hamanaka, Smith et al. 1995; Lee, Yuan 
et al. 1995).  
PLK1 is an important regulator of mitotic entry, progression and exit. Interestingly, it exhibits 
characteristics similar to our studies of G2E3. Besides being expressed in G2-phase, it has 
been reported to be inhibited in response to DNA damage (van Vugt, Smits et al. 2001). 
Furthermore, PLK1 blocks p53-independent apoptosis by inhibition of the p53-family member 
p73-alpha through interaction and phosphorylation (Koida, Ozaki et al. 2008). Since we have 
not yet identified the mechanism of G2E3’s pro-survival function, it should be investigated 
whether G2E3 could inhibit p73. Knockdown of PLK1 inhibits proliferation, connected to cell 
cycle arrest in G2/M-phase and induction of apoptosis (Tyagi, Bhui et al. 2010). This is similar 
to our observations that G2E3 depletion blocks proliferation and induces apoptosis, though 
G2E3 knockdown induces a G1- and not a G2/M-arrest in U2OS cells. Furthermore, Tyagi et 
al. show that depletion of PLK1 renders cells more sensitive to cisplatin. Since we do not 
know how G2E3 levels are decreased upon DNA damage, we were interested in the 
mechanism of PLK1 down-regulation upon DNA damage which was investigated very 
recently (Qin, Gao et al. 2013). PLK1 is regulated by protein degradation of a protein called 
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Bora. Qin et al. show that upon phosphorylation by ATR, Bora is degraded by the multi-
subunit ubiquitin ligase SCFβ-TRCP which leads to a yet not explainable inhibition of PLK1. 
Interestingly, SCFβ-TRCP was also shown to target Mdm2 for degradation and has further 
substrates relevant in apoptosis like procaspase 3, p53 and the p53 family member p63 (Tan, 
Gallegos et al. 2006; Gallegos, Litersky et al. 2008; Xia, Padre et al. 2009; Inuzuka, Tseng et 
al. 2010). It would be very interesting to elucidate whether G2E3 down-regulation is mediated 
in a similar fashion. Apart from comparable characteristics of PLK1 and G2E3, the question 
remains whether both proteins are also regulated in a similar fashion or not. We show that 
G2E3 is transcriptionally regulated (Figure 5.25A,B) and could probably be cleaved by 
caspases (Figure 5.20B). However, we have further evidence that G2E3 is regulated on the 
protein level. We observed an accumulation of overexpressed HA-G2E3 after 4 h of 
treatment with the proteasome inhibitor MG132 (Figure 5.18). This finding hints at an 
ubiquitin-dependent regulation of G2E3. With the objective of exploring whether G2E3 could 
be ubiquitinated, we investigated the existence of G2E3 post-translational modifications using 
the PhosphoSitePlus® online systems biology resource. PhosphoSitePlus® provides 
information and tools to study protein post-translational modifications (Hornbeck, Kornhauser 
et al. 2012). According to the database, human G2E3 was found by mass spectrometry to be 
ubiquitinated at Lys442. Thus, degradation of G2E3 by another ubiquitin ligase like SCFβ-TRCP 
could be possible. This could be tested by inactivation of β-TRCP, the F-box protein 
component of the ubiquitin ligase complex. An approach using shRNA-mediated depletion of 
β-TRCP has been proven successful for demonstrating that Mdm2 and Bora stability are 
controlled by SCFβ-TRCP (Inuzuka, Tseng et al. 2010; Qin, Gao et al. 2013). Furthermore, co-
immunoprecipitation of G2E3 and β-TRCP should be conducted to check for a direct 
interaction of both proteins. On the other hand, G2E3 has been shown to be auto-
ubiquitinated using an in vitro assay and to catalyze Lys48-linked poly-ubiquitination, a signal 
for proteasomal degradation (Brooks, Helton et al. 2008). Thus, it is possible that G2E3 
protein levels are also or additionally regulated by auto-degradation. 
 
 
6.1.4 The role of G2E3 in apoptosis  
6.1.4.1 How could G2E3 be involved in p53-independent apoptosis? 
Besides its DNA damage-responsive, cell cycle-dependent features, we found G2E3 to affect 
cell survival. Depletion of G2E3 resulted in p53-independent apoptosis in colon carcinoma 
and osteosarcoma cell lines (Figure 5.6). This result suggests that G2E3 is an anti-apoptotic 
protein that is down-regulated upon DNA damage, thereby promoting apoptosis. The role of 
G2E3 in cell survival was also shown in G2E3 knock-out mice which die at a very early stage 
in development due to apoptosis and involution of the blastocyst (Brooks, Helton et al. 2008). 
In order to investigate the p53-dependency of their observations, the authors established 
double heterozygous mice for G2E3 and p53 (i.e. G2E3+/- and p53+/-). Remarkably, they did 
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not obtain any G2E3-/-/p53-/- mice, meaning that loss of p53 could not rescue the lethal 
phenotype of G2E3 knock-out mice.  
The finding that apoptosis induced by G2E3 depletion is p53-independent (Figure 5.6B and 
Brooks, Helton et al. (2008)) raises the question of how G2E3 protects cells against 
apoptosis. The ubiquitin ligase was localized predominantly in the nucleus (Figure 5.5). 
Therefore, G2E3 might not play a role in cytoplasmic and mitochondrial apoptotic processes. 
Rather, G2E3 could influence transcription of apoptotic genes. Three domains of G2E3 have 
similarity to both PHD and RING domains. PHD domains infrequently have E3 activity, but 
bind methylated histones and are involved in chromatin-mediated gene regulation 
(Musselman and Kutateladze 2011). It is not known whether G2E3 can bind chromatin and 
hence affect gene expression. This could be tested by performing a chromatin fractionation 
and exploring if G2E3 is enhanced in the chromatin-bound fraction. Furthermore and perhaps 
more likely, G2E3 could influence proteins that regulate expression of apoptotic genes. In 
such a scenario, G2E3 could either suppress transcription factors of pro-apoptotic genes or 
support the activity of anti-apoptotic gene regulators. Since we do not have evidence for such 
a mechanism, we can only speculate of how this could be accomplished. As an example, 
p53-independent apoptosis can be mediated by the p53-related transcription factor p73.  
Urist et al. have shown that Chk1 and Chk2 stabilize the transcription factor E2F1 in response 
to DNA damage which is then capable of inducing p73 expression (Urist, Tanaka et al. 2004). 
It is well established that p73 can bind to p53 DNA-binding sites and thus activate expression 
of p53-responsive genes involved in apoptosis, cell cycle arrest and senescence (Jost, Marin 
et al. 1997). How exactly p73 induces apoptosis is not completely understood. However, it 
has been shown that p73 can induce apoptosis via transactivation of genes like Puma 
(Melino, Bernassola et al. 2004). The authors imply that Puma leads to mitochondrial 
translocation of Bax, further leading to cytochrome c release during the intrinsic pathway. The 
impact of p73 on translocation of Bax seems to be indirect since p73 localizes to the nucleus 
while inducing cell death. G2E3 is also a nuclear protein which could conduct its pro-survival 
role by inhibition of p73 or other nuclear proteins which indirectly affect apoptotic signaling in 
the cytoplasm. On this line, p73 transcriptional activity has been shown to be repressed by 
mono-ubiquitination of p73 through the Cullin4A ubiquitin ligase (Malatesta, Peschiaroli et al. 
2012). Thus, repression of p73 by ubiquitination could be a possible, though speculative 
mechanism explaining the pro-survival role of G2E3.  
Although we found overexpressed G2E3 to be localized predominantly in the nucleus (Figure 
5.5), it is not impossible that it also plays a role in cytoplasmic events. Brooks et al. described 
G2E3 to possess a CRM1-independent nuclear export domain and a sequence that 
antagonizes the nuclear export signal (Brooks, Banerjee et al. 2007). Furthermore, the 
authors found that G2E3 is exported from the nucleus of Cos-7 cells in a CRM1-independent 
manner. Therefore, we reasoned that G2E3 could have a supportive function on p53-
independent pro-survival proteins in the cell. Since we found an interaction of co-expressed 
G2E3 and Mdm2 (Figure 5.14 and Figure 5.15), it is a possibility that G2E3 supports Mdm2 in 
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carrying out an anti-apoptotic action. Interestingly, Mdm2 has been shown to prevent 
apoptosis by increasing the expression of XIAP (X-chromosome-linked inhibitor of apoptosis 
protein) (Gu, Zhu et al. 2009). The authors report binding of Mdm2 to XIAP mRNA which 
enhances translation and thus increases XIAP expression. Hence, G2E3 could perhaps 
support Mdm2 in enhancing XIAP expression. This could be explored by detection of XIAP 
protein levels after G2E3 and Mdm2 knockdown as well as double-knockdown of both 
proteins under the conditions used in the paper of Gu et al. Another option of how G2E3 
could support anti-apoptotic processes in the cell is by regulating the important pro-survival 
regulator Bcl-2. Bcl-2 was shown to prevent p53-independent cell death in lymphoid cells 
(Strasser, Harris et al. 1994). Thus, it should be investigated whether G2E3 affects Bcl-2, for 
example by detecting Bcl-2 mRNA and protein levels after G2E3 knockdown.  
These examples point out that it should be clarified whether G2E3 can affect cytoplasmic 
apoptotic regulators or not. Regulation of such proteins could be either indirect or mediated 
by G2E3 export into the cytoplasm. Consequently, it should be investigated by subcellular 
fractionation whether G2E3 is present in the cytoplasm.  
It is of note that the ubiquitin ligase activity of G2E3 could be important for its anti-apoptotic 
function. As a possibility, G2E3 could promote ubiquitination and degradation of pro-apoptotic 
proteins. Several ubiquitin ligases and DUBs have been shown to play a role in apoptosis. 
These include Mdm2 (by regulating p53) and aforementioned inhibitor of apoptosis (IAP) 
proteins. The ubiquitin ligase XIAP not only binds and blocks the catalytic activity of caspases 
3, 7 and 9, but also reduces their levels by ubiquitination and hence degradation (Suzuki, 
Nakabayashi et al. 2001; Vucic, Dixit et al. 2011). Furthermore, c-IAP1 (cellular inhibitor of 
apoptosis 1) promotes ubiquitination of caspase 3 and 7 (Choi, Butterworth et al. 2009) and 
regulates XIAP and c-IAP2 (Conze, Albert et al. 2005; Vucic, Dixit et al. 2011). In addition, 
ubiquitin ligase complexes have significant impact on regulation of apoptosis. As mentioned 
before, the multi-subunit ubiquitin ligase SCFβ-TRCP is an important regulator of apoptosis with 
substrates like procaspase 3 and the p53 family members p53 and p63 (Tan, Gallegos et al. 
2006; Gallegos, Litersky et al. 2008; Xia, Padre et al. 2009). Hence, it should be investigated 
whether G2E3 E3 ligase activity is necessary for its pro-survival function. To this end, G2E3 
mutants without ubiquitin ligase activity should be designed and the survival of cells after 
cisplatin treatment should be compared between wild-type and mutant G2E3. If G2E3 
ubiquitin ligase activity is a prerequisite for its pro-survival role, the endogenous substrate(s) 
of G2E3 have to be identified as discussed in more detail below (see section 6.3).  
 
6.1.4.2 Could G2E3 inhibit apoptosis through checkpoint regulation? 
Interestingly, it has been demonstrated that p53-independent apoptosis can be enhanced by 
inactivation of cell cycle checkpoints. For instance, cancer cells without p53 depend on 
ATM/ATR-p38-MK2 signaling in order to arrest the cell cycle (Reinhardt, Aslanian et al. 
2007). Without this response, cells run into apoptosis and mitotic catastrophe. Thus, G2E3 
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could also be an important cell cycle checkpoint regulator whose loss (by knockdown or 
down-regulation following DNA damage) leads to induction of apoptosis. This raises the 
question whether G2E3 is directly involved in prevention of apoptosis or whether its loss 
indirectly causes apoptosis since it is an important regulator of the cell cycle and DDR. Our 
findings that G2E3 represents a strongly regulated, DNA damage-responsive, cell cycle-
dependent protein argue in favor of the latter case.  
As mentioned earlier, G2E3 knock-out in mice die at a very early stage in development 
(Brooks, Helton et al. 2008). During embryonic development, cell division has to be correctly 
coordinated and mutations have to be prevented. Thus, proteins that regulate cell cycle, 
checkpoints and the DDR are among the most important factors during embryogenesis. Their 
inactivation often causes developmental abnormalities or embryonic lethality. Examples of 
proteins whose inactivation causes embryonic lethality in mice include cell cycle proteins 
such as cyclin B1 and A2 (Murphy, Stinnakre et al. 1997; Brandeis, Rosewell et al. 1998) and 
CDK11 (Li, Inoue et al. 2004). Also, inactivation of DDR regulators like ATR, Chk1, BRCA1, 
BRCA2 and Rad51 results in embryonic lethality in mice (Liu, Flesken-Nikitin et al. 1996; 
Tsuzuki, Fujii et al. 1996; Ludwig, Chapman et al. 1997; Brown and Baltimore 2000; Liu, 
Guntuku et al. 2000). On the other hand, inactivation of ATM and FANC proteins causes 
developmental abnormalities as seen in the respective diseases ataxia telangiectasia and 
Fanconi anemia (Savitsky, Bar-Shira et al. 1995; Elson, Wang et al. 1996; Niedernhofer, Lalai 
et al. 2005). Hence, it is a possibility that G2E3 is an important regulator of DDR and cell 
cycle whose loss promotes apoptosis induction. 
However, arguments that support a direct role of G2E3 in suppressing apoptosis come from 
insights of the mechanisms underlying embryonic lethality of some genes mentioned above. 
Besides G2E3 knock-out, apoptosis-dependent embryonic lethality has also been shown in 
ATR and Chk1 knock-out mice (Brown and Baltimore 2000; Liu, Guntuku et al. 2000). Brown 
et al. show that ATR-/- blastocyst cells die of caspase-dependent apoptosis, probably due to 
chromosomal breaks and accompanying loss of genomic integrity. Further on, Liu et al. report 
that Chk1-/- blastocysts die of apoptosis as seen by labeling ends of fragmented DNA using a 
TUNEL (Terminal deoxynucleotidyl transferase dUTP nick end labeling) assay. Apoptosis in 
Chk1-/- blastocysts is p53-independent, just as in G2E3 knock-out cells. The authors report 
that double-knockout of Chk1 and p53 cannot rescue or delay early lethality in  
Chk1-/- embryos (Liu, Guntuku et al. 2000). ATR and Chk1 were first reported to be involved 
in signaling of single-stranded DNA, but furthermore have been shown to suppress apoptosis 
in response to replicative stress in both p53-proficient and p53-deficient cells (Myers, Gagou 
et al. 2009).  
Thus, G2E3 could also be a regulator of DDR and cell cycle with an additional role in 
protecting cells against apoptosis. Further investigations are needed to clarify G2E3 function. 
Since G2E3 knock-out mice display embryonic lethality, generation of a conditional G2E3 
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knock-out mouse would constitute a promising possibility to investigate the role of G2E3 in 
apoptosis, but also in cell cycle regulation and DDR.  
 
6.1.4.3 Does G2E3 protect Mdm2 against caspase cleavage? 
We were interested in consequences of G2E3 function and studied the impact of G2E3 
depletion in the cell. Thereby we found that loss of G2E3 resulted in decreased Mdm2 protein 
levels after cisplatin and neocarzinostatin treatment independently of p53-status (Figure 
5.21). This result suggests that G2E3 regulates Mdm2 levels independently of p53, the 
principal transcription factor for Mdm2 expression. Looking more closely at the underlying 
mechanism, we found that inhibition of apoptosis could rescue decreased Mdm2 protein 
levels after G2E3 knockdown in p53-proficient, but not in p53-deficient HCT116 cells (Figure 
5.23). This finding suggests that apoptosis induced by G2E3 knockdown in p53-proficient 
cells causes caspase-dependent cleavage of Mdm2. Interestingly, Mdm2 had previously 
been reported to be cleaved by a caspase 3-like activity (Chen, Marechal et al. 1997; Erhardt, 
Tomaselli et al. 1997). Chen et al. reported that this cleavage leads to removal of the C-
terminal RING domain of Mdm2, still allowing binding to p53. It had furthermore been shown 
that truncated versions of Mdm2 that cannot target p53 for degradation anymore result in 
increased p53 levels (Pochampally, Fodera et al. 1999; Honda and Yasuda 2000). However, 
the identity of the responsible caspase remained unknown. Only recently, it has been 
revealed that Mdm2 is a direct target of caspase 2 cleavage in response to DNA damage 
(Oliver, Meylan et al. 2011). Thus, upon DNA damage, p53 is activated and its stability is 
promoted by caspase 2-mediated cleavage of Mdm2.  
With these findings in mind, our results could be explained by two different mechanisms: 
First, G2E3 could protect Mdm2 against cleavage by caspase 2, hence G2E3 knockdown 
results in proteolytic cleavage of Mdm2. Secondly, decreased Mdm2 levels could indirectly 
depend on G2E3 knockdown since it induces apoptosis. Thus, it is of importance to elucidate 
whether the response of Mdm2 after apoptosis is directly dependent on G2E3 or not. We 
suggest performing a double-knockdown of G2E3 and caspase 2, followed by cisplatin 
treatment and subsequent detection of Mdm2 protein levels.  
Since reduction in Mdm2 levels can only be rescued by caspase inhibition in p53-proficient 
cells, the mechanism of decreased Mdm2 levels after G2E3 knockdown seems to be different 
in p53-deficient cells. In p53-proficient cells, cisplatin treatment leads to activation of p53 
which at a later stage activates Mdm2 expression. Upon caspase inhibition, Mdm2 is not 
cleaved by caspases anymore, thus p53-dependent transcription of Mdm2 could result in the 
rescue of decreased Mdm2 levels which we observe. However, in p53-deficient cells, Mdm2 
does not seem to be cleaved by caspases since Z-VAD treatment could not rescue 
decreased Mdm2 levels. So far, we have no explanation for this difference in p53-deficient 
cells. It is possible that in HCT116 p53+/+ cells p53 is to some extent involved in apoptosis 
induced by G2E3 knockdown which is not the case in HCT116 p53-/- cells. We can exclude 
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that G2E3 knockdown affects Mdm2 mRNA levels and Mdm2 protein stability in p53-deficient 
cells (Figure 5.22B,C). Since Mdm2 levels in HCT116 p53-/- cells are not decreased due to 
apoptotic cleavage, it is a possibility that G2E3 knockdown attenuates translation of Mdm2 in 
these cells. Translational inhibition of Mdm2 had been shown before. Xiong et al. reported 
that inhibition of IGF-1R (insulin-like growth factor 1 receptor) reduces Mdm2 translation and 
that eIF4E (eukaryotic translation initiation factor 4E) is involved (Xiong, Kou et al. 2007). In 
order to study translational regulation, a common method applied is polysomal profiling using 
sucrose gradients. Hereby, cellular components are separated by size and information can be 
obtained on polysomes (two or more ribosomes) and other components of the translation 
machinery. Hence, in order to check if G2E3 can modulate Mdm2 translation, it could be 
explored if the association of Mdm2 mRNA with polysomes is changed upon G2E3 
knockdown.  
 
6.1.5 The role of G2E3 in the DDR 
By means of a high-content siRNA screen, we found that knockdown of G2E3 decreases 
γH2AX levels in U2OS cells (Figure 5.2 and Figure 5.3) and we searched for an explanation. 
So far, we did not identify a direct role of G2E3 in the DDR explaining changes in H2AX 
phosphorylation. However, we showed that knockdown of G2E3 resulted in G1-arrest and 
decreased percentage of cells in S-phase in untreated and cisplatin treated U2OS cells 
(Figure 5.8 and Figure 5.9) as well as p53-dependent p21 induction in U2OS cells (Figure 
5.10). Thus, we propose that after G2E3 knockdown arrested U2OS cells do not continue 
replicating their DNA and are therefore less prone to be harmed by cisplatin treatment. 
Interestingly, Mdm2 knockdown also leads to induction of G1-arrest (Figure 5.8) and exhibits 
decreased γH2AX levels upon cisplatin treatment as seen in the screen (Figure 5.2). This 
finding supports our hypothesis, as well as data of Kranz et al. that revealed reduced H2AX 
phosphorylation upon Mdm2 knockdown in UV-irradiated U2OS cells (Kranz, Dohmesen et 
al. 2008).  
 
Still, the question remains whether G2E3 plays a direct role in the DDR besides its levels 
being regulated in a DNA damage-responsive manner. So far, we have not identified an 
impact of G2E3 knockdown on the ATR-Chk1 and ATM-Chk2 pathway (Figure 5.4), two 
cascades that are induced upon cisplatin treatment. However, cisplatin treatment also 
activates the Fanconi anemia (FA) pathway. Many open questions remain as to how this 
pathway is functioning. Still, the key event is described as the mono-ubiquitination of the 
FANCD2-FANCI-complex (Ulrich and Walden 2010). This complex interacts with BRCA2 
(FANCD1) and other repair enzymes. In order to check if G2E3 is involved in the FA pathway, 
mono-ubiquitination of FANCD2 and FANCI could be explored. Furthermore, ATM and ATR 
activate the p38-MK2 stress response pathway which could be affected by G2E3 knockdown. 
This can be investigated by exploring phospho-p38 and phospho-MK2 levels after G2E3 
knockdown and cisplatin treatment.  
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6.2 A role of G2E3 in the p53-pathway? 
6.2.1 Is G2E3 a new regulator of the p53-pathway? 
When investigating how G2E3 knockdown leads to a G1-arrest in U2OS cells (Figure 5.8), we 
found that the cell cycle regulators p53 and p21 were up-regulated upon G2E3 depletion 
(Figure 5.10). This finding led us to explore if G2E3 is involved in the p53-pathway. We got 
further hints in this direction when we observed that depletion of the p53-pathway regulators 
RBBP6 and STUB1 resulted in decreased γH2AX levels after cisplatin treatment, similar to 
G2E3 knockdown (Figure 5.11). The ubiquitin ligase RBBP6 interacts with Mdm2 and 
enhances Mdm2-mediated ubiquitination and degradation of p53 due to increased p53-
Mdm2-affinity (Li, Deng et al. 2007). The authors report that RBBP6 knockdown attenuates 
the interaction of p53 and Mdm2 and reduces polyubiquitination of p53. This enhances p53 
accumulation, promoting its pro-apoptotic function and repressive role in cell growth. 
Remarkably, RBBP6 knock-out mice show early embryonic lethality (Li, Deng et al. 2007) as 
it was also shown for G2E3 knock-out mice. Moreover, it was reported that RBBP6 interacts 
with p53 and RB (Simons, Melamed-Bessudo et al. 1997). On the other hand, STUB1 (or 
CHIP) is a chaperone-associated ubiquitin ligase which leads to poly-ubiquitination and 
proteasomal degradation of p53 (Esser, Scheffner et al. 2005). Since knockdown of Mdm2 
also resulted in decreased γH2AX levels upon cisplatin treatment (Figure 5.2), we were 
wondering whether G2E3 could be a new regulator of p53 (like CHIP) or of Mdm2 (like 
RBBP6). Further ubiquitin ligases and DUBs have been identified to affect the p53-pathway. 
For instance, Pirh2 has been shown to ubiquitinate p53, leading to its proteasomal 
degradation (Leng, Lin et al. 2003). Interestingly, regulation of p53 by ubiquitination does not 
only lead to its degradation. For example, Msl2 was reported to poly-ubiquitinate p53, 
resulting in nuclear export of p53 (Kruse and Gu 2009) and WWP1 was shown to stabilize 
p53 by ubiquitination, leading to p53 accumulation in the cytoplasm (Laine and Ronai 2007).  
Thus, we posed the question whether G2E3 could be a newly identified regulator of the p53-
Mdm2 pathway.  
 
6.2.2 Do G2E3, Mdm2 and p53 interact?  
The ubiquitin system plays an important role in regulating p53 and Mdm2, with new ubiquitin 
ligases and DUBs being identified in the last years. This motivated us to investigate whether 
G2E3 affects both proteins. In the absence of a high quality antibody for G2E3, we co-
expressed HA-tagged G2E3 together with Mdm2 or p53. We did not observe a co-localization 
of p53 and HA-G2E3, but found that co-expressed HA-G2E3 and Mdm2 co-localized and 
relocalized to subnuclear structures in untreated and cisplatin treated cells (Figure 5.12 and 
Figure 5.13). This observation suggested a possible complex formation of both proteins. 
Indeed, overexpressed HA-G2E3 and Mdm2 interacted as seen by co-immunoprecipitation 
(Figure 5.14 and Figure 5.15). Remarkably, we found that Mdm2 and p53 interacted 
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independently of co-expressed HA-G2E3, and Mdm2 was bound to HA-G2E3 independently 
of co-expressed p53 (Figure 5.15). Furthermore, G2E3 was bound to p53 independently of 
co-expressed Mdm2 though the interaction was only weakly detectable (Figure 5.15). Thus, 
G2E3, Mdm2 and p53 might be found in a heterotrimeric complex. As an alternative, G2E3 
could be bound by Mdm2, whereas p53 is bound to Mdm2 and only indirectly connected to 
G2E3 via Mdm2. In order to distinguish between these alternatives, CoIPs with co-expressed 
HA-G2E3 and Mdm2 should be conducted in p53 null cells, e.g. H1299 cells. If G2E3 and 
Mdm2 still interact, binding would be independent of p53. On the other hand, an interaction of 
HA-G2E3 and p53 should be investigated in cells after Mdm2-knockdown to clarify whether 
both proteins are directly bound to each other. This experiment cannot be conducted in 
Mdm2-/- cells, since those cells are not viable due to induction of p53-mediated apoptosis. Co-
localization of HA-G2E3 and Mdm2 was shown in both untreated and cisplatin treated cells. 
Interaction of overexpressed HA-G2E3, Mdm2 and p53 was shown for untreated U2OS cells 
only, so CoIPs upon cisplatin treatment should be performed to explore if the proteins interact 
also upon DNA damage. In order to identify the interacting domains of G2E3, Mdm2 and p53, 
CoIPs could be performed with deletion mutants of these proteins (e.g. with deletion of the 
RING domain) to investigate if interaction still persists or not.  
Still, we have to add that the CoIPs were conducted with overexpressed proteins that do not 
reflect the in vivo situation. Thus, we were skeptical when we could not detect an 
endogenous interaction of G2E3 and Mdm2 independent of p53-status (Figure 5.16). This 
could be explained by extremely low levels of detectable endogenous G2E3, whereby 
endogenous G2E3 could also not be detected in input samples (Figure 5.16). Unfortunately, 
we were not provided with a high-quality G2E3 antibody. Another reason for low G2E3 levels 
could be that binding of G2E3 to Mdm2 (or p53) results in hiding of the epitope detected by 
the G2E3 antibody.  
So far, we cannot prove an interaction of endogenous G2E3, Mdm2 and p53. Interaction of 
exogenous proteins should be interpreted cautiously since they sometimes do not withstand 
the in vivo situation. Hence, we were looking for functional consequences of this interaction. 
We tested whether co-expressed HA-G2E3 and Mdm2 affect each other’s protein levels in 
untreated cells, which they did not (Figure 5.18). Additionally, overexpressed HA-G2E3 did 
neither affect Mdm2 nor p53 levels in cisplatin treated cells (Figure 5.19). In search of a 
biological significance, we examined whether G2E3 affects p53 transcriptional activity. We 
found that overexpressed G2E3 had no impact on p53 transcriptional activity or on Mdm2-
dependent inhibition of p53 transactivation (Figure 5.17).  
Besides an impact on p53, interaction of G2E3 and Mdm2 could also have p53-independent 
consequences. For instance, Mdm2 was shown to positively regulate cell proliferation by 
stimulating the S-phase inducing transcription factor E2F1 (Martin, Trouche et al. 1995) and 
by inhibiting retinoblastoma protein (RB) (Xiao, Chen et al. 1995). Mdm2 promotes RB 
degradation in a proteasome-dependent, but ubiquitin-independent fashion (Sdek, Ying et al. 
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2005). Furthermore, Mdm2 can antagonize the F-box protein SKP2 which targets E2F1 for 
degradation (Zhang, Wang et al. 2005). All these positive effects of Mdm2 on the E2F 
pathway are p53-independent. As G2E3 knockdown led to a decreased proliferation rate in 
p53-proficient and p53-deficient cell lines (Figure 5.7), it could be possible that G2E3 has an 
impact on Mdm2 in regulating proliferation. For example, G2E3 could be an agonist of Mdm2 
which supports p53-independent functions of Mdm2 associated with cell proliferation. 
Hypothetically, depleting cells of G2E3 would eliminate the interaction of Mdm2 and G2E3 
which potentially would inhibit cell proliferation. Thus, it should be investigated if G2E3 
together with Mdm2 is a positive regulator of E2F1 activity. This could be tested by 
investigation of E2F1 activity and RB protein levels upon G2E3 knockdown. Furthermore, a 
luciferase reporter assay could be conducted by overexpressing G2E3 and detecting 
luciferase activity of a reporter construct harboring an E2F1-responsive promoter. 
Since G2E3 is a nuclear protein, it makes sense to consider further ways of how G2E3 could 
affect p53-independent tasks of Mdm2 in the nucleus. Mdm2 was reported to interact with 
chromatin and chromatin-associated proteins independently of p53, thereby affecting gene 
expression and DNA repair. It can promote genetic instability and transformation by induction 
of chromosomal breaks and a delay in repair of DNA DSBs by interaction with Nbs1, a 
component of the MRN complex (Bouska, Lushnikova et al. 2008). The MRN complex is 
important in detection and processing of DSBs. So far, we do not have evidence that G2E3 is 
directly involved in DDR or repair. Still, as detailed above, three G2E3 domains possess 
similarity to PHD domains which in principle can bind methylated histones and have been 
shown to be involved in chromatin-mediated gene regulation (Musselman and Kutateladze 
2011). Since it is not known whether G2E3 can bind chromatin, this could be tested by 
chromatin fractionation. If it does, it should be tested whether G2E3 is involved in regulation 
of Mdm2-dependent functions at the chromatin.  
 
 
6.3 Ubiquitin ligase activity of G2E3 
In search for a functional role of G2E3, we explored whether G2E3 can ubiquitinate and 
degrade Mdm2 or p53. As mentioned before, overexpressed HA-G2E3 did not affect Mdm2 
and p53 levels in untreated and cisplatin treated cells (Figure 5.19) and co-expression of 
Mdm2 and HA-G2E3 did not influence their protein levels (Figure 5.18). In order to clarify in 
more detail whether G2E3 could ubiquitinate Mdm2 or p53, an in vitro ubiquitin assay could 
be performed, but the following issues should be thought of. G2E3 has already been 
described to have ubiquitin ligase activity using an in vitro ubiquitination assay and to 
catalyze Lys48-linked poly-ubiquitination, usually a signal for proteasomal degradation 
(Brooks, Helton et al. 2008). Two of the four G2E3 domains (namely PHD/RING2 and 
PHD/RING3) were shown to have ubiquitin ligase activity. G2E3 harbors another PHD/RING1 
and a HECT domain which were shown to exhibit no ubiquitin ligase activity in this assay. 
However, the authors tested only seven out of 35 known E2 ubiquitin-conjugating enzymes 
Discussion             117 
and cannot exclude that PHD/RING1 and HECT domain have in vivo ubiquitin ligase activity, 
perhaps with other E2 enzymes. Hence, for any in vitro ubiquitination assay, it should be 
taken into consideration that the E2 enzyme of G2E3 is not known yet, though high reactivity 
with the E2 enzyme UbcH5a has been detected (Brooks, Helton et al. 2008). Moreover, in 
vitro ubiquitination assays have been shown to be sometimes too far away from the in vivo 
situation since in these assays E3 ligases tend to ubiquitinate every substrate. Therefore, 
performing an in vitro ubiquitination assay with G2E3 might not be the most suitable 
approach. 
The endogenous substrate(s) of G2E3 are not known. To identify G2E3 substrates, a mass 
spectrometric analysis could be conducted. In the past, identification of substrates of ubiquitin 
ligases has been proven difficult due to the diversity and high number of ubiquitinated 
proteins. Zhuang et al. have recently proposed a powerful tool to identify substrates (Zhuang, 
Guan et al. 2013). The authors were interested in finding substrates of inhibitors of apoptosis 
proteins (IAPs). For this purpose, they used the NEDDylator whereby a NEDD8  
E2-conjugating enzyme (Ubc12) is fused to the ubiquitin ligase of interest, in their case XIAP 
or c-IAP1. NEDD8 is a rare ubiquitin homolog which then gets transferred to the E3 
substrates. These proteins can be purified and examined by mass spectrometry. Using this 
technology, it would principally be possible to identify G2E3 substrates.  
 
6.4 A high-content siRNA screen to identify new regulators in the 
DDR to cisplatin  
Considering the importance of the ubiquitin system in the DDR and open questions in the 
response to cisplatin treatment, we performed a siRNA screen and depleted cells from 
human ubiquitin ligases and DUBs (Figure 5.1 and Figure 5.2). High-content siRNA screening 
had previously been shown to be a valuable method to identify new regulators in signaling 
pathways, for example in DDR and DNA repair (Higgins, Prevo et al. 2010; Cotta-Ramusino, 
McDonald et al. 2011).  
Besides G2E3, we identified more candidates which have been shown to be involved in the 
DDR or p53-pathway. Identification of known regulators indicated that the developed screen 
procedure was suitable to identify new regulators of the DDR after cisplatin treatment. 
We identified various genes that showed a strong decrease in H2AX phosphorylation upon 
knockdown. Interestingly, depletion of two proteasomal subunits, PSMD7 and PSMD14  
(26S proteasome non-ATPase regulatory subunit 7 and 14) led to the strongest decrease in 
γH2AX levels. The proteasomal de-ubiquitinating enzyme PSMD14 (also called POH1) had 
been shown to negatively regulate the RNF8-dependent response to DNA DSBs (Butler, 
Densham et al. 2012). Furthermore, knockdown of Mdm2 and knockdown of three regulators 
of the p53-Mdm2-pathway named Mdm4 (also called Mdmx), RBBP6 and STUB1 (also called 
CHIP) resulted in alleviated H2AX phosphorylation. RBBP6 and STUB1 have been described 
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in more detail above. Mdmx is found as a heterodimer with Mdm2 and both proteins have 
sequence homology and a RING domain. Mdmx does not have ubiquitin ligase activity 
towards p53, but can repress p53 transactivation activity (Stad, Ramos et al. 2000).  
We also found DUBs whose knockdown led to decreased H2AX phosphorylation. 
Interestingly, one of them, ATXN3 (or Ataxin-3) is involved in STUB1/CHIP regulation by 
deubiquitinating STUB1-substrates and STUB1 itself (Scaglione, Zavodszky et al. 2011). 
Another identified deubiquitinating enzyme, USP1 (ubiquitin-specific protease 1), is a 
negative regulator of DNA damage repair which specifically deubiquitinates FANCD2, a 
protein involved in the Fanconi anemia pathway (Nijman, Huang et al. 2005). USP1 is also 
involved in translesion synthesis (TLS) since it deubiquitinates PCNA (Huang, Nijman et al. 
2006). We identified two more DUBs, BAP1 and USP42, whose knockdown leads to 
decreased H2AX phosphorylation. BAP1 was reported to interfere with BRCA1 (Jensen, 
Proctor et al. 1998) and to regulate H2A ubiquitination (Scheuermann, de Ayala Alonso et al. 
2010). USP42 was reported to interact and deubiquitinate p53 (Hock, Vigneron et al. 2011). 
The authors show that USP42 function is needed for induction of p53-dependent transcription 
and cell cycle arrest under stress. Apart from these candidates, we identified a number of 
genes whose knockdown affects the DDR after cisplatin treatment and which would be 
interesting to investigate further.  
Unexpectedly, we identified only a small number of genes with a strong increase in γH2AX 
fluorescence intensity upon knockdown. These could have been candidates whose inhibition 
sensitizes cells to cisplatin. Two of the candidates with the strongest increase in H2AX 
phosphorylation upon knockdown were RFWD2 and RFWD3 (RING finger and WD repeat 
domain protein 2 and 3). RFWD2 is also called COP1 and represents a negative regulator of 
p53 since it targets p53 for proteasomal degradation, independently of Mdm2 (Dornan, Wertz 
et al. 2004). Furthermore, the authors show that knockdown of COP1 sensitized U2OS cells 
to cell death induced by ionizing radiation. In contrast, RFWD3 is a positive regulator of p53 
which mediates ubiquitination and stabilization of p53 in response to DNA damage (Fu, Yucer 
et al. 2010). Moreover, it is involved at stalled replication forks and ATR-dependent activation 
of Chk1 in response to replicative stress (Gong and Chen 2011).  
Together, these results of known regulators of the DDR and p53-pathway show that the 
screen is suitable to identify so far unknown proteins in the response to cisplatin. Thus, the 
data should be further analyzed and other candidates should be characterized for their role 
and function in the cell, especially after cisplatin treatment. It has to be added that at the time 
of siRNA library preparation in 2008, less ubiquitin ligases were described than today (327 
versus more than 600 in 2013). Hence, even more regulators of the DDR could exist which 
could be identified in different screens and systems. 
Remarkably, we did not only identify proteins involved in the DDR and p53-pathway, but also 
regulators of apoptosis and cell cycle. This suggests that new candidates could furthermore 
be investigated for their role in this respect. For example, USP39 has been reported to be 
Discussion             119 
involved in mitotic progression and cytokinesis (van Leuken, Luna-Vargas et al. 2008) and 
TRIM17-mediated ubiquitination can initiate apoptosis (Magiera, Mora et al. 2013). 
Furthermore, we found several proteins connected to the endoplasmic reticulum (ER). It has 
been previously demonstrated that cisplatin does not only induce the DDR, but also the ER 
stress pathway (Mandic, Hansson et al. 2003). This is reasonable since cisplatin does not 
only react with DNA, but also with other nucleophilic molecules. Mandic et al. showed in 
enucleated cells (so-called cytoplasts, with removed nucleus) that cisplatin induces DNA 
damage-independent apoptosis by activating the ER-specific caspase 12, leading to 
activation of caspase 3 and further executioner caspases. Thus, activation of the ER stress 
response is a secondary mechanism to explain cytotoxic effects of cisplatin treatment. We 
found that knockdown of the two ER membrane-associated proteins RNF13 and ZNRF4 led 
to decreased γH2AX levels. These two RING finger proteins have only recently been 
explored. RNF13 was shown to mediate ER stress-induced apoptosis (Arshad, Ye et al. 
2013) and was reported to be overexpressed in pancreatic cancer (Zhang, Meng et al. 2009). 
ZNRF4 plays a role in ER homeostasis and regulates the stability of the ER-associated 
chaperone calnexin (Neutzner, Neutzner et al. 2011). Further research is necessary to 
understand the details of the ER stress response and how induced apoptosis is connected to 
phosphorylation of H2AX.  
 
6.5 Conclusions and future perspectives  
We performed a high-content siRNA screen targeting human ubiquitin ligases and 
deubiquitinating enzymes to identify new regulators in the DDR to cisplatin. Thereby, we 
identified several genes whose knockdown modulates phosphorylation of H2AX. Further 
studies of candidates from our screen could give insights into the cellular response to 
cisplatin treatment. Knockdown of one of the candidates, the ubiquitin ligase G2E3, led to 
decrease in γH2AX levels. We studied the protein in more detail and found that G2E3 mRNA 
and protein levels are down-regulated upon DNA damage. Knockdown of G2E3 resulted in 
p53-independent apoptosis and decreased proliferation in colon carcinoma and 
osteosarcoma cell lines. Furthermore, we verified that G2E3 levels are maximal in G2-phase, 
suggesting a cell cycle-dependent regulation of G2E3. Depletion of G2E3 resulted in 
decreased Mdm2 protein levels after cisplatin treatment independently of the p53-status. This 
result suggests that G2E3 regulates Mdm2 levels independently of p53, the principal 
transcription factor for Mdm2 expression. In summary, our results suggest that G2E3 is 
required for cell proliferation and survival. DNA damage induces a strong down-regulation of 
G2E3 levels, possibly contributing to apoptosis. One of the mechanisms by that G2E3 
ensures cell survival could consist in the maintenance of Mdm2 levels.  
In the future, increasing knowledge about proteins like G2E3 that regulate DDR, cell survival 
and cell cycle could lead us to new ways of cancer therapy. For instance, it would be 
beneficial to develop therapeutics that specifically target components of the DDR that are 
Discussion             120 
involved in ubiquitination events. These specific agents could have advantages like 
decreased toxicity compared to general drugs. That ubiquitination events are interesting 
therapeutic targets has already been shown by the proteasome inhibitor Bortezomib 
(marketed as Velcade). It is approved in the United States for treatment of multiple myeloma 
and mantle cell lymphoma (Voorhees, Dees et al. 2003; Adams and Kauffman 2004). 
Besides therapeutic approaches, ubiquitination could be explored for diagnostic purposes, 
and not only for treatment of cancer, but also of other illnesses. Numerous diseases are 
associated with defects in the DDR, accumulated DNA damage or impact on genome 
stability, like neurodegenerative disorders, immune-deficiencies and age-related diseases 
(Jackson and Bartek 2009). 
 
Platinating agents like cisplatin as well as other chemotherapeutics are limited from reaching 
their full potential due to resistance mechanisms and toxicities. It was reported for several 
cancer types that patients respond initially well to cisplatin therapy, but that the relapse rate is 
high. Examples include treatment of small cell lung carcinomas with a relapse rate of 95 % 
(Rabik and Dolan 2007). Another example is treatment of head and neck cancers for which 
cisplatin is the first-line therapy. Here, the response rate is only 20-30 % (Jacobs, Lyman et 
al. 1992). Reasons for resistance towards cisplatin include increased efflux or decreased 
influx, detoxification mechanisms (e.g. by glutathione), increased DNA repair (e.g. through 
activation of NER, MMR, and/or HR pathways) and bypassing lesions during replication – or 
a combination of these processes (Rabik and Dolan 2007). Thus, it is of great interest to 
improve cisplatin therapy, by overcoming resistance or by decreasing toxicity. Since 
resistance mechanisms include increased DNA repair, it is one aim of research to better 
understand the DDR and repair pathways upon cisplatin treatment. Enzymes involved in 
these pathways are potentially new therapeutic targets. We hope that with more research on 
proteins identified in our screen, increased knowledge of signaling could one day lead to 
improvements in therapy, for example by applying a combination therapy of cisplatin with a 
specific inhibitor involved in the DDR or repair pathway.  
 
Proteins like G2E3 that modulate different cellular responses to DNA damage are interesting 
therapeutic targets for cancer therapy. P53 is another good example for a protein involved in 
multiple responses, for example in apoptosis and cell cycle arrest. Research in the last 
decades has focused on elucidating the pathways up- and downstream of p53 function for a 
better understanding of tumorigenesis and in order to manipulate p53 for therapeutic 
approaches. Since p53 function is abrogated in more than 50 % of human tumors (Hollstein, 
Sidransky et al. 1991), it is of great importance to understand the pathways involved in p53-
independent apoptosis. These pathways could represent important targets for cancer cells 
with inactivated p53. Thus, we propose to investigate in more detail how loss or down-
regulation of G2E3 leads to p53-independent apoptosis.  
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We were interested if G2E3 could potentially play a role in cancer. Using the GeneSapiens 
database (for details see section 3.13), we explored G2E3 expression in healthy and 
cancerous tissue. GeneSapiens is the world’s largest human gene expression data source. It 
contains information from healthy and malignant tissue types as well as tissue from non-
tumor diseases and includes information of tissue of origin and cancer type (Kilpinen, Autio et 
al. 2008). According to the database, G2E3 expression is substantially increased in testicular 
cancer, especially in seminoma, a germ cell tumor of the testis. Interestingly, high G2E3 
expression is also found in healthy testis tissue. Furthermore, G2E3 expression is enhanced 
in ovarian germ cell tumors and ovarian adenocarcinoma. Our data presented here suggest 
that high G2E3 expression in these tumors could protect cancer cells from apoptosis. 
Seminoma is a well treatable and curable testicular cancer type. Since cisplatin is used to 
treat testicular cancer, it could be possible that cisplatin treatment of a testicular tumor with 
high G2E3 levels leads to down-regulation of G2E3 and induction of apoptosis. This could be 
tested in samples from cancer patients before and after cisplatin treatment by 
immunohistochemical staining of G2E3 and apoptosis markers. Brooks et al. investigated 
protein expression in adult heterozygous G2E3 mice using β-galactosidase as a marker 
under the control of the endogenous G2E3 promoter (Brooks, Helton et al. 2008). 
Remarkably, the authors found enriched β-galactosidase expression in brain (Purkinje cells of 
the cerebellum) and testis (interstitial cells and cells lining the ductus deferens). This 
observation of high expression of G2E3 in mice testis is consistent with human samples 
investigated in the GeneSapiens database. We tested several testis cancer cell lines (germ 
cell tumor cell lines GH and NCCIT, teratocarcinoma cell lines Tera2 and 833K), but could not 
observe higher G2E3 levels in this selection. More testicular cancer cell lines should be 
tested for G2E3 levels. Using a cell line with increased G2E3 expression would be of 
advantage to investigate endogenous G2E3 levels and effects of DNA damage. Also, G2E3 
could be evaluated as a diagnostic or therapeutic marker of chemotherapeutic treatment. The 
fact that down-regulation of G2E3 leads to induction of apoptosis constitutes an interesting 
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